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Introduction: Obesity, and in particular central fat accumulation, is associated with a number of 
metabolic disturbances such as dyslipidaemia and insulin resistance. Such `clustering' of factors 
is known as the Insulin Resistance Syndrome (IRS). More recently, hypofibrinolysis as a result of 
elevated concentrations of PAI-1 at rest has been included in the IRS. Acute exercise in normal 
weight individuals results in an increase in fibrinolytic capacity due to a rise in t-PA and a 
reduction in PAI-1 concentrations. The primary aim of the following studies therefore was to 
determine the effect of acute exercise and exercise training on fibrinolytic markers in obese 
populations. The secondary aim of this work was to examine the relationships between PAI-1 
concentrations and other markers of the IRS to determine a potential role for these factors in the 
short-term regulation of plasma PAI-1 concentrations. 
Methods: Premenopausal female and male overweight and obese volunteers underwent acute 
bouts of exercise at intensities ranging from 50% to 100% V02 max A group of obese 
premenopausal women also underwent a graded maximal exercise test to exhaustion before and 
after 12 weeks of exercise training at 50% or 70% VO2 max. Venous blood samples were taken 
at rest, immediately post exercise and up to 2 hours post exercise. Samples were analysed for 
fibrinolytic factors (t-PA, total PAI-1 & active PAI-1), markers of endothelial damage (vWF) as well 
as other components of the IRS including lipid profiles, insulin and leptin. 
Results: Plasma t-PA concentrations rose with acute exercise at intensities greater than 50% 
V02 max in all study populations with the exception of obese sedentary males. In all cases t-PA 
returned to baseline levels 30 minutes post exercise. None of the protocols administered were 
sufficient to lower total PAI-1 concentrations immediately post exercise but exercise at an 
intensity of 70% V02 max and a duration of greater than 30 minutes resulted in elevated PAI-1 
concentrations 30 minutes post exercise in the overweight and obese populations. Active PAI-1 
concentrations decreased with exercise either immediately or within 30 minutes post exercise at 
an intensity of 70% V02 max and durations greater than 30 minutes. Exercise training at both 
50% and 70% V02 max increased the t-PA response to maximal exercise but only exercise 
training at 70% V02 max resulted in greater decrease in active PAI-1 with exercise. No factors 
were consistently associated with PAI-1 throughout the studies although anthropometric 
measures and blood pressure were regularly associated with PAI-1 at rest. 
Conclusions: Overall, exercise at an intensity of 70% V02 max for duration of at least 30 
minutes in obese populations results in an increased fibrinolytic capacity as shown by elevated t- 
PA concentrations and decreased active PAI-1 concentrations. It is important to remember 
however that obese populations still remain hypofibrinolytic with respect to non-obese 
populations at rest, during exercise and in the recovery period. 
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Obesity and Coronary Heart Disease (CHD) are highly prevalent conditions in 
developed countries (Despres 1994). Recent statistics show that the prevalence of 
obesity in the UK has tripled since 1980 and will increase further on present trends. 
21 % of women and 17% of men are now reported to have a Body Mass Index (BMI), 
[expressed as weight (kg)/ height (m2)] greater than 30 kg/m2 the level defined as 
obesity (National Audit Office report 2001). This increase in obesity contrasts with 
decreasing energy intakes since 1970 suggesting an increasingly sedentary lifestyle 
as a key cause (Prentice and Jebb 1995). Obesity is associated with an increased 
risk of CHD, non insulin dependant diabetes mellitus (NIDDM), cancer, reproductive 
disorders, sleep apnoea, gall stones, osteoarthritis and psychological disorders 
(Despres 1994). 
11 
Measurements of BMI (>30 kg/m2) and total body fat (>20% in men and >30% in 
women) reveal only the cosmetic and weight bearing problems associated with 
obesity. There is now a large body of evidence to suggest that the regional 
distribution of body fat is a critically important consideration in the relationship 
between obesity, metabolism and health (Despres 1994). Obesity can be divided 
into two main types. Gynoid or gluteal-femoral obesity is the accumulation of excess 
body fat around the hips and buttocks. This excess fat is metabolically relatively 
benign and is most commonly found in pre-menopausal women (Despres & 
Lamarche 1994). The second form of obesity is known as central, visceral or android 
obesity and is most commonly found in men and post-menopausal women (Despres 
& Lamarche 1994). Central obesity or even pre obesity (BMI 25 - 30 kg/m2) is 
associated with a cluster of metabolic disturbances known as the Insulin Resistance 
Syndrome (IRS), Plurimetabolic syndrome, Metabolic syndrome or Syndrome X and 
is characterised by insulin resistance and increased lipolysis leading to dyslipidaemia 
2 
(Despres and Lamarche 1994). The IRS has now been defined as having three or 
more of the following abnormalities: waist circumference > 102 cm in men and 88 cm 
in women; serum triglycerides of > 1.69 mmoVL, HDL cholesterol of < 1.04 mmoVL 
blood pressure of> 135/85 mmHg or blood glucose of >6.1 mmoVL (National Institute 
of Health 2001). 
The type of obesity can be clinically determined or catagorised using the waist 
circumference or waist to hip ratio (WHR). A WHR greater than 0.95 in men and 
0.80 in women is defined as central obesity and poses an increased risk of the 
metabolic disturbances associated with accumulation of excess abdominal fat 
(Despres et al 1995). Another measure of excess abdominal adipose tissue is the 
waist circumference (WC). A WC greater than 1.02m in men and 0.88m in women is 
associated with increased incidence of the metabolic abnormalities associated with 
the IRS (Lean 1998). 
a 
1.2 The Insulin Resistance Syndrome 
In 1988, Reaven first proposed the presence of a cluster of metabolic disturbances 
associated with a state of insulin resistance. He suggested that insulin resistance 
associated with compensatory hyperinsulinaemia and possible glucose intolerance 
are frequently linked to increased triglyceride levels, decreased HDL concentrations 
and hypertension and, that this cluster of abnormalities may increase the risk of 
cardiovascular disease. In 1989, abdominal obesity was included in the cluster of 
risk factors associated with an increased risk of CVD (Jensen eta/1989). Since then 
the metabolic abnormalities associated with CVD have been expanded to include low 
plasma HDL concentrations, increased small dense LDL concentrations, increased 
non-esterified fatty acid (NEFA) concentrations, elevated total cholesterol, increased 
3 
apolipoprotein B-100, increased fibrinogen concentrations, elevated uric acid 
concentrations and increased leptin levels. 
More recently impaired fibrinolysis due to elevations in plasminogen activator 
inhibitor -1 (PAI-1) has also been defined as part of the IRS (Juhan-Vague et al 
1991). In 1985 it was demonstrated that reduced fibrinolytic activity, i. e. low Tissue 
Plasminogen Activator (t-PA) activity, after venous occlusion was due to elevated 
levels of PAI-1 activity and that this may have a pathogenic importance in myocardial 
infarction, particularly in hypertriglyceridaemic patients (Hamsten eta11985). 
1.3 Fibrinolysis 
Fibrinolysis is the process by which clots formed by the coagulation system are 
dissolved (see fig 1). Plasmin is a serine protease that catalyses the lysis of the 
fibrin framework of a thrombus by cleavage of arginine and lysine residues on a 
number of sites on both fibrin and fibrinogen resulting in successively smaller soluble 
fragments known as fibrin (ogen) degradation products (Rapaport 1990). Plasmin 
also catalyses proteolysis on or around cell surfaces in tissues and thus plays an 
important role in the inflammatory response and in tissue remodeling. An inert 
circulating precursor of plasmin, plasminogen, is converted to plasmin by cleavage of 
a single arginine-valine amino acid bond by t-PA and single chain urokinase type 
plasminogen activator (scU-PA). 
1.3.2Tissue Plasminogen Activator (t-PA) 
T-PA is the most important activator of plasminogen in humans and is normally 
present in human plasma in only trace amounts i. e. -100 pM concentrations. These 
limited concentrations reflect a balance between limited basal secretion from the 
vascular endothelium and hepatic tissue and a rapid hepatic clearance. The 
intravascular half-life of non-complexed t-PA is approximately 2.4 minutes (Chandler 
4 
et a/1997) and the half-life of t-PA in complex with PAI-1 is approximately 5 minutes 
(Rapaport 1990). T-PA concentrations increase rapidly in response to a number of 
stimuli including venous occlusion, exercise, catecholamines and vasopressin (Streiff 
& Bell 1994). The activity of t-PA is dependent on the presence of the obligatory 
cofactor fibrin (van Meijer & Pannekoek 1995). The binding of t-PA to fibrin 
increases its affinity for plasminogen by two to three orders of magnitude, resulting in 
a significant acceleration of the conversion of plasminogen to plasmin (van Meijer & 
Pannekoek 1995). Approximately 90% of circulating t-PA is in complex with its 
primary inhibitor PAI-1. The remainder circulates either in the active form or in 
complex with an additional inhibitor C1 (Chandler et a/1997). The inhibition of t-PA 
by PAI-1 occurs in a rapid stochiometric manner resulting in a covalent bond 
between the two molecules (Bastard & Pieroni 1999). Active PAI-1 acts as a 
pseudo-substrate for t-PA forming a stable, inactive, covalent 1: 1 equimolar complex 
(van Meijer & Pannekoek, 1995). PAI-1 is consumed in this process and is thus 
referred to as a "suicide inhibitor". 
Liver 
Plasma 
PAI-1 & Endothelium 
\ Platelets 
Adipose 
Figure 1.1: A schematic representation of fibrinolysis. T-PA = tissue plasminogen 
activator, PAI-1 = plasminogen activator inhibitor type 1. 
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1.3.3 Plasminogen Activator inhibitor (PAI-1) 
PAI-1 is a 47 KDa single chain glycoprotein that belongs to the serine protease 
inhibitor (serpin) family with an in vivo half-life of approximately 7.5 minutes (Huber 
2001a). It consists of 379 amino acids (Kruithof, 1988) and exists in 3 main forms 
active, latent and substrate as well in complex with t-PA. Among the serpins, PAI-1 
exhibits a unique conformational flexibility. Although it is synthesised in the active 
conformation, PAI-1 spontaneously converts into the inactive latent form due to a 
lack of cysteine residues (Huber 2001 a). This latent form can however, be partially 
reactivated by denaturing agents such as sodium dodecyl sulphate (SDS), guanidium 
chloride and urea, as well as platelet activation (Debrock & Declerk 1997). In 
plasma, active PAI-1 circulates in a complex with vitronectin, which stabilises this 
conformation thus increasing its biological half-life (van Meijer & Pannekoek, 1995). 
Substrate PAI-1 
The third conformation of PAI-1 described reacts as a non-inhibitory substrate 
towards t-PA (Declerk et a11992). The reactive centre of PAI-1, known as the P1-P'1 
bond, is located in an exposed loop that contains 20 to 30 amino acids at the carboxy 
terminal of the protein (Debrock & Declerk 1997). In latent PAI-1 this site is not 
accessible for interaction and therefore does not react with t-PA (Mottonen et al 
1992). 
PAI-1 SYNTHESIS 
1 LATENT FORM 4010 ACTIVE FORM 4 SUBSTRATE FORM 
It It 
COMPLEXED FORM 1 COMPLEXED FORM 2 
It 1 Cleavage of both t-PA & Cleavage of PAI-1 Only 
PAI-1 j 
Figure 1.2: A schematic representation of the conformations of PAI-1 
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In contrast, the non-inhibitory substrate form does react with t-PA resulting in 
cleavage of the P1-P'1 bond but without the formation of a stable t-PA/PAI-1 complex 
and with the subsequent regeneration of t-PA (Mottonen et al 1992). This is in 
contrast to the active PAI-1 formation of a stable PAI-1/ t-PA complex in which both 
molecules are cleaved (Debrock & Declerk 1997). This mechanism however is slow 
and may not be physiologically relevant as the liver clears the substrate PAM/ t-PA 
complexes before dissociation occurs (Mottonen eta! 1992). 
Regulation of PAI-1 
PAI-1 has two transcripts the largest of which (3.2kb as opposed to 2.2kb) is less 
stable and has a shorter half-life (Tremoli et al 1993). Both forms of PAI-1 are 
synthesised in the active form in a number of cells including hepatocytes, endothelial 
cells and adipocytes (Bastard & Pieroni 1999) and stored in platelets (which harbour 
100-200 ng/ml) and in plasma (harbouring -10ng/ml) (van Meijer & Pannekoek 
1995). Normal plasma PAI-1 concentrations range from 6-80 ng/ml and demonstrate 
a circadian rhythm with the highest levels recorded between midnight and 6 a. m. 
(Kruithof 1988) PAI-1 concentrations can change rapidly in response to a wide 
variety of agents and physiological states, indicating that the regulation of PAI-1 is a 
complex process (Bastard & Pieroni 1999). 
PAM is removed from the circulation either in complexed form with t-PA via manose 
receptors and LDL related protein (LRP) or in active form (Chandler et al 1997). 
Approximately 50% of the PAI-1/t-PA complexes in the circulation are cleared by the 
liver per pass in contrast to only 10-20% of active PAI-1 (Chandler et al 1997). 
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1.4 Regulation of PAI-1 Secretion and Expression 
1.4.1 PAI-1 Secretion and Release by Adipose Tissue 
There is a considerable amount of evidence to suggest that PAI-1 is secreted from 
endothelial cells (Schneider et al 1993, Sawdey et al 1989) and hepatic tissue 
(Kooistra et a11989, Alessi eta! 1988). Adipose tissue, specifically visceral depots, 
has recently been postulated as a major source of the elevated PAI-1 concentrations 
in obesity (Janand-Delenne et al 1998). Resting PAI-1 Ag and activity have been 
shown on numerous occasions to positively correlate to BMI, waist to hip ratio, waist 
circumference and visceral fat mass (Janand-Delenne eta11998, Vague eta11989). 
Initial clues for the role of adipose tissue in PAI-1 expression and secretion came 
from the observation that murine adipose tissue contained significant amounts of 
PAI-1 mRNA (Samad et al 1996, Samad & Loskutoff 1996). Moreover, clinical 
studies have demonstrated that fat loss due to surgical treatment and diet 
significantly reduces PAI-1 concentration in obese volunteers (Loskutoff & Samad 
1997). The key role of adipose tissue in the biosynthesis of PAl-1 is further 
emphasised by the production of PAI-1 by adipocytes in response to a number of 
stimuli as well as localisation of PAI-1 mRNA in fully differentiated mature 3T3 
adipocytes (Loskutoff & Samad 1997). Yudkin et al (1999) attempted to quantify the 
contribution of adipose to total PAI-1 secretion by measuring the arterio-venous 
difference in PAI-1 concentrations across the subcutaneous fat depot in lean 
subjects. This group determined that the relative contribution of subcutaneous 
adipose tissue to total PAI-1 concentrations is only 1.6%. As the contribution of 
visceral fat to PAI-1 concentrations is greater than that of subcutaneous fat (Loskutoff 
& Samad 1997) and as obese subjects have a greater amount of both subcutaneous 
and visceral fat than their lean counterparts, we can deduce that adipose tissue does 
play a significant part in elevated PAI-1 concentrations in obesity although the 
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contribution of other factors of the IRS to both increased adipose tissue mass and 
elevated PAI-1 concentrations may make the associations between anthropometric 
and PAI-1 concentration seem greater. 
1.4.2 PAI-1 and Insulin 
In vitro studies have demonstrated an increase in PAI-1 secretion and expression in 
response to insulin in arterial endothelial cells (Schneider et al 1993), human 
hepatocytes (Kooistra et al 1989), Hep G2 cells (Alessi et al 1988) and 3T3-L1 
cultured adipocytes (Samad & Loskutoff 1996). Increases in PAI-1 secretion in 
response to insulin have also been demonstrated in vivo in mice (Samad & Loskutoff 
1996). Several studies in human volunteers however, found that hyperinsulinaemia 
did not modify plasma PAI-1 concentrations (Grant et al 1990, Landin et al 1991, 
Potter van Loon et a11990). Studies in humans that have examined the relationship 
between insulin and PAl-1 secretion in vivo directly using either the hyperinsulinemic 
euglycemic clamp (Landin et al 1990, Potter van Loon et a11993) or the minimal 
model (Apslund-Carlson et a11993) have reported conflicting data. Potter van Loon 
et al (1990) observed that insulin was the major determinant of excess PAI-1 
secretion in obesity, when measured against insulin resistance, diastolic blood 
pressure, BMI and WHR. Using the minimal model, a determinant of insulin 
resistance however, Apslund-Carlson et al (1993) demonstrated that plasma 
triglycerides and BMI, not insulin concentrations, were the major determinants of PAI- 
1 secretion in males and in females, HDL cholesterol and 2-hour post-load insulin 
concentration were the major determinants of PAI-1. 
Increased PAI-1 levels however are not always associated with increased 
concentrations of insulin. For example, non-diabetic patients with Cushing's 
syndrome have normal PAI-1 levels in spite of hyperinsulinaemia (Vague 1993). In 
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contrast to the Apslund-Carlson study the majority of experimental data suggests that 
elevations in PAI-1 are related to insulin resistance rather than hyperinsulinaemia 
suggesting a mechanism controlled by insulin receptors as opposed to insulin itself. 
When cells are made insulin resistant (by pre incubation with high doses of insulin to 
reduce receptor numbers) PAI-1 secretion and expression are enhanced (Vague 
1993). 
1.4.3 PAI-1 and Lipids 
Greig & Rundle first suggested the influence of plasma lipoproteins on PAI-1 in 1956. 
This group observed an increase in an as yet unknown inhibitor of the fibrinolytic 
system after the ingestion of a fatty meal. Since then, many groups have described 
an elevation in PAI-1 in hyperlipidemic patients (Epstein eta! 1970, Vague etal 1996) 
although other markers of the insulin resistance syndrome are often present. A direct 
relationship between lipids and PAI-1 was demonstrated in patients with type IV 
hyperlipidemia (Fredrickson's classification) who had no history of cardiovascular 
disease, hypertension, diabetes or obesity compared to controls (Tremoli eta! 1993). 
After a diet regimen only those patients who had reduced their triglycerides by more 
than 20 % showed a normalisation of PAI-1 levels. 
Further in vitro work demonstrated that application of VLDL to Hep G2 cells and 
cultured endothelial cells increased expression and secretion of PAI-1 (Tremoli et al 
1993) with the greatest increase in secretion from hepatocytes. The greater 
response from hepatocytes may be due to the expression of a distinct apo E receptor 
for VLDL binding in hepatic cells as well as the classical apo B/E receptor observed 
in endothelial cells (Dawson et a1.1991) Moreover, VLDL from hypertriglyceridaemic 
patients had a greater effect than VLDL from normolipidemic patients. This may be 
due to the larger VLDL particle size in hypertriglyceridaemic patients that contains 
freshly transferred apoE that has a greater affinity for both receptor types (Stiko- 
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Rahm et a! 1990). Sironi et a! (1996) also demonstrated an increase in PAI-1 
expression in response to stimulation by VLDL. Interestingly, this group noted that 
the PAI-1 expressed was the more stable 2.2kb form and that application of insulin 
further increased PAI-1 secretion. Nilsson et a! (1999) demonstrated that it is the 
unsaturated fatty acid component of VLDL that is responsible for increasing PAI-1 
secretion in endothelial cells. 
The negative correlations between HDL and plasma PAI-1 concentrations observed 
in numerous epidemiological studies (Vague 1993, Vague et al 1995) have been 
attributed to the close metabolic relationship between triglycerides and HDL particles 
as HDL concentrations are dependent on rates of triglyceride uptake (Frayn 1999). 
This was confirmed by Cimminello et al (1997) who showed that patients with 
triglyceride levels > 2.25 mmol/L and HDL concentrations <0.91 mmol/L had 
increased plasma concentrations of PAI-1 compared to controls and patients with 
only low HDL cholesterol. There is limited research however to suggest that glycated 
HDL cholesterol, that occurs in insulin resistance and type li diabetes increases PAI- 
1 secretion from vascular endothelial cells independently of triglycerides (Ren & 
Shen 2000). This may explain the few studies that show a negative correlation 
between PAl-1 concentration and HDL cholesterol despite controlling for triglyceride. 
1.4.4 PAM and Cytokines 
Tumour Necrosis Factor a (TNFa) 
It has been shown that TNFa is a potent inducer of PAI-1 secretion and expression in 
a wide variety of tissues in a dose dependent manner (Samad eta! 1996). Cigolini et 
a/ (1999) demonstrated a TNFa stimulated secretion of PAI-1 from cultured adipose 
tissue and a dose dependent decrease in PAl-1 expression and secretion in 
response to TNFa antagonists. TNFa-induced PAI-1 expression has also been 
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shown in vascular endothelial cells, HepG2 cells and adipocytes (Samad eta/1996). 
Sakamoto et al (1999) demonstrated that both superoxides and hydrogen peroxide 
were potent inducers of PAI-1 and that hydroxyl radical scavengers completely 
abolished the TNFa induction of PAI-1. This group further demonstrated that TNFa 
and insulin exert synergistic effects and hypothesised that TNFa stimulates PAI-1 
production and this effect is potentiated by insulin. 
Transforming Growth Factor ß (TGFJ) 
TGF3 has also been shown to induce PAI-1 synthesis and secretion in a variety of 
tissues including the endothelium (Sawdey eta! 1989), smooth muscle cells (Reilly & 
McFall 1991), fibroblasts (Lund et al 1987), epithelial cells (Thalacker & Nilsen- 
Hamilton 1987), adipocytes (Samad et a11997) and Hep G2 cells (Westerhausen et 
al 1991). Infusion of TGFf into mice results in an increase in PAI-1 expression in a 
number of tissues with the largest increase being observed in adipose tissue 
(Sawdey & Loskutoff 1991). Furthermore, TGFI induces a greater increase in PAI-1 
expression than TNFa and insulin (Sawdey & Loskutoff 1991). Adipose tissue 
expression of TGFJ mRNA is also significantly higher in obese mice compared with 
lean controls and this increase can be attributed to increased expression of TGFß 
mRNA in mature adipocytes, stromal cells and vascular cells within the adipose 
tissue (Samad eta! 1997). As TGFf is stored and released from the a granules of 
activated platelets (Lundgren et a11996) and is known to augment PAI-1 synthesis, 
this cytokine may provide a positive feedback mechanism inducing further PAI-1 
synthesis. 
1.4.5 PAI-1 and Leptin 
The evidence for a link between PAI-1 and plasma leptin concentrations comes 
mainly from epidemiological studies. De Mitrio et al (1999) found that after 
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adjustment for fat mass, waist to hip ratio and BMI, PAH Ag correlated only with 
leptin, insulin and HDL. The correlations between PAH and leptin were thought to 
result from the strong correlations between insulin and leptin but Soderburg et a/ 
(1999) demonstrated a positive correlation between PAH and leptin concentrations 
after adjustment for fasting insulin concentrations in obese male volunteers. Studies 
in adolescents however, have shown that the increased levels of leptin that occur 
with puberty do not result in increases in PAH suggesting that leptin is not 
independently associated with PAH concentrations (Sudi et al 2000). This is 
confirmed by the limited in vitro data. Aprath-Husmann et al (2001) showed that 
when supraphysiological concentrations of leptin were applied to mature and 
preadipocytes no change in PAH secretion was observed. There is still limited 
cellular data on the role of leptin in PAI-1 secretion and expression. Many more 
studies on different cell types must be conducted before firm conclusions can be 
drawn. 
1.4.6 PAI-1 and the Renin-Angotensin-Aldosterone System (RAAS) 
Obesity is associated with elevated plasma angiotensin, plasma renin activity, tissue- 
specific angiotensin converting enzyme (ACE) and plasma aldosterone levels (Egan 
et al 2001). Alterations in the renin-angiotensin-aldosterone system (RAAS) are 
thought to be responsible for the relationship between fat mass and blood pressure 
and thus may indirectly account for the rise in PAI-1 concentration with increasing fat 
mass due to increased shear stress induced endothelial damage. 
In vivo (Ridker eta!, 1993, Van Leeuven eta11994) and in vitro studies (Vaughan et 
al 1995) however, implicate the RAAS directly in the regulation of PAI-1. Early 
evidence appears to confirm this link as patients treated with ACE inhibitors show 
reduced concentrations of PAI-1 (Huber et al 2001). These studies have also shown 
that these changes are not mediated via secondary changes in haemodynamics. 
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In vitro, (figure 1.3) Angiotensin II has been shown to up-regulate PAI-1 production 
from both smooth muscle and endothelial cells (Huber 2001 a, Brown et al 1998) and 
this suggests an indirect role for ACE in the regulation of PAI-1 secretion and 
expression. Furthermore, infusion of exogenous angiotensin II has been shown to 
increase PAI-1 Ag selectively in both normotensive and hypertensive individuals 
(Brown et al 1998). Increased expression of PAI-1 in response to angiotensin II in 
cultured endothelial cells however, does not appear to be mediated via either 
angiotensin type I or type II receptors. Rather, angiotensin II is metabolised to the 
hexapeptide angiotensin IV that acts on the specific AT4 receptor (Kerins et a11995) 
to up regulate PAI-1 secretion. In contrast, increases in PAI-1 expression observed in 
rat aorta and heart ventricle appear to be mediated via the angiotensin II/ angiotensin 
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Figure 1.3: Relationship between renin-angiotensin-aldosterone system, kallikrein- 
kinnogen system and the fibrinolytic system. ACE= angiotensin converting enzyme, 
ECs= endothelial cells, VSMCs= vascular smooth muscle cells, PA! - 1=plasminogen 
activator inhibitor 1, t-PA= tissue plasminogen activator. Adapted from Vaughan 
(2001) 
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Inhibition of ACE therefore, results in reduced formation of both angiotensin 11 and 
angiotensin IV leading to an abatement of PAI-1 expression and secretion. 
ACE inhibitors not only block the formation of angiotensin 11 but also inhibit the 
breakdown of bradykinin. Bradykinin is a potent stimulus for t-PA secretion from 
endothelial cells as well as being a stimulus for nitric oxide production and therefore 
vasodilatation (Brown et al 1998). 
Research in this area is limited but promising and suggests that treatment with ACE 
inhibitors will not only reduce blood pressure, but will also increase fibrinolytic 
potential via stimulation of t-PA secretion and expression and inhibition of synthesis 
and release of PAI-1. 
1.4.7 PAI-1 and Oestrogen 
Premenopausal women have lower plasma PAI-1 concentrations than both men and 
postmenopausal women (Gebara et a! 1995). The potential role for oestrogen in 
regulation of PAI-1 secretion and expression comes from preliminary data showing a 
reduced plasma PAI-1 concentration in women undergoing oestrogen replacement 
therapy compared to controls (Teede et al 2000). Oestrogen may lower PAI-1 
concentrations in vivo by inhibiting cytokine stimulated increases in PAI-1 secretion 
and expression via an oestrogen receptor mediated mechanism thus contributing to 
the cardioprotective effects of oestrogen replacement therapy (Huber 2001 a). Oral 
oestrogen is also known to influence the proportion of t-PA/PAI-1 complexes via a 
stimulation of hepatic t-PA clearance. 
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1.4.8 Release of PAI-1 by Platelets. 
Over 90% of available PAI-1 is associated with platelets and its release has been the 
subject of a large number of studies (Erickson et al 1984, Erickson et al 1985, 
Kruithof et a! 1986, Kruithof et al 1987). PAI-1 is stored in the alpha granules of 
platelets with approximately 80% present in the latent form (Huber 2001 a). This 
latent PAI-1 is converted to the active confirmation by triggers such as platelet 
activation and aggregation caused by vessel trauma. Whilst the exact mechanism by 
which this conversion occurs is unknown, large amounts of active PAI-1 can be 
released from activated platelets at sites of arterial platelet rich thrombi (Huber 
2001a). Stabilisation of PAI-1 within platelets appears to be a function of Ca 2+ 
binding rather than formation of PAI-1/vitronectin complexes (Lang & Schleef 1997). 
The release of PAI-1 from the alpha granules of platelets occurs in parallel with 
release of vitronectin, phosphokinase A, platelet factor 4 and ß thromboglobulin 
(Erickson et a11985, Kruithof et a11986). 
Platelet 
Activation 
mr V 44 Vitronectin 
Stable Active PAI-1 + Vitronectin 
Phospho Kinase A 
Active PAI-1 Vitronectin 
Latent PAI-1 
Figure 1.4: Schematic representation of the conformational changes in PAI-1 
following platelet activation. 
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Once released from the alpha granule, if available, the newly activated PAI-1 is 
stabilised by vitronectin thus increasing its biological half-life (van Meijer & 
Pannekoek 1995) (figure 1.4). Phosphokinase A (PKA) however is also translocated 
onto the fibrin network from the surface of platelets (Morgenstern et al 2001). 
Phosphorylation of vitronectin by PKA releases the active form of PAI-1 that 
`spontaneously' converts back to the latent conformation thus promoting fibrinolysis. 
1.5 Acute Exercise and Fibrinolysis 
An increase in fibrinolysis with exercise was first reported by John Hunter in 1794 (EI- 
Sayed 1996) but the exact mechanism by which this occurs still remains to be 
elucidated. Dilute blood clot lysis time has been documented to decrease between 
20 and 83% following strenuous exercise (Streiff & Bell 1994, Bourey & Santoro, 
1988) and is dependent on a wide variety of factors including exercise intensity, 
fitness of subjects, exercise protocol and correction for haemoconcentration. In 
general, increases in fibrinolytic activity are not seen following exercise at intensities 
below 50% maximal heart rate (Andrew et al 1986, Szymanski & Pate 1994) and the 
greatest increases in fibrinolytic activity occur between 70 and 90% of maximal 
workload (Andrew et al 1986). The increase in fibrinolytic activity is only transient 
and levels generally return to base line 30-60 minutes post exercise (Desouza et al 
1997, Ferguson et al 1987. ) 
1.5.2 Acute Exercise and t-PA 
T-PA antigen levels have been shown to increase significantly with exercise. 
Elevations of 10-3000% have been recorded using a wide variety of test protocols. 
Van den Burg et al (1994) demonstrated a 51 % increase in t-PA antigen and a 109% 
increase in t-PA activity in young untrained males undertaking 15 minutes of exercise 
on a cycle ergometer at 70% of their respective V02 max. Szymanski and Pate 
(1994) demonstrated that the rise in t-PA activity is dependent on exercise intensity, 
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with exercise at 80% V02 max eliciting a greater t-PA response than exercise at 50% 
V02 max, and time of day with t-PA antigen increased in the evening compared to 
the morning. There is no reported evidence of an age effect on t-PA concentrations. 
Van den Burg eta! (1995) found no correlation between t-PA secretion in response to 
25 minutes cycling at 70% V02 max, and age in 38 sedentary males aged 20 to 60 
years. There is also no reduction of t-PA secretion in response to exercise in older 
hypertensive men compared to age matched normotensive controls (Desouza et al 
1997). 
There is also evidence of a rise in scU-PA with exercise suggesting that the 
acceleration in blood fibrinolytic activity also includes activation of scU-PA (Van den 
Burg et a/ 1994). It should be noted however that peak levels of t-PA and scU-Pa do 
not coincide in time and magnitude in response to maximal exercise (EI-Sayed, 
1996). The mechanism behind the increase in t-PA with exercise involves a shift in 
the balance between t-PA secretion and clearance. T-PA secretion during exercise 
is linearly related to plasma adrenaline concentrations that act via both a and 0 
receptor types (Chandler eta! 1997). Stimulation of a adreno-receptors increases 
plasma t-PA concentrations by decreasing hepatic blood flow that in turn leads to a 
decreased clearance t-PA by the liver (Chandler eta11995). Stimulation of ß adreno- 
receptors results in an increased plasma t-PA concentration via stimulation of t-PA 
secretion (Chandler et al 1995). Additional evidence for the role of ß adreno- 
receptors comes from exercise studies where administration of propranolol prior to 
exercise partially decreased but did not fully abolish the t-PA response (EI-Sayed 
1996). 
The relative contributions of increased t-PA secretion and decreased t-PA clearance 
to plasma t-PA concentrations are dependent on the exercise protocol administered. 
18 
Sustained submaximal exercise results in reduced hepatic blood flow and therefore 
decreased t-PA clearance (Chandler et a! 1995). T-PA rises gradually during the 
exercise period in parallel to the reduced hepatic clearance. When exercise ceases 
hepatic blood flow and therefore t-PA concentrations rapidly return to baseline levels 
(Booth eta! 1987). 
When a graded exercise protocol to exhaustion, such as a modified Bruce protocol is 
applied, initially there is little or no change in plasma t-PA concentration. This is 
followed by an exponential increase in t-PA that peaks at the point of maximal 
exercise. Whilst a decrease in hepatic blood flow and therefore a increase in t-PA 
concentration do occur, it is insufficient to account for the rapid rise in plasma t-PA. 
Instead, increased t-PA secretion is predicted to be the main contributor to elevated 
t-PA concentrations during graded exercise to exhaustion (Chandler eta! 1995). The 
increase in t-PA secretion can be attributed to the exponential increase in plasma 
adrenaline in response to this type of exercise protocol (Chandler et al 1995). 
1.5.3 Acute Exercise and PAI-1 
PAI-1 antigen has been reported to either be unaffected by acute bouts of exercise or 
decreased by up to 30% (Streiff & Bell 1994). Szymanski and Pate (1994) showed 
significant reductions in PAH in response to acute bouts of cycle ergometer exercise 
at both 50% and 80% V02 max. Surprisingly there was no significant difference in 
the magnitude of the PAI-1 response to exercise intensity, as the majority of studies 
have reported a decreasing PAI-1 concentration with increasing exercise intensity 
(EI-Sayed 1996). As with t-PA, Szymanski and Pate (1994) demonstrated that PAI-1 
reduction with exercise is dependent on time of day and is highest in the morning. 
No aging (Van den Burg eta! 1995) or hypertensive effect (Desouza eta! 1997) has 
been observed in PAI-1 secretion in response to acute bouts of sub-maximal 
exercise. 
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The mechanisms that lead to a reduction in PAI-1 remain to be fully elucidated. 
Sustained submaximal exercise results in decreased hepatic blood flow (Chandler at 
al 1995) and may therefore decrease PAI-1 secretion from the liver. Increased PAI-1 
secretion from the a granules of activated platelets resulting from increased 
endothelial damage during exercise may mask the true extent of this effect. PAl-1 
however is also cleared from the circulation by the liver and therefore this mechanism 
would suggest that PAI-1 clearance might also be reduced resulting in a lack of 
significant change in plasma PAI-1 concentration. Numerous studies have reported 
a reduction in PAI-1 activity without a reduction in total PAI-1 Ag (Fernhall eta! 2000, 
DeSouza et al 1997). This suggests that the reduction in PAI-1 activity is a direct 
result of increased t-PA concentrations and the formation of t-PA/PAI-1 complexes. 
Further research is needed in this area to determine the effect of exercise on plasma 
PAI-1 secretion and clearance. 
1.5.4 Effectiveness of Increased Fibrinolytic Capacity 
How effective the increases in t-PA and scU-PA and the decrease in PAI-1 are on 
fibrin(ogen)olysis remains a matter of debate. Ferguson et al (1987) reported a 
significant increase in fibrin and fibrinogen degradation products in response to 
maximal exercise, whether other studies have reported no significant change in 
fibrinogen concentration in response to a variety of test protocols (El-Sayed et al 
1999). Particularly, Collen et al (1977) found no significant change in the plasma 
fibrinogen concentration but did observe a shortened half life of radio labeled 
fibrinogen. EI-Sayed et al (1999) demonstrated a decrease in plasma fibrinogen 
concentration in response to both maximal and sub maximal (75%) cycle ergometer 
exercise in healthy moderately active males. Conversely, several groups have found 
a rise in fibrinogen concentration in response to acute bouts of exercise but these 
studies did not correct for plasma volume changes which may account for the 
increase (Streiff & Bell 1994). The most recent plasma volume adjusted studies 
20 
show good evidence to suggest that fibrinogen concentrations do indeed decrease 
and fibrin (ogen) degradation products increase in response to maximal and sub- 
maximal exercise (EI-Sayed, 1999, Prisco et al 1998). 
The mechanisms responsible for the observed decrease in plasma fibrinogen 
concentration are not well understood but may be linked to an enhanced rate of 
fibrinogen catabolism (hyperf ibrinogenolysis) or increased removal of fibrinogen from 
the plasma into the interstitial spaces (EI-Sayed etal 1999). Further investigation is 
required to examine fibrinogen concentration with simultaneous measurements of 
fibrinogen/fibrin degradation products and thrombin activation to elucidate the 
mechanisms responsible for exercise induced changes in plasma fibrinogen 
concentration. 
Considering all the available information Streiff & Bell (1994) proposed a model of 
fibrinolysis in response to acute bouts of exercise. As exercise intensity reaches 
approximately 50% V02 max the release of t-PA from endothelial cells begins. The 
trigger factor for the release of t-PA remains controversial but increases in regional 
blood flow, signals of local ischaemia and increasing lactate concentrations have 
been correlated to t-PA release (Ferguson et al 1987). When exercise intensity 
reaches 70 - 90% V02 max large increases in t-PA occur. Available fibrin 
microdeposits are degraded and elevations in fibrin degradation products can be 
measured depending on the proportions of soluble and insoluble fibrin present 
(Ferguson et al 1987). Relatively little fibrinogenolysis occurs due to the relative 
fibrin specificity of t-PA and scU-PA and the presence of PAI-1. With strenuous 
exercise PAI-1 concentrations decrease thus increasing overall fibrinolytic capacity. 
After the completion of exercise, fibrinolytic activity rapidly dissipates due to the short 
half-life of t-PA, scU-PA and plasmin. T-PA antigen concentrations may fall to sub 
21 
baseline levels (reflecting a transient exhaustion of endothelial stores) but fibrinolytic 
activity may remain at baseline levels due to a decrease in PAI-1 concentration. 
1.6 Fibrinolysis and Exercise Training 
Numerous cross sectional (Kvernmo & Osterund 1997, Ferguson & Guest 1994, 
Ferguson et al 1987, DePaz et al 1992) and longitudinal (Traber 1999, Stratton eta! 
1994) studies have shown an increase in fibrinolytic activity with exercise training. 
Kvernmo & Osterund (1997) found that although there were no significant differences 
in resting fibrinolytic activity between athletes and controls, the athletes 
demonstrated an increased fibrinolytic capability with reduced PAI-1 antigen 
concentrations following a maximal exercise test. DePaz et a! (1992) also showed 
that athletes were hyperfibrinolytic compared to controls after a maximal exercise test 
with an increased release of t-PA antigen and a decreased formation of t-PAIPAI-1 
complexes in the athletes. This is in contrast to Ferguson and Guest (1994) and 
Ferguson et al (1987) who observed that fibrinolytic activity both at rest and after 
acute exercise bouts are based on both current and former physical fitness levels. 
Longitudinal studies have shown that favorable changes in the fibrinolytic system can 
be achieved over a relatively short period. Stratton et al (1994) showed an 88% 
reduction in PAI-1 activity following a 6-month training programme in elderly 
individuals. Traber (1999) however demonstrated a rise in fibrinolytic activity 
following a1 month training programme at 80% maximal heart rate and Bowman et 
al (1996) observed a decrease in PAI-1 activity following a 14 day skiing tour. These 
results confirm the observations by Tofler et al (1990) that the risk of triggering 
myocardial infarction (MI) by heavy physical activity is reduced in physically fit 
individuals. 
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1.7 Exercise as a Trigger for Myocardial Infarction and Sudden Cardiac Death 
There is evidence that unaccustomed physical activity acts as a trigger for acute MI 
and sudden cardiac death (SCD). Tofler et a/ (1990) reported that among the 849 
patients or relatives interviewed after acute MI, 49% reported exposure to one or 
more trigger factors. The trigger factors included emotional upset (19%), moderate 
physical activity (14%) and heavy physical activity (9%). Similar results were 
observed in a number of other studies (Sumiyoshi 1986, Behar et a! 1993). In an 
effort to quantify the risk associated with physical exertion the TRIMM (Mittleman et 
al 1993) and Onset (Willich et al 1993) studies were conducted. Both studies 
reported a significantly increased risk of acute MI during and up to 1 hour after the 
completion of heavy physical exertion. Heavy physical exertion was defined in both 
studies as 6 metabolic equivalents per minute (METS) and included slow jogging, 
tennis, snow shovelling, fast biking and sexual activity (1 MET is equal to the energy 
expended per minute by a subject sitting quietly and is approximately 3.5 mis 02 
/kg/min). The overall increased risk of MI was 5.9 in the TRIMM study and 2.1 in the 
Onset study. The results of both studies however, showed massive variation with the 
usual frequency of physical exertion. The Onset study observed a relative risk of 107 
in those persons who exercised less than once a week and a risk of 2.4 in those who 
engaged in heavy physical exertion five or more times a week. The TRIMM study 
reported a risk of 6.9 in persons who exercised less than four times a week 
compared to 1.3 in those who exercised more than 4 times a week. 
The exact mechanism by which exercise triggers acute MI remains unknown. A 
proposed mechanism is the rupture of a vulnerable coronary vessel atherosclerotic 
plaque in response to the haemodynamic stresses of exercise (Mittleman & Siscovick 
1996) for example increased blood pressure and heart rate due to increased 
sympathetic output (Gibbons et al 1980). The haemostatic and vasoconstrictive 
processes that follow determine whether the formed thrombus occludes the lumen of 
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the coronary artery. Heavy physical exercise has also been demonstrated to acutely 
activate platelet function in sedentary persons and those persons with a previous 
history of MI (Kestin et al 1993). Conversely exercise has been demonstrated to 
increase fibrinolytic activity (Winther et al 1992). The net effect of thrombus 
formation and increased fibrinolysis may be the determining factor in the triggering of 
acute MI. In persons with the metabolic abnormalities associated with the IRS 
fibrinolysis is impaired at rest and may be impaired during exercise leading to an 
increased risk of MI with unaccustomed heavy physical exertion. The response of 
these patients to exercise requires investigation. 
1.8 Aims of the Investigation 
The aims of this investigation therefore are to determine the effect of acute exercise 
and exercise training on plasma PAI-1 concentrations in overweight and obese 
subjects and to examine the correlations between plasma PAl-1 Ag and other factors 
of the IRS over a variety of physiological conditions to highlight the role of these 
factors in the short term regulation of PAI-1 secretion. 
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Chapter 2 
Materials & Methods 
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2.1 Body Fat Analysis - Air Displacement Plethysmography BODPODTM 
(Life Measurement Instruments, Concord CA) 
Principle of the Measurement 
The system consists of two chambers, one for the subject and one serving as a 
reference for volume (see fig 2.1). With the subject in one chamber the door is 
closed and sealed. The pressure is then increased slightly and the diaphragm 
separating the two chambers is oscillated to slightly alter the volumes of the two 
chambers by 350ml (Ellis 2000). These volume perturbations lead to small 
complementary pressure fluctuations (approximately 1cm H20) between the two 
chambers. The pressure before and after the subject enters the chamber are 
recorded and using Boyle's law (Pressure, / Pressure2 = Volume, / Volume2) the 
volume of the subject is then determined. From the volume of the subject the 
subject' s density can be determined (Volume/Mass = Density) and percentage body 
fat calculated using the equation of Siri (1961). 
Percent Fat = 495 / Density - 450 
Fig 2.1: Diagrammatic representation of the BODPOD (Dempster & Aitkens 1995) 
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Procedure 
Firstly the BODPOD is calibrated using a 50L cylinder. Subjects were required to 
remove all clothing except for a close fitting swimming costume or trunks and to put 
on a close fitting swimming cap. The subject was then weighed. Details of the 
subjects height, age and sex were then input into the computer. The subject was 
then required to sit in the BODPOD for two consecutive cycles. If these cycles 
determined the volume to be different by more than 150ml a third cycle was added. 
The mean volume of the two cycles closest in agreement was used to determine the 
percentage body fat. r 
Limitations 
This method has been shown to accurately determine volumes ranging from 25 - 
150 L with a sensitivity of 0.001 L (Dempster & Aitkens 1995). 
Coeff 1 cient of Variation 
The coeff icient of variation for this method has been reported as 1.7% (McCrory et al 
1995) (n=68) 
The coefficient of variation within this laboratory was assessed by completing 20 
consecutive cycles on a single subject and was determined to be 2.1 % 
2.2 Waist Circumference 
Waist circumference was assessed by placing a tape measure snugly around the 
midpoint between the lower intercostal and iliac crest. Measurements were taken at 
the end of a normal expiration and recorded in centimetres. 
2.3 Hip Circumference 
Hip circumference was measured by placing a tape measure snugly around the 
maximal posterior extension of the buttocks at the level of the greater trochanter. 
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2.4 Body Fat Analysis - Tetrapolar Bioelectrical Impedance (Body Stat 1500, 
Body Stat UK) 
Principle of Measurement 
Four electrodes are attached to the subject before a weak alternating current is 
passed through the outer pair of electrodes, while the voltage drop is measured using 
the inner pair of electrodes from which the body impedance is derived. The method is 
based on 2 main assumptions firstly, the body can be modelled as an isotropic 
cylindrical conductor with its length proportional to the subjects height (Ht). Secondly, 
the reactance (X) term contributing to the body's impedance (Z) is small, such that 
the resistance component (R) can be considered equivalent to the body impedance. 
When these two assumptions are combined, it can be shown that the conducting 
volume is proportional to the term Ht2/R, called the impedance index. Body fat is then 
calculated using proprietary equations 
Procedure 
Subjects rested in the supine position for 15 minutes before measurement. The areas 
for electrode placement were cleaned thoroughly with alcohol and allowed to dry. 
Electrodes were placed on the dorsal side of the foot at the midpoint between the 
medial and lateral malleoli, between the first and second digit of the foot, on the wrist 
at the midpoint between the medial and lateral styloid processes and between the 
second and third digits of the hand. The electrodes were then connected to the Body 
Stat 1500 (Body Stat UK) before a current was passed between the electrodes at a 
frequency of 50Hz. 
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Limitations 
The human body is not a cylindrical conductor. The tissues are also not electrically 
isotropic and therefore the reactance component of the body's impedance is not 
zero. 
Coefficient of Variation 
The coefficient of variation for this procedure is 3% (n=1 00) (Body Stat, UK) 
The coefficient of variation for this procedure within this laboratory was assessed by 
performing 20 consecutive measurements on the same subject and was determined 
tobeis3% 
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2.5 Body Fat Analysis - Leg to leg Bioelectrical Impedance Body Fat Analysis 
(Tanita Corp, USA) 
Principle of Measurement 
The metal sole plates are each divided into two parts. A weak alternating current is 
passed from the front portion of the two plates, while the voltage drop is measured 
using back portion of the two plates from which the body is impedance is derived. 
As in tetrapolar bioelectrical impedance analysis this the method is based on two 
assumptions. Firstly, the body can be modelled as an isotropic cylindrical conductor 
with its length proportional to the subjects height (Ht). Secondly, the resistance 
component (R) can be considered equivalent to the body impedance (Z). This is 
then used to determine the body density. 
Calculations 
Body density (BD) is calculated from height, weight and impedance using the 
following equations (Jebb et al 2000): 
BD = 1.100696 -0.107903 x Wt x ZJHt2 + 0.00017 xZ 
Wt = Weight (kg) Ht = Height (m) Z= Impedance (S2) 






Subjects were required to empty their bladders before standing for a minimum of 10 
minutes before analysis to minimise potential errors from acute shifts in body fluid 
distribution. Subjects stood on the metal sole plates of the machine in swimwear to 
allow accurate determination of body mass before a current was passed between the 
electrodes at a frequency of 50Hz. 
Limitations 
This method of body composition analysis is limited by the fact that the current 
travels through the path of least resistance and therefore only passes through the 
lower body. Upper body fat therefore must be predicted from lower body fat. As with 
tetrapolar bioelectrical impedance analysis resistance is dependent on hydration 
status. 
Coefficient of Variation 
The coefficient of variation in this laboratory was assessed by completing 30 
consecutive measurements on the same subject and was calculated to be 2% 
2.6 Height 
All measures of height were recorded using a standard wall mounted stadiometer. 
2.7 Body Mass 
All measures of body mass were recorded using TanitaTM BWB-600 weighing scales. 
Subjects were asked to wear minimal clothing for each measurement. 
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2.8 Submaximal and Maximal Fitness Test Using a Modified Bruce Protocol 
Subjects conducted a test of (sub)maximal oxygen uptake using a modified Bruce 
treadmill protocol (see table 2.1). All tests were performed using a standard 
motorised treadmill (Cardiosport Powerjog) 
Table 2.1: Modified Bruce protocol used for the determination of V02 max. 
STAGE SPEED (Km h'') GRADIENT( %) TIME @STAGE 
0 2.7 0.0 3mins 
1 2.7 5.0 3mins 
2 2.7 7.5 3mins 
3 4.0 10.0 3mins 
4 5.4 12.5 3mins 
5 6.7 15.0 3mins 
6 8.0 17.5 3mins 
7 8.8 20.0 3mins 
8 9.6 22.0 3mins 
Expired air was collected through a mouth piece with nose clip via a plastic tube into 
Douglas Bags for the last minute of each stage and analysed for percentage oxygen 
(Servomex 572 Oxygen Analyser), percentage carbon dioxide (Servomex PA404, 
Carbon Dioxide Analyser), and volume (Harvard Dry Gas Meter). Alternatively, 
expired air was collected and analysed using an online system (Cortex Meta Max 
3B). V02 was then calculated using the equation: 
V02 = Volume Expired in 1 minute (L) _% 02 inspired -% 02 Expired 
100 -% C02 expired 
32 
All measurements were corrected to standard temperature and pressure using the 
method of Weir (1949). Heart rate was recorded (Polar Vantage) and ratings of 
perceived exertion were taken using the Borg scale (see table 2.2. ) throughout the 
last minute of each stage. 
For the submaximal fitness test, maximum intensity was achieved when the subjects 
heart rate reached 80% of predicted maximum. Predicted maximal heart rate was 
calculated from the following equation: 
Predicted Maximal Heart Rate (bpm) = 220 - Subject's Age 
For the maximal oxygen uptake test, V02 max was achieved when 3 out the 4 
maximal criteria were met. 
1. A V02 that did not vary over 2 consecutive stages 
2. A heart rate equal to 220 - Subject's age 
3. A rating of perceived exertion using the Borg Scale over 18 for 2 consecutive 
stages 
4. An RER equal or greater than 1.1 
At the end of each test subjects were required to walk for 5 minutes at stage 1 of the 
protocol to act as a cool down. 
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2.9 Ratings of Perceived Exertion 
Ratings of perceived exertion were collected in the last minute of each stage of the 
oxygen uptake test using the Borg scale of perceived exertion (Borg 1982). 
Table 2.2: The Borg scale of perceived exertion 
NUMERIC RATING OF YOUR DESCRIPTION OF YOUR 
EXERTION EXERTION 
6 NONE 
7 VERY, VERY LIGHT 
8 
9 VERY LIGHT 
10 
11 FAIRLY LIGHT 
12 




17 VERY HARD 
18 
19 VERY, VERY HARD 
20 
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2.10 Blood Sampling Procedures 
2.10.1 Venepuncture 
All venepuntures were performed after 5 minutes of venous occlusion at 100 mmHg 
with a standard sphygmometer cuff. Cuff sizes were determined after measurement 
of arm circumference at the midpoint between the acromomion and the medial 
epicondyle of the humerous and classed according to the manufacturers instructions. 
Sampling was performed using a closed vaccutainer system. Sodium citrate 
samples were withdrawn first followed by no additives samples and then EDTA 
samples. All venepuncture blood samples were taken following a single 
venepuncture to standardise for the effect of venous occlusion and venepuncture. 
2.10.2 Cannulation 
Cannulations were performed using a standard 21G Venflon' cannula after 5 
minutes of venous occlusion at 100 mmHg with a standard sphygmomometer cuff. 
Prior to each sample a 2.5ml bolus of non-heparinised isotonic saline was 
administered. A3 ml blood sample was then withdrawn using a standard 5ml syringe 
and discarded. Blood samples were then withdrawn using standard 10 ml syringes 
before a final 2.5ml bolus of non-heparinised isotonic saline was administered. 
Samples were then divided among vaccutainers with sodium citrate samples being 
taken first followed by no additives samples and finally EDTA samples. Cannulations 
were all performed after a single attempt to reduce the effect of venous occlusion and 
venepuncture. 
2.10.3 Mean Arterial Pressure 
Mean arterial pressure was calculated using the following equation: 
((Systolic Pressure - Diastolic Pressure) + 3) + Diastolic Pressure 
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2.11 Calculation of Procedure Coefficient of Variation 
A single sample was taken from a volunteer and divided into equal aliquots. Samples 
were then assayed at various points across a sample run, or in various wells within a 
single ELISA plate and over several different ELISA plates. Coefficients of variation 
were then calculated as: 
Coefficient of Variation = (Standard Deviation / Mean) *100 
Data is reported for each procedure including the number of samples 
All assays were performed in the laboratories at the University of Hertfordshire 
unless otherwise stated. 
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2.12 Total Cholesterol - Beckman Synchron CX Systems Procedure 467825 
L&D Pathology Department 
Procedure 
Blood samples (2ml) were collected in tubes containing no additives or 
anticoagulants. The samples were centrifuged (IEC CL3) for 10 minutes at 3000 rpm 
and the serum separated. The serum was separated and analysed immediately. 
This assay was performed and analysed by Synchron CX automated system and 
was read at a wavelength of 520nm with a blank (isotonic saline) and a standard (7 
mmol/I). 
Principle of the Assay 
Cholesterol esters are enzymatically hydrolysed in a reaction catalysed by 
cholesterol Esterase (CE) to form cholesterol and free fatty acids. Free cholesterol in 
the serum and the resultant cholesterol are then oxidised by Cholesterol Oxidase to 
Cholestene-3-one and Hydrogen Peroxide (H202). Finally in a reaction catalysed by 
Peroxidase the H202 reacts with 4-aminoantipyrine (4AAP) and Phenol to produce a 
Quinoeimine dye. The absorbance of this dye at 520nm is proportional to the 
concentration of cholesterol in the sample. 
Cholesterol Esters Cholesterol Esterase Cholesterol + Free Fatty Acids 
10 
Cholesterol + O2 Cholesterol Oxidase, Cholestene-3-one + H202 
2 H2O2+ 4AAP + Phenol Peroxidase Quinoeimine Dye + H2O 10 
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Calculation of Results 
The results were calculated as follows: 
Cholesterol Concentration (mmoVI) 
= 
1Absorbance 
of Unknown X Standard Concentration X 0.0259* 
Absorbance of Standard 
* 0.0259 equals the molecular weight of Cholesterol 
Limitations 
This assay is linear up to 19.4 mmol/I with a sensitivity of 0.01 mmoVl 
Coeff icient of Variation 
The coefficient of variation for this procedure is 3.0 % (n=40) (Beckman Synchron 
Systems) 
The coeff icient of variation for this procedure within this laboratory is 1 69 % (n=20) 
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2.13 HDL Cholesterol (EZ HDL Method) Sigma Diagnostics Procedure 354L 
L&D Pathology Department 
Procedure 
Blood samples (2ml) were collected in tubes containing no additives or anticoagulant. 
The samples were then centrifuged (IEC CL3) for 10 minutes and the serum 
separated. This was then analysed immediately. Analysis was performed using a 
Beckman Synchron Automated system and read at a wavelength of 600nm with a 
blank (isotonic saline) and a standard (4 mmol/I). 
Principle of the Assay 
Anti human ß-lipoprotein antibody bind to lipoproteins (Chylomicrons, VLDL & LDL) 
other than HDL. The antigen antibody complexes formed block cholesterol esterase 
(CE) and cholesterol oxidase (CHO) reactions. When these enzymes are added they 
react with HDL cholesterol to form cholestenone, fatty acid, and hydrogen peroxide 
(H202). H202 yields a blue colour complex upon oxidase condensation with FDAOS 
(N-ethyl-N- (2-hydroxy-3-su lp hop ropyl) -3,5-dimethoxy-4-fluoroanaline, sodium salt) 
and 4AAP (4-aminoantipyrine) in the presence of peroxidase. The Absorbance of this 
blue product at 600nm is proportional to the HDL concentration in the sample. 
LDL, VLDL, Chylomicrons Anti human 0 lipoprotein antibody Ag / Ab complex 
HDL Cholesterol + H2O + 02 CHE & CO Cholestenone + Fatty Acid + H202 
H202 + FDAOS + 4AAP Peroxidase Blue Colour Complex 
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Calculation of Results 
The results were calculated as follows: 
HDL Concentration Absorbance of Unknown X Standard ConcentrJa ion X 0.0259 
(mmol/I) Absorbance of Standard 
Limitations 
This assay is linear up to 4.66 mmol/I with a sensitivity of 0.026 mmol/I 
Coefficient of Variation 
The coeff icient of variation for this procedure is 0.98 % (n=90) (Sigma Diagnostics) 
The coefficient of variation for this procedure within this laboratory is 1.2 % (n=20) 
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2.14 Triglyceride - (GPO) Beckman Synchron CX Systems Procedure 445850 
L&D Pathology Department 
Procedure 
Blood samples (2ml) were collected in tubes containing no additives or 
anticoagulants. The samples were centrifuged (I EC CL3) for 10 minutes at 3000 rpm 
and the serum separated. The serum was separated and analysed immediately. 
This assay was performed and analysed by Synchron CX automated system and 
was read at a wavelength of 520nm with a blank (isotonic saline) and a standard (2.2 
mmol/I). 
Principle of the Assay 
Triglycerides are enzymatically hydrolysed by lipase to free fatty acids and glycerol. 
The glycerol is then phosphorylated by ATP in a reaction catalysed by glycerol 
kinase (GK) to produce glycerol 3 phosphate (G3P) and ADP. The G3P is then 
oxidised to form dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H202) 
catalysed by glycerol phosphate oxidase (GPO). Finally in a reaction catalysed by 
peroxidase the H202 reacts with 4-aminoantipyrine (4AAP) and 3,5 dichloro 2 
hydroxybenzene sulphonate (3,5 DHBS) to produce a red quinoeimine dye. The 
absorbance of this dye is proportional to the concentration of triglycerides in the 
sample. 
Triglycerides + H2O Lipase Glycerol + Free Fatty Acids 
Glycerol + ATP Glycerol Kinase + Mg 2+ Glycerol 3 Phosphate + ADP 
Glycerol 3 Phosphate + 02 Glycerol Phosphate Oxidase DAP + H202 
1101 
H202+ 4AAP + 3,5 DHBS Peroxidase Quinoeimine Dye + HCL + 2H20 10. 
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Calculation of Results 
The results were calculated as follows: 
Triglyceride Concentration (mmoVl) 
= Absorbance of Unknown X Concentration oX0.0113* 
Absorbance of Standard Standard 
*0.0113 equals the molecular weight of Triglyceride 
Limitations 
a, 
This assay is linear up to 11.3 mmol/I with a sensitivity of 0.04 mmoVl 
Coefficient of Variation 
The coefficient of variation for this procedure is 3.0 % (n=40) (Beckman Synchron 
Systems) 
The coefficient of variation within this laboratory is 0.9% (n=20) 
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2.15 LDL Cholesterol 
LDL cholesterol was calculated using the Friedewald equation: 
LDL Cholesterol (mmol/L) 
= Total Cholesterol (mmol/I) - 
1(Triplyceride 
(mmol/I) 1+ HDL(mmol/I) 2.19 
/ 
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2.16 Total Plasminogen Activator Inhibitor (PAI-1) Technoclone ELISA 
Procedure TC 12075 
Procedure 
Blood samples (3ml) were collected in tubes containing sodium citrate as an 
anticoagulant. The samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the plasma separated and stored in eppendorf tubes at -80°C until analysis. 
All samples were analysed within 3 hours of thawing and the plate was read at 
450nm with a blank and 4 standards (10,30,55.5 & 89 ng/ml). 
Principle of the Assay 
The plate is pre-coated with antihuman PAI-1 monoclonal antibodies (stage 1) to 
which the plasma PAI-1 antigen binds (stage 2). A peroxidase (POX) linked anti PAI- 
1 antibody was then added to bind to the plasma PAI-1 antigen (stage 3). The 
enzyme substrate, Tetramethylbenzidine (TMB) containing H2O2 is then added and 
results in the formation of a blue colour complex (stage 4). Finally the enzyme 
reaction is stopped with sulphuric acid and the reaction causes formation of a yellow 
product. The plate is read at 450nm and the absorbance of each well at 450nm is 
proportional to the concentration of PAI-1 in the sample 
Anti PAI-1 Plasma POX Conjugated Substrate 
Anti PAI-1 
YYY 
Stage 1 Stage 2 Stage 3 Stage 4 
Monoclonal Antibody PAI-1 Ag in plasma Enzyme-linked Ab binds Addition of substrate. 
is bound to the plate binds Ab on plate proportionally to PAI-1 Ag 
Y 
Anti-PAI-1 Ab = PAI-1 Ag W--( =POX-conjugated anti-PAI-1 Ab 
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Calculation of Results 
Sample concentrations were determined from a graph of standard solutions of PAI-1 
concentration Vs absorbance. 
Limitations 
This method measures total PAI-1 (free, complexed and latent PAI-1). 
Coefficient of Variation 
The coeff icient of variation for this procedure is 5% (Technoclone) 
The coeff icient of variation for this procedure within this laboratory is 4.3% (n=15) 
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2.17 Imulyse PAI-1 Biopool International ELISA procedure 101005 
Procedure 
Blood samples (3ml) were collected in tubes containing sodium citrate as an 
anticoagulant. The samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the plasma separated and stored in eppendort tubes at -80°C until analysis. 
All samples were analysed within 3 hours of thawing and the plate was read at 
492nm with a blank and 5 standards (100,75,50,25,12.5 ng/ml). 
Principle of the Assay 
This assay utilises the double antibody principle utilising both quenching and normal 
antibodies as a control for PAI-1 specificity. This excludes false positives which are 
not uncommon in conventional PAI-1 ELISAs. The plate is coated with goat anti- 
human PAI-1 immunoglobulin (stage 1) and incubated for 16-18 hours. Normal goat 
immunoglobulin is added to odd numbered columns (A) and goat anti-human PAI-1 
immunoglobulin is added to even numbered columns (N) (stage 2). The plasma 
samples are then added and the plasma PAI-1 binds to the antibody (stage 3). 
Horseradish peroxidase labelled goat anti-human t-PA IgG is added and binds to a 
second site on the plasma PAI-1(stage 4). The enzyme substrate (OPD) is then 
incubated for 30 minutes (stage 5) before the reaction is stopped by addition of 
H2SO4. Finally, the plate is read at a wavelength of 492 nm. 
Anti PAI-1 Goat Anti Plasma POX linked Substrate 






y-0 7ý\ y 
NN 
YY 
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
Plate coated Goat Ag added to odd PAI-1 antibody Enzyme linked Addition of substrate. 
with anti PAI-1 `N' columns binds to antigen antibody binds Change in absorbance 
AB Anti PAI-1 added to on plate proportionally ti proportional to bound 
even `A' columns PAI-1 PAI-1 
-=anti PAI-1 0= goat IgG = plasma PAI-1 = enzyme linked antibody 
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Calculation of Results 
The difference between the "N" value and "A" value is calculated for each standard 
and sample. This represents the t-PA specific part of the response and is denoted 
AA. The AA value of each of the standards is plotted against their known 
concentration and a straight line is fitted to the points using a minimal least square 
procedure. The function of this line is used to calculate the PAI-1 concentration of 
the plasma samples. 
Limitations 
This assay measures only free and latent PAI-1 (not t-PA/PAI-1 complexes) 
The detection limit is 50 ng/ml 
The sensitivity of the assay is 0.9 ng/ml 
Coefficient of Variation 
The coefficient of variation for this assay is 5% (Biopool International) 
The coefficient of variation for this assay in our laboratory is 4% (n=20) 
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2.18 Active Plasminogen Activator Inhibitor (PAI-1) Technoclone ACTIBIND 
Procedure TC 16075 
Procedure 
Blood samples (3ml) were collected in tubes containing sodium citrate as an 
anticoagulant. The samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the plasma separated and stored in eppendorf tubes at -80°C until analysis. 
All samples were analysed within 3 hours of thawing and the plate was read at 
450nm with a blank and 4 standards (7,15,34,70 ng/ml). Control samples were 
used to determine the acccuracy of the procedure. 
Principle of the Assay 
The Actibind test is a solid phase enzyme immunoassay in which an anti-t-PA 
monoclonal antibody is utilised to immobilise t-PA onto a 96 well plate (stage 1). The 
t-PA active site remains exposed and was used to bind active PAI-1 (stage 2). A 
POX linked monoclonal antibody, which recognises a specific site on the PAI-1 
molecule, was incubated simultaneously incubated with the plasma sample (stage 3). 
Unbound POX labelled PAI-1 was washed away and Tetramethylbenzidine (TMB) 
containing H2O2 was then added resulting in the formation of a blue colour complex 
(stage 4). Finally the enzyme reaction is stopped with sulphuric acid and the reaction 
causes formation of a yellow product. The plate is read at 450nm and the 
absorbance of each well at 450nm is proportional to the concentration of active PAI-1 
t-PA bound to Plasma 
Anti t-PA Ab 
Stage 1 
Monoclonal t-PA 
antibody is bound to 
plate. T-PA binds to 
antibody 
Stage 2 
Plasma added and 
active PAI-1 binds to 
t-PA 
t-PA bound to t-PA El = Active 




POX labelled anti PAI- 
1 antibody added. 




Addition of substrate. 
Change in absorbance 
at 450 nm is 
proportional to active 
PAI-1 concentration 
POX labelled anti 
= PAI-1 antibody 
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Calculation of Results 
The standard solutions were used to create a graph of active PAI-1 concentration Vs 
absorbance from which sample concentrations could be determined. 
Limitations 
This method exclusively measures free, active PAI-1 and is not affected by other 
forms of PAI-1. The assay range is 1-70 U/ml. 
Coefficient of Variation 
The coefficient of variation for this procedure is 5% (n=20 Technoclone) 
The coefficient of variation for the assay in this laboratory is 5% (n=20) 
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2.19 Tissue Plasminogen Activator (T-PA) Technoclone ELISA 
Procedure TC 12075 
Procedure 
Blood samples (3ml) were collected in tubes containing sodium citrate as an 
anticoagulant. The samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the plasma separated and stored in eppendorf tubes at -80°C until analysis. 
All samples were analysed within 3 hours of thawing and the plate was read at 
450nm with a blank and 4 standards (4.5,10.5,24.5 & 30 ng/ml). 
Principle of the Assay r' 
The plate is pre coated with antihuman T-PA monoclonal antibodies (stage 1) to 
which the plasma T-PA antigen binds (stage2). A POX linked anti T-PA antibody then 
added to bind to the plasma T-PA antigen (stage 3). The enzyme substrate, 
Tetramethylbenzidine (TMB) containing H202 is then added and results in the 
formation of a blue colour complex (stage 4). Finally the enzyme reaction is stopped 
with sulphuric acid and the reaction causes formation of a yellow product. The plate 
is read at 420nm and the absorbance of each well at 420nm is proportional to the 
concentration of T-PA in the sample. 
Anti T-PA Plasma POX Conjugated Substrate 
Anti T-PA 
Y Y Y Y 
Stage 1 Stage 2 Stage 3 Stage 4 
Monoclonal Ab is bound T-PA Ag in plasma Enzyme-linked Ab Addition of 
to the plate binds to Ab proportionally binds substrate. Change in 
to t-PA Ag absorbance 
proportional to 
enzyme bound 
Y= Anti-T-PA Ab = T-PA Ag %/* =POX-conjugated anti-T-PA Ab 
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Calculation of Results 
The standard solutions were used to create a graph of T-PA concentration Vs 
absorbance and the sample concentrations were read off from there. Control 
samples were also used to determine the accuracy of the procedure. 
Limitations 
This method measures total T-PA (free, &complexed). 
Coefficient of Variation 
The coefficient of variation for this procedure is 5% (Technoclone) 
The coefficient of variation for the procedure within this laboratory is 4.2% (n=15) 
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2.20 Imulyse T-PA Biopool International ELISA procedure 101005 
Procedure 
Blood samples (3ml) were collected in tubes containing sodium citrate as an 
anticoagulant. The samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the plasma separated and stored in eppendorf tubes at -80°C until analysis. 
All samples were analysed within 3 hours of thawing and the plate was read at 
492nm with a blank and 7 standards (1.5,3,6,12,18,24,30 ng/ml). 
Principle of the Assay 
This assay utilises the double antibody principle utilising both quenching and normal 
antibodies as a control for t-PA specificity this excludes false positives which are not 
uncommon in conventional t-PA ELISAs. The plate is coated with goat anti-human t- 
PA immunoglobulin (Ig) (stage 1) and incubated for 16-18 hours. Normal goat Ig is 
added to odd numbered columns (A) and goat anti-human t-PA Ig is added to even 
numbered columns (N) (stage 2). The plasma samples are then added and the 
plasma t-PA binds to the antibody (stage 3). Horseradish peroxidase labelled goat 
anti-human t-PA IgG is added and binds to a second site on the plasma t-PA (stage 
4). The enzyme substrate (OPD) is then incubated for 30 minutes (stage 5) before 
the reaction is stopped by addition of H2SO4. Finally, the plate is read at a 
wavelength of 492 nm. 
Goat Anti POX linked 





Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
Plate coated Goat Ag added to odd T-PA antibody Enzyme linked Addition of substrate. 
with anti T-PA 'N' columns binds to antigen antibody binds Change in absorbance 
AB Anti T-PA added to on plate proportionally to proportional to bound 





40 = goat IgG = 
ý 
plasma t-PA = enzyme lin ked Ab 
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Calculation of Results 
The difference between the "N" value and "A" value is calculated for each standard 
and sample. This represents the t-PA specific part of the response and is denoted 
AA. The AA value of each of the standards is plotted against their known 
concentration and a straight line is fitted to the points using a minimal least square 
procedure. The function of this line is used to calculate the t-PA concentration of the 
plasma samples. 
Limitations 
This procedure measures both free and complexed t-PA and has a sensitivity of 1.5 
ng/ml. This assay is accurate in the range of 1.5-30 ng t-PA/mi. Samples with a t-PA 
concentration >30 ng/mI were diluted. 
Coefficient of Variation 
The coefficient of variation for this procedure is 8% (Biopool International) 
The coefficient of variation for this procedure in this laboratory is 6% 
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2.21 Von Willebrand Factor (vWF) In House ELISA Procedure HCVWF 
Addenbrookes Hospital Coagulation Department 
Procedure 
Blood samples (3ml) were collected in tubes containing sodium citrate as an 
anticoagulant. The samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the plasma separated and stored in eppendorf tubes at -80°C until analysis. 
All samples were analysed within 3 hours of thawing and the plate was read at 
450nm with a blank and 6 standards (0.2,0.4,0.6,0.8,1.0 & 2.0 IU/ml). 
Principle of the Assay 
The plate is coated with antihuman vWF monoclonal antibodies (stage 1) to which 
the plasma vWF antigen binds (stage2). A peroxidase linked anti vWF antibody then 
added to bind to the plasma vWF antigen (stage 3). The enzyme substrate (OPD) 
with H202 is then added and results in the formation of a orange colour complex 
(stage 4). Finally the enzyme reaction is stopped with sulphuric acid and the reaction 
causes formation of a yellow product. The plate is read at 420nm and the 
absorbance of each well is proportional to the concentration of vWF in the sample. 







Stage 1 Stage 2 Stage 3 Stage 4 
Monoclonal Ab is VWF Ag in plasma Enzyme linked Ab Addition of substrate. 
bound to plate binds to Ab on plate binds proportionally to Change in absorbance 
vWF Ag is proportional to vWF 
bound 
Y= 
Antibody O= plasma vWF }-ý = POX conjugated anti-vWF Ab 
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Calculation of Results 
The standard solutions were used to create a graph of vWF concentration Vs 
absorbance and the sample concentrations were read off from there 
Limitations 
This method measures total vWF 
Coefficient of Variation 
The coefficient of variation for this procedure is 6% (Addenbrookes Hospital) 
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2.22 Immunozym vWF: Ag ELISA. Immuno Ag procedure 5450200 
Procedure 
Blood samples (3ml) were collected in tubes containing sodium citrate as an 
anticoagulant. The samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the plasma separated and stored in eppendorf tubes at -80°C until analysis. 
All samples were analysed within 3 hours of thawing and the plate was read at 
450nm with a blank and 5 standards (0.07,0.5,0.9,1.1 & 1.5 IU/ml). 
Principle of the Assay 
Plates are first coated with polyclonal anti-vWF antibodies (stage 1). Diluted plasma 
samples are then incubated in the test wells and plasma vWF binds to the antibodies 
(stage 2). An anti-vWF-peroxidase conjugate is then added which bind to an 
alternative site on the plasma vWF (stage 3). Finally H202 is added as a substrate 
for the peroxidase (stage 4). The reaction is stopped with sulphuric acid and the plate 
is read at a wave length of 450 nm. 
Anti vWF Plasma POX Conjugated Substrate 
Anti vWF 4 
0 
Stage 1 
Monoclonal Ab is 
bound to plate 
Oý-* 
. 
Stage 2 Stage 3 Stage 4 
VWF Ag in plasma Enzyme-linked Ab binds Addition of substrate. 
binds to Ab proportionally to vWF ag Change in absorbance 
proportional to vWF 
bound 
= vWF Ag>--* =POX-conjugated anti-VWF Ab 
y= 
Anti-VW F Ab 
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Calculation of Results 
The standard solutions were used to create a graph of vWF concentration Vs 
absorbance and the sample concentrations were read off from there. Control 
samples were also used to determine the accuracy of the procedure. 
Limitations 
This method measures total vWF Ag 
The sensitivity of this assay is 0.05 IU/ml 
Coefficient of Variation 
The coeff icient of variation for this procedure is 4% (Immuno AG) 
The coeff icient for this procedure in this laboratory is 5% 
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2.23 Insulin In house DELFIA Time Resolved Flurometric Assay, 
Addenbrookes Hospital Cambridge 
Procedure 
Blood samples (2ml) were collected in tubes containing no additives or 
anticoagulants. Samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the serum separated and stored in eppendorf tubes at -20°C until analysis. 
All samples were analysed within 3 hours of thawing. 
Principle of the Assay 
Plastic balls are coated with a first anti human antibody (stage 1). The serum 
samples are the incubated with coated balls and the insulin antigen binds to the 
antibody (stage 2). A second antihuman antibody labelled with fluorescent Europium 
is then incubated with the samples (stage 3). Finally, the fluorescence is measured 
















Europium labelled antibody 
binds to serum insulin. 
Fluorescence measured 
Q =Plastic Coated ý/ =Antibody 1, =Insulin Europium Labelled Balls I Antigen Antibody 2 
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Limitations 
The limit of detection for this procedure is 1.3 pmoVL 
The assay range is 1100 pmol/L 
The cross reactivity with proinsulin is 0.0005% 
Coefficient of Variation 
The coefficient of variation for this procedure is 3.1 % (n=20) (Department of 
Biochemistry, Addenbrookes Hospital, Cambridge). 
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2.24 Insulin Microparticle Enzyme Immunoassay (MEIA) Imx Systems 
L&D Pathology Department 
Procedure 
Blood samples (2ml) were collected in tubes containing no additives or 
anticoagulants. Samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the serum separated and stored in eppendorf tubes at -20°C until analysis. 
All samples were analysed within 3 hours of thawing. This is an automated procedure 
performed at the department of Biochemistry Luton and Dunstable NHS Trust 
Hospital. 
Principle of the Assay 
A probe/electrode assembly delivers the sample, anti-insulin coated microparticles 
and assay buffer into the incubation well of the reaction cell forming an anti-insulin / 
serum insulin complex. An aliquot of the anti-insulin / serum insulin coated 
microparticles is then transferred to a glass fibre matrix which is then washed to 
remove unbound materials. An anti- insulin / alkaline phosphatase conjugate is then 
dispensed onto the matrix and binds to the coated microparticles. Finally, the 
substrate (4-methylumbelliferryl phosphate) is added to the matrix yielding a 
fluroescent product which is measured by the MEIA optical assembly. 
Stage 1 
Serum sample + buffer added to 
anti-insulin coated 
microparticles. Serum Insulin 
binds forming anti-insulin / 
C serum complex 









Anti-insulin / enzyme 
conjugate added which 







Enzyme substrate added. 
Resulting f luroescence 
proportional to insulin in 
serum sample 
= Antibody 1T =anti-insulin / enzyme 
conjugate 




This assay is linear to 30µU/ml with a sensitivity of 1.0µU/mI. The specificity of the 
assay is unaffected by triglyceride concentrations <1600 mg/dL and haemoglobin 
<400 mg/dL. The cross reactivity of this assay with proinsulin is 0.005%. there is no 
detectable cross reactivity with either C-peptide (1000 ng/ml ) or glucagon (1,000,000 
pg/ml). 
Coeff icient of Variation 
The coeff icient of Variation for this procedure is 4% (n= 432, lmx ltd) 
The coefficient of variation for this procedure in the Dept Biochemistry, Luton & 
Dunstable NHS Trust Hospital is 3.5% (n=1 0). 
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2.25 Leptin In house DELFIA Time Resolved Flurometric Assay 
Addenbrookes Hospital Cambridge 
Procedure 
Blood samples (2ml) were collected in tubes containing no additives or 
anticoagulants. Samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the serum separated and stored in eppendorf tubes at -20°C until analysis. 
All samples were analysed within 3 hours of thawing. 
Principle of the Assay 
Plastic balls are coated with a first anti human antibody (stage 1). The serum 
samples are the incubated with coated balls and the leptin antigen binds to the 
antibody (stage 2). A second antihuman antibody labelled with fluorescent Europium 
is then incubated with the samples (stage 3). Finally, the fluorescence is measured 






Stage 1 Stage 2 Stage 3 
First Anti-Human Serum Leptin Europium labelled antibody 
antibody is coated onto antigen binds to the binds to serum leptin. 
plastic balls antibody Fluorescence measured 
= 
0 
=Plastic Coated ý/ =Antibody 1 =Leptin 
Europium 
Labelled 





The limit of detection for this procedure is 0.5 ng/ml 
The assay range is 100 ng/ml 
Coefficient of Variation 
The coefficient of variation for this procedure is 10.2 % (n=50) (Department of 
Biochemistry, Addenbrookes Hospital, Cambridge). 
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2.26 Quantikine Human Leptin ELISA (Kit No DLP00 R&D Systems) 
Procedure 
Blood samples (2ml) were collected in tubes containing no additives or 
anticoagulants. Samples were then centrifuged (IEC CL3) for 10 minutes at 3000 
rpm and the serum separated and stored in eppendorf tubes at -20°C until analysis. 
All samples were analysed within 3 hours of thawing and read at a wave length of 
450nm with a blank and 7 standards (15.6,31.2,62.5,125,250,500 & 1000 pg/ml). 
Principle of the Assay 
This assay employs a quantitative sandwich enzyme immunoassay technique. A 
murine monoclonal antibody specific for leptin was coated onto a standard 96 well 
microtitre plate (stage 1). 100 X diluted plasma samples were then incubated in the 
test wells and serum leptin bound to the immobilised antibodies (stage 2). A further 
enzyme linked, anti-leptin antibody was then added binding to an alternative site on 
the serum leptin (stage 3). Finally a substrate for the enzyme was added (stage 4). 
The reaction is stopped with sulphuric acid and the plate read at a wave length of 
450nm. 






Stage 1 Stage 2 Stage 3 Stage 4 
Monoclonal antibody Leptin-antigen in plasma enzyme-linked antibody addition of substrate. 
Is bound to plate binds to antibody on binds proportionally to change in absorbance 
on plate leptin-antigen is proportional to 
Y= Anti-leptin Ab = leptin Ag = conju 
enzyme bound 
gated anti-leptin Ab 
64 
Calculation of Results 
The standard solutions were used to create a graph of leptin concentrations Vs 
absorbance and sample concentrations were read off from there. 
Limitations 
The sensitivity of this assay is 7.8pg/mI 
This assay is linear to 1000 pg/ml 
Coefficient of Variation 
The coefficient of variation of this assay is 3.2% (R&D Systems ltd) (n=20) 
The coefficient of variation for this procedure within this laboratory is 4.2% (n=20) 
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2.27 Haemoglobin (Azidemethaemoglobin Method) Hemocue Sweden 
Procedure 
Blood samples (2ml) were collected in tubes containing TriPotassium EDTA as an 
anticoagulant and were well mixed. Whole blood was analysed immediately and read 
at a wavelength of 570nm. (Hemocue, Angelholm, Sweden). 
Principle of the Assay 
Haemoglobin is released from the erythrocytes by sodiumdeoxycholate. The 
haemoglobin is then methylated by nitrite to form methaemoglobin. This is then 
reacted with sodium azide to form the coloured compound azidemethoglobin. The 
absorbance of this compound at 570nm is proportional to the amount of haemoglobin 
in the sample. 
Erythrocytes + Sodiumdeoxycholate 10 Haemoglobin 
Haemoglobin + N02 Methaemoglobin 
Methaemoglobin + N3' 10 Azidemethaemoglobin 
Limitations 
This procedure is accurate from 0 to 25.6 g/dI with a sensitivity of 0.1 g/dl 
Coefficient of Variation 
The coeff icient of variation for this procedure is 1.5% (Hemocue) 
The coefficient of variation for this procedure within our laboratory is 0.98% 
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2.28 Haemoglobin (Azidemethaemoglobin Method) GDS Technology Inc UK. 
Procedure 
Blood samples (2ml) were collected in tubes containing TriPotassium EDTA as an 
anticoagulant and were well mixed. Whole blood was then analysed immediately 
and read using 470 nm (Hemosite, GDS, Indiana USA) with a standard of (15 g/dI) 
Principle of the Assay 
Haemoglobin (Hb) is first methylated to methaemoglobin (mHb) by the actions of 
sodium nitrite. The methehaemoglobin is then converted to coloured 
azidemethaemoglobin (AMHb) in a reaction with sodium azide. The absorbance of 
the azidemethaemoglobin at 470nm is proportional to the haemoglobin 
concentration. 
Haemoglobin + Sodium Nitrite 10 Methaemoglobin 
Methaemoglobin + Sodium Azide--- 0, Azidemethaemoglobin (Colour) 
Calculations 
Concentration of Hb (g/I) 
1Absorbance 
of Unknown X Concentration of Standard 
Absorbance of Standard 
Limitations 
This procedure is linear from 8.0 g/l to 17.0 g/dl with a sensitivity of 0.1 g/dl. 
Coefficient of Variation 
The coefficient of variation for this assay is 3.5 % (n=20) (GDS Technology Inc) 
The coeff icient of variation for this assay within this laboratory is 1.2% 
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2.29 Haematocrit (Microhaematocrit Method) Hawksley UK 
Procedure 
Blood samples (2ml) were collected in tubes containing TriPotassium EDTA as an 
anticoagulant and were, well mixed. The samples were then transferred to 3 
haematocrit capillary tubes and sealed with Cristaseal (Hawksley, Lancing, Sussex). 
The samples were then centrifuged at 12,000 rpm for 10 minutes. The separated 
samples were read using a Microhaematocrit reader (Hawksley, Lancing, Sussex) 
and the results expressed as the percentage of total volume taken up by 
erythrocytes. 
2.30 Plasma Volume Calculations 
Plasma volume was calculated according to the method of Dill & Costhill (1974) 
which calculates plasma volume changes using both haemoglobin (Hb) and 
haematocrit (Hct) and thus prevents distortion of the results by changes in red cell 
volume. 
Calculation: 
A= New Result 
B= Baseline Result 
A BV % =100 (BVA - BVB) / BV8 
A CV %= 100 (CVA- CVB) / CVs 
ePV%= 100 (PVA - PVB) / PVB 
Where: 
BVB=100 
BVA = BVB (HbB / HbA) 
CVA = BVA (HctA) 
PVA = BVA - CVA 
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2.31 Other Methods 
Measurements of both TNFa and platelet aggregation were attempted. In both cases 
the variability in the baseline measurements between subjects and more importantly, 
within subjects were too great for meaningful results to be gained. 
Table 2.3: Coefficient of Variations for platelet aggregation and TNFc 
Marker Between Subject Within Subject Number of Subjects 
C. V. (%) C. V. (%) 
Platelet Aggregation 42 32 12 
TNF a 31 28 15 
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Chapter 3: Reliability of body fat assessment: a comparison of three commonly 
used techniques. 
3.1 Introduction 
There is growing interest in the measurement of body composition, in particular the 
assessment of fat mass. Body composition is of interest to obesity researchers 
because of the impact of total body fat and body fat distribution on the metabolic 
profile. The only direct methods of body fat assessment are by post mortem analysis 
and neutron activation analysis but many indirect methods have been developed 
including bioelectrical impedance (BIA), air displacement plethsymography (ADP), 
computer topography (CT), magnetic resonance imaging (MRI) and dual energy x- 
ray absorptiometry (DEXA). Indirect methods are by definition based on 
assumptions and are therefore subject to error. Common sources of error in ADP 
and BIA are subject hydration status, disease and medication (Jebb et al 2000). 
New body composition techniques are frequently compared to `gold standard' indirect 
methods such as MRI and underwater weighing as well as undergoing repeatability 
studies. Little information is available however, on day to day variation in body 
composition measurements for researchers undertaking intervention trials such as 
exercise training or caloric restriction studies. 
The aim of this study therefore is to assess the variation in body fat measurement as 
analysed by three different methods on three consecutive days to calculate the error 
that must be taken into- account when analysing body composition data in 
intervention trials. 
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3.2 Subjects and Methods. 
Ten subjects (5 male &5 female) reported to the laboratory at 9 am on 3 consecutive 
days. Subjects were fasted for a minimum of 6 hours and each emptied their bladder 
immediately prior to the start of measurements. 
Height and Weight: Weight was measured with subjects in swimwear to the nearest 
1 Og using a digital scale and height was measured to the nearest 5mm using a wall 
mounted stadiometer. Height was measured on the first session only and used in all 
subsequent body composition measurements. 
3.2.2 Air displacement plethsymography: 
ADP was measured using the BODPOD (Life Measurement Instruments, California 
USA) The BODPOD was first calibrated according to manufacturer's instructions 
using a 50 litre cylinder. Subjects were seated in the chamber, wearing close fitting 
swimwear and swim cap, for two cycles. If the two measures of volume differed by < 
0.2% then the result was accepted. If the two results differed by >0.2% then the 
machine was recalibrated and the measurement repeated (as per manufacturers 
guidelines). The results were calculated based on predicted rather than measured 
lung volumes. 
3.2.3 Tetrapolar bioelectrical impedance analysis: 
Tetrapolar bioelectrical impedance analysis was measured using the Bodystat 1500 
system (Bodystat, Dougals, Isle of Man, UK) with electrodes placed at the standard 
sites on the hand and foot. The location of the electrodes were measured and 
recorded for accuracy of subsequent measurements. Subjects remained supine for 
15 minutes before analysis to minimise potential errors from acute shifts in body 
water distribution. Body fat was calculated according to the equation provided by the 
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manufacturer. Exercise levels included in the calculation were standardised as 
medium for all subjects. 
3.2.4 Leg- to-leg bioelectrical impedance analysis: 
Leg-to leg bioelectrical impedance analysis was measured using the Tanita-305 body 
fat analyser (Tanita Corp, IL, USA). Subjects stood on the metal sole plates of the 
machine in their swimwear. Measurements were made after a 10 min period of 
standing to minimise potential errors from acute shifts of body water. Fat mass was 
calculated according to manufacturer's equations. Subjects were standardised as 
non athletes regardless of exercise habits. 
3.2.5 Statistical Analysis: 
Reliability of estimating %body fat was determined by calculation of the coefficient of 
variation (CV) for repeated measures. To determine whether there was a significant 
difference between CV the non-parametric Wilcoxon sign-rank test was used. The 
first, second and third trial within each method were compared using a one way 
analysis of variance. All data is reported as mean ± SEM 
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3.3 Results 
Ten subjects (5 male &5 female) of a variety of body weights (range 65.2 -102.7 kg) 
completed the study. There were no significant differences between days for any of 
the methods of body composition analysis (Body mass P= 0.882, BODPOD P=0.822, 
BodyStat P=0.809, Tanita P= 0.778). The between trial CV were: body mass 0.35% 
± 0.22 BODPOD, 2.21% ± 0.46%, BodyStat, 2.49% ± 0.64% and Tanita, 2.42% ± 
0.43%. This reflects a body fat percentage variation of 0.70% for the BODPOD, 
0.77% for the BodyStat and 0.73% for, the Tanita. There were no significantly 
differences in the amount of variation between the three methods of body 
composition analysis but, there was significantly less variation in body mass (P= 0.02 
Body Mass Vs BODPOD, P=0.04 Body Mass Vs Tanita, P=0.04 Body Mass Vs Body 
Stat). 
3.4 Discussion 
The reliability of all three methods over the three days was found to be excellent in a 
variety of subjects (obese and normal weight as well as men and both pre and post 
menopausal women). The average CV corresponds to trial-to-trial variations of 
0.70% fat for BODPOD, 0.77% fat for BodyStat and 0.73% fat for Tanita. Further, the 
CVs for the body fat measurements were not significantly different from each other 
indicating that each compares favourably to the others when standard acceptance 
criteria for reliability are applied. The variations were however significantly greater 
than the day-to-day variations in body mass reflecting additional sources of error in 
the composition analysis systems such as hydration status. When conducting 
intervention trials this small error must however be taken into consideration when 
reporting changes in body composition. 
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Chapter 4: Relationships between plasma PAI-1 concentrations and other 
markers of the insulin resistance syndrome in three obese populations 
4.1 Introduction 
Since elevated plasma concentrations of plasminogen activator inhibitor (PAI-1) were 
included as part of the Insulin Resistance Syndrome (IRS) numerous studies have 
been conducted to establish the nature of the relationships between PAI-1 and the 
various other markers of the IRS (Vague 1989, Juhan-Vague et al 1991, Jannad- 
Delanne et al 1998). These studies provide indications to the possible mechanisms 
responsible for elevated PAI-1 concentrations that may be confirmed by further in 
vitro or in vivo studies. 
The results of these studies are conflicting. Jannad-Delanne etal(1998) determined 
that anthropometric measures were the main determinants of PAI-1 concentrations 
confirming earlier work by Vague (1989). Potter van Loon (1990) however, reported 
that insulin was the major determinant of excess PAl-1 in obesity when measured 
against BMI, waist to hip ratio, diastolic blood pressure and insulin resistance. Other 
groups have reported that plasma triglyceride and BMI (Apslund-Carlson eta11993), 
VLDL cholesterol (Vague 1993, Vague et a11995) and leptin (De Mitro et a11999) 
are all responsible for elevated plasma PAI-1 concentrations in obesity. 
Reasons for the inconsistency in results include measurement of different markers of 
the IRS and the use of different methodologies to measure components of the IRS 
including a number of available ELISA assays for the determination of plasma PAI-1. 
In most PAI-1 assays the definition of total PAI-1 includes concentrations of the 
active and latent PAI-1 conformation but does not always include measures of PAI-1 
in complex with t-PA. 
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The primary aim of this study therefore is to determine the nature of the relationships 
between plasma PAI-1 concentrations and other markers of the IRS in a local 
population from which volunteers for future studies will be drawn. 
4.2 Subjects & Methods 
144 (54 premenopausal females, 52 post menopausal females, 38 men) obese 
volunteers were recruited for participation in the study. Inclusion criteria for the study 
were BMI >29 kg/m2 and waist circumference >88 cm in women and 102 cm in men. 
No subject was taking any prescription or "over the counter" medication for 4 weeks 
prior to the trial day with the exception of oral contraceptives and hormone 
replacement therapy. 
4.2.2 Experimental Design 
All subjects arrived at the Centre for Obesity Research between 9 and 10 am to 
standardise for the effects of diurnal variation having fasted overnight, abstained from 
smoking for 8 hours, alcohol for 24 hours and strenuous exercise for 48 hours. 
Premenopausal women attended the laboratory in the early follicular phase (day 7- 
11) of their menstrual cycle to standardise for the effect of hormonal fluctuation on 
markers of the insulin resistance syndrome. 
On the trial day, subjects underwent measures of height (standard stadiometer), 
weight (TBF-310, Tanita Corp) waist circumference, hip circumference and blood 
pressure. Average blood pressure was determined by the mean of three values 
recorded (Omron 711) 10 minutes apart in a seated position. A1 Oml blood sample 
was taken before blood pressure analysis. 
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4.2.3 Laboratory Methods 
Blood samples were collected in tubes containing no additives and sodium citrate. 
The no-additives samples were allowed to clot for 20 minutes before being 
centrifuged at 3000rpm for 15 minutes (IEC Centra-2). The resultant serum was 
analysed immediately for insulin (MEI, Imx systems) total cholesterol (procedure 
467825 Beckman systems), triglyceride (procedure 445850 Beckman systems), and 
HDL cholesterol (EZHDL Sigma Diagnostics). LDL cholesterol was calculated using 
the Friedewald equation. Sodium citrate samples were immediately centrifuged at 
3000 rpm for 15 minutes (IEC Centra-2) and the resultant plasma stored at -80°C 
until analysis for PAI-1 Ag by ELISA (procedure 101005 Biopool International). All 
samples were analysed within 1 hour of thawing. 
4.2.4 Statistical Analysis 
Data was initially assessed for normality of distribution using a Shapiro-Wilks test. 
The relationships between PAI-1 and other markers of the IRS were assessed 
utilising a Spearman's rho correlation test. Data was then log transformed to assume 
normality before multiple partial correlations were performed. Relationships were 
considered significant when P<0.05. 
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4.3 Results 
4.3.1 Demographic Data 
The demographic data for the populations studied is presented in table 4.1. All 
subjects were Caucasian with the exception of 3 males (2 Asian, 1 Afro-Caribbean) 
and 2 postmenopausal females (Afro-Caribbean). All subjects were classed as 
obese (BMI > 29 kg/m2) according to study criteria possessing a waist circumference 
greater than 102 cm (males) and 88 cm (pre and post menopausal females). 
Table 4.1: Demographic features of the population studied. All samples were taken between 9 
and 10 am following an overnight fast. Data is shown as median (range) 
Marker Premenopausal Post menopausal Males 
Females Females 
Number of patients 54 52 38 
Body Mass (kg) 89.20 (72.70-143.60) 84.90 (72.50-125.00) 94.40 (60.80-162.20) 
BMI (kg/m) 34.37 (29.92-47.90) 34.00 (29.68-44.00) 35.20 (29.00-47.00) 
Waist 98 (90-131) 102 (90- 120) 121 (106-146) 
circumference (cm) 
Waist to hip ratio 0.86 (0.76-0.97) 0.85 (0.76-0.92) 1.02 (0.86-1.12) 
Systolic blood 126 (97-160) 130 (110-191) 127 (110-161) 
pressure (mmHg) 
Diastolic blood 84(60-97) 83 (56-99) 87 (63-99) 
pressure (mmHg) 
Insulin (pmol/L) 9.10 (2.50-38.00) 9.20 (1.30-27.20) 19.50 (2.30-60.50) 
Total Cholesterol 5.28 (3.05-7.40) 5.75 (3.90-8.10) 6.00 (4.70-7.18) 
(mmol/L) 
Triglycerides 1.17 (0.50-3.07) 1.55 (0.70-3.66) 2.35 (1.00-5.00) 
(mmol/L) 
HDL Cholesterol 1.21 (0.66-2.03) 1.60 (1.06-2.28) 1.04 (0.76-1.40) 
(mmol/L) 
LDL Cholesterol 3.42 (1.39-4.80) 3.80 (1.90-5.70) 4.00 (2.30-4.52) 
(mmol/L) 
PAI-1 (ng/ml) 13.50 (3.70-74.20) 6.85 (3.30-65.10) 24.40 (8.20-98.60) 
79 
The relationships between total PAI-1 Ag and other markers of the IRS (table 4.2) 
were assessed by Spearman's rho correlations. Total PAI-1 Ag showed significant 
positive relationships with body mass, BMI, waist circumference, systolic blood 
pressure, insulin and triglyceride concentrations in all three subject groups. 
Significant negative correlations were also observed between total PAI-1 and HDL 
cholesterol in all three populations studies. The relationships between waist to hip 
ratio and PAI-1 as well as total cholesterol and PAI-1 only reached significance in 
postmenopausal females and the male populations studied. There were no 
significant correlations between PAI-1 and LDL cholesterol in any of the groups at 
rest. 
Table 4.2: Relationships between total PAI-1 Ag and other markers of the IRS in the three 
patient groups as assessed by Spearman's rho correlation test. Significant relationships 
(P<0.05) are shown in red. 
Premenopausal Postmenopausal Males 
Females Females 
Body Mass (kg) 
BMI (kg/m2) 
Waist circumference (cm) 
Waist to hip ratio 
Systolic blood pressure 
(mmHg) 
Diastolic blood pressure 
(mmHg) 
Insulin (pmol/L) 
Total cholesterol (mmol/L) 
Triglyceride (mmol/L) 
HDL cholesterol (mmol/L) 
LDL cholesterol (mmol/L) 
R P R P R P 
0.538 0.000 0.336 0.015 0.586 0.001 
0.467 0.002 0.318 0.022 0.616 0.001 
0.486 0.001 0.396 0.004 0.655 0.000 
0.189 0.230 0.343 0.013 0.495 0.009 
0.437 0.026 0.374 0.006 0.582 0.031 
-0.178 0.260 -0.074 0.602 0.326 0.097 
0.326 0.035 0.298 0.032 0.581 0.001 
-0.114 0.473 0.279 0.045 0.430 0.025 
0.463 0.021 0.558 0.000 0.573 0.050 
-0.220 0.042 -0.129 0.036 -0.222 0.026 
-0.019 0.905 0.230 0.100 0.355 0.070 
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4.3.2 Partial Correlations 
In an attempt to determine whether the correlating factors may have a direct 
influence on total PAI-1 Ag or may exert an indirect influence via other measured 
factors multiple partial correlations were performed controlling for each factor in turn 
(tables 4.3,4.4,4.5). 
No factor was independently associated with total PAI-1 Ag in any of the three 
subject groups. In all three groups however, body mass, BMI and waist 
circumference were significantly correlated with total PAI-1 when controlling for waist 
to hip ratio, blood pressure and blood markers of the IRS. Furthermore, when 
controlling for each of these factors in turn, no other measured variables significantly 
correlated with PAI-1. Systolic blood pressure was also significantly correlated with 
total PAI-1 Ag when controlling for blood markers of the IRS in all three subject 
groups. 
Unexpectedly, insulin, triglyceride and total cholesterol were not independently 
associated with total PAI-1 Ag when controlling for blood pressure and other blood 
markers of the IRS in males and, with the exception of insulin when controlling for 
HDL cholesterol, the same was true in post menopausal females. 
HDL cholesterol was not independently significantly associated with total PAI-1 in 
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women however, HDL cholesterol was significantly correlated with PAI-1 Ag despite 
controlling for BMI (R= -0.429 P= 0.032) as well as a trend towards a relationship 
between the 2 factors despite controlling for body mass (R= -0.357 P=0.079). In 
premenopausal women, HDL cholesterol retained a significant association with total 
PAI-1 Ag when controlling for blood pressure (systolic R= -0.292, P=0.054, diastolic 
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4.4.1 Summary of the Study 
144 obese volunteers (54 premenopausal women, 52 post menopausal women, 38 
men) underwent measures of height, weight, waist and hip circumference and each 
had a blood sample taken which was subsequently analysed for insulin, total 
cholesterol, triglyceride, HDL cholesterol, LDL cholesterol and total PAI-1. The assay 
for total PAI-1 measures the active and latent forms of PAI-1 only. Multiple bivariate 
and partial correlations were used to assess the relationship between PAI-1 Ag and 
each of the markers of the IRS measured. 
4.4.2 Correlations with PAI-1 Ag. 
Total PAI-1 Ag (table 4.2) showed significant positive relationships with body mass, 
BMI, waist circumference, systolic blood pressure, insulin and triglyceride 
concentrations in all three subject groups. Significant negative correlations were also 
observed between total PAI-1 and HDL cholesterol in all three populations studies. 
Numerous research studies have reported significant correlations between PAl-1 Ag 
and BMI (Mavri eta! 1999, Alessi eta! 2000), waist circumference (Landin eta! 1990, 
Mertens & Van Gaal 2002), waist to hip ratio (Mertens & Van Gaal 2002), systolic 
blood pressure (Poll et al 2000), insulin (Giltay et a! 1998, Abassi et al 1999), 
triglyceride (Mertens & Van Gaal 2002) and HDL cholesterol (Abassi eta! 1999). 
Interestingly, most of these studies (Cigolini eta/ 1996, Alessi et a12000, Mertens & 
Van Gaal 2002) as with this one, observed that the significant correlations between 
PAI-1 and the various metabolic variables disappeared after controlling for 
anthropometric variables, particularly measures of visceral fat mass such as waist to 
hip ratio and waist circumference. These are however crude measures of visceral 
adipose tissue mass. Cigolini et al (1996) determined the effect of visceral adipose 
tissue on PAI-1 Ag more precisely utilising computed tomography at the L4-L5 level. 
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This group concluded that visceral fat mass was an independent predictor of PAI-1 
activity. The results of this study, as well as our own, suggest that the associations 
between PAI-1 and the measured blood pressure and metabolic markers of the IRS 
are mediated via an increase in adipose tissue mass in particular, visceral fat, 
possibly via adipose tissue-secreted factors such as leptin or cytokines. 
Measurement of these variables may further elucidate the mechanism by which 
increased visceral adipose tissue results in hypofibrinolysis via elevated active and 
latent PAI-1 Ag. These results combined with significant in vitro evidence suggest a 
role for adipose tissue in the expression and secretion of PAI-1 in response to a 
number of stimuli including insulin (Samad & Loskutoff, 1996) and triglycerides 
(Vague et al 1986). 
The relationships between waist to hip ratio and PAI-1 Ag (table 4.2) and total 
cholesterol and PAI-1 only reached significance in postmenopausal females and the 
male population studied. Furthermore, the correlations between these factors were 
weaker in postmenopausal females than males. This may be due to the non 
exclusion of premenopausal females taking oral contraceptives and postmenopausal 
females taking hormone replacement therapy. Oral oestrogen is known to decrease 
PAI-1 Ag directly (Villablanca eta12002), as well as influencing the proportion of PAI- 
1 in the complexed form via increases in t-PA clearance (Nozaki et a11999, Lansink 
et al 1999). Failing to exclude those patients either taking oral contraceptives or 
undergoing hormone replacement therapy may have lead to unreliable results and a 
potential masking of significant relationships. 
In all three subject groups systolic blood pressure retained a significant positive 
relationship with PAI-1 independently of insulin, total cholesterol, triglyceride, HDL 
cholesterol and LDL cholesterol and in the case of post menopausal women, body 
mass and BMI. There are two possible explanations for the relationship between 
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systolic pressure and PAI-1 Ag. The first is release of PAI-1 from endothelial and 
platelet stores in response to endothelial damage. Elevations in blood pressure 
increase the shear stresses imposed on the vessel wall thus increasing the likelihood 
of vessel wall damage and rupture of vulnerable atherosclerotic plaques (Mittleman & 
Siscovick 19960. Measurement of von Willebrand factor (vWF, a marker of 
endothelial damage) would indicate if this was a viable mechanism. The Framingham 
offspring study however, reported that there was no significant relationship between, 
systolic or diastolic blood pressure and vWF (Poli et a/ 2000). This group however, 
did not report the time between cannulation and withdrawal of the samples that may 
have resulted in the lack of a significant relationship. 
A second possible explanation is the involvement of the renin-angiotensin- 
aldosterone system (RAAS). Angiotensin II, angiotensin IV and aldosterone have all 
been shown to stimulate PAI-1 synthesis and secretion in vitro as well and increasing 
mean arterial pressure (Brown et a! 1999). Furthermore, inhibition of angiotensin 
converting enzyme (ACE) leads to reductions in both mean arterial pressure and 
plasma PAI-1 Ag in a dose dependent manner (Vaughan 2001). In addition, t-PA 
synthesis and release is also affected by ACE, which metabolises bradykinin, a 
stimulant of endothelial t-PA secretion, therefore decreasing t-PA secretion. The 
effect of this system on active and latent PAI-1 Ag may be therefore influenced by the 
availability of t-PA to form the t-PA/PAI-1 complex. 
The lack of a relationship between systolic pressure and plasma PAI-1 when 
controlling for anthropometric markers of visceral obesity could also be explained by 
the involvement of the RAAS. Obesity, in particular visceral obesity is associated 
with elevated plasma levels of angiotensin and renin and increased amounts of 
tissue specific ACE (Egan et al 2001). This has long been thought to be the link 
between central obesity and hypertension but is beginning to be proposed as a 
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possible mechanism for elevated PAI-1 concentrations and the resultant 
hypofibrinolysis. 
Finally, an interesting result in this study was the persistence of a relationship 
between PAI-1 and HDL cholesterol in premenopausal females despite controlling for 
triglyceride concentration (R= -0.277 P=0.043). Although this may be an artefact of 
the inclusion of subjects taking oral contraceptives, there is evidence to suggest that 
insulin resistant patients develop a glycated form of HDL that increases PAI-1 
secretion from vascular endothelial cells (Ren & Shen 2000). 
Overall this study has confirmed the results of a number of other groups by indicating 
that anthropometric variables including body mass, and BMI, but in particular, 
measures of central obesity such as waist to hip ratio and waist circumference are 
the main predictors of PAI-1 secretion in obese healthy volunteers. This provides 
additional evidence to support the role of adipose tissue in expression and secretion 
of PAI-1 in vivo in response to a number of different stimuli. 
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Chapter 5 
The effect acute, moderate 
intensity exercise on 
plasma PAI-1 concentration in 
obese Vs non obese 
sedentary male volunteers. 
Chapter 5: The effect acute, moderate intensity exercise on plasma PAI-1 
concentration in obese Vs non obese sedentary male volunteers. 
5.1 Introduction 
Obesity and central fat accumulation in particular are known to be risk factors for 
coronary heart disease and thrombotic events (Despres et al 1990). The 
hypofibrinolytic state observed at rest in central obesity has been attributed to 
elevated concentrations of plasminogen activator inhibitor type 1 (PAI-1), which is 
now considered an independent risk factor in the insulin resistance syndrome (IRS) 
(De Pergola eta! 1997). 
Regular physical activity is known to reduce resting plasma PAI-1 concentration by 
up to 58% (Streiff & Bell 1994). Unaccustomed acute bouts of strenuous exercise 
however, result in an increased risk of myocardial infarction (MI) onset and sudden 
cardiac death (SCD) in both obese and sedentary populations during and up to one 
hour post exercise (Mittleman & Siscovick 1996). This increased risk has been 
attributed to increased platelet number and platelet hyperactivity in these populations 
(Kestin et al 1993). Activation of platelets results in alpha granule secretion of, 
amongst others, PAI-1. It is therefore possible that hypofibrinolysis due to elevated 
concentrations of PAI-1 may be responsible for MI onset as a result of exercise. 
Acute exercise in non obese subjects at an intensity greater than 50% of maximal 
heart rate has been shown to significantly decrease plasma PAI-1 concentration with 
a concomitant increase in tissue plasminogen activator (t-PA), increasing overall 
fibrinolytic capacity (Streiff & Bell 1994). The largest increases in fibrinolytic activity 
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occur with exercise intensity greater than 70% of maximal oxygen uptake (VO2 max) 
(Streiff & Bell 1994) when the largest reductions of PAI-1 are observed. 
Work in non obese patients with markers of the IRS have produced conflicting 
results with hypertensive subjects showing no significant reduction in fibrinolytic 
capacity (DeSouza et al 1997) and NIDDM patients demonstrating a reduced 
fibrinolytic capacity (Schneider et a11988) compared to healthy controls both at rest 
and in response to acute exercise bouts. The fibrinolytic response to an acute 
exercise bout has not been investigated in an obese population. 
The purpose of this present study therefore was to determine the effect of an acute 
bout of exercise at 70% predicted V02 max on plasma t-PA and PAI-1 
concentrations in habitually sedentary obese versus sedentary non-obese male 
volunteers. 
5.2 Subjects & Methods 
8 obese, sedentary, male volunteers were matched for age (+/- 1 year) and ethnic 
origin with 8 sedentary non obese males. Obesity was defined as BMI >30 kg/m2 
and waist circumference >102 cm. "Sedentary" was defined as <20 min recreational 
exercise per week and having a non manual profession. 
5.2.2 Experimental Design 
All subjects underwent physical examinations and biochemical and haematological 
screening prior to entry into the study. Maximal oxygen uptake was predicted by 
means of a submaximal fitness test to 80% predicted maximal heart rate on a 
motorised treadmill employing a modified Bruce protocol. Expired air was collected 
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(using the Douglas bag method) for the last minute of each stage and analysed for 
FEO2, FECO2, and volume to allow calculation of V02 (all volumes were corrected to 
STPD). A workload corresponding to 70% V02 max was then determined during a 
30 minute treadmill walking trial in which subjects were familiarised with the protocol. 
Measures of height, weight and percent body fat (using air displacement 
plethysmography (BODPODTm)) as well as waist and hip circumferences were also 
recorded during this visit. 
On the trial day, all subjects arrived at the laboratory at 09.00h to standardize for the 
effects of diurnal variation, after an overnight fast having abstained from smoking for 
8 hours, alcohol for 24 hours and strenuous exercise for 48 hours. No subject was 
taking prescription or "over the counter medication" for 6 weeks prior to the 
commencement of the study. A 21G cannula was inserted into a suitable forearm 
vein (during 3 minutes of venous occlusion at 100 mmHg) and a fasting blood 
sample (VO) was taken. Subjects then consumed a standardised 281 kcal breakfast 
(62.2g carbohydrate, 2. Og fat, 7.6g protein). Subjects were then required to rest in a 
seated position for 75 minutes before a resting blood sample (REST) was taken. This 
was followed by an acute bout of walking exercise on a motorised treadmill for thirty 
minutes at 70% predicted V02 max (preceded by a3 minute warm up period (2.7 
km/h'', 0% gradient) before a further blood sample (END) was taken. Subjects then 
performed a5 minute cool down (2.7 km/h'', 0% gradient). A final blood sample was 
taken 30 minutes after the completion of the exercise bout (POST). 
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5.2.3 Laboratory Methods. 
Blood samples were distributed between evacuated sealed test tubes containing 
sodium citrate or EDTA. The EDTA samples were analysed immediately for 
concentrations of haemoglobin (azidemethaemaglobin method, Hemocue, Sweden) 
and haematocrit (microcentrifugation, Hawksley, UK). The sodium citrate samples 
were centrifuged immediately at 3000 rpm for 15 minutes and the resultant plasma 
stored at -70°C until analysis by ELISA for total PAI-1 Ag (Kit 12075 Technoclone, 
Austria), active PAI-1 Ag (Actibind Kit 16075 Technoclone, Austria) and t-PA Ag (Kit 
12005 Technoclone, Austria). 
5.2.4 Calculations and Statistical Analysis 
Plasma volume changes were calculated according to the method of Dill and Costill 
(1974). All data shown are corrected for plasma volume changes. Data was 
assessed for normality of distribution using the Shapiro-Wilks test. Comparisons 
between groups and between time points were performed using Wilcoxon rank tests 
and Mann-Whitney tests. Differences were considered significant when P<0.05. 
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5.3 Results 
5.3.1 Physical Characteristics of the Subjects 
Physical characteristics of the subjects are shown in table 5.1. Both groups 
contained 6 Caucasians and 2 Asians. There were no significant differences in age 
or V02 max between the two groups. The obese group however had a significantly 
greater body mass, BMI, waist circumference, waist hip ratio and mean arterial 
pressure than their non obese counterparts. 
Table 5.1: Comparison of physical characteristics between the obese and non obese subject groups. 
Values shown are mean ± SEM for normally distributed data and median (range) for skewed data. N= 
number of subjects. *= Significantly different from non obese group, P50.05. 
Group 
Variable Obese Non Obese 
(N=8) (N=8) 
Age (years) 43.25 ± 0.56 43.38 ± 0.60 
Body Mass (kg) 
BMI (kg/m2) 
Waist Circumference (cm) 
Waist Hip Ratio 
V02 max (ml/kg/min) 
Mean Arterial Pressure (mmHg) 
Total t-PA Ag (ng/ml) 
Total PAI-1 Ag (ng/ml) 
Active PAI-1 (U/ml) 
97.78 t 2.36* 
31.6 t 0.88* 
112.0 t 2.09* 
1.05 t 0.02* 
26.51 t 2.43 
104.0 t 1.31 * 
14.38 (11.36 to 27.72) 
125.75 (88.41 to 148.59)* 
33.98 (7.60 to 98.35)* 
79.43 ± 3.92 
25.0±0.941 
88.25 t 2.07 
0.86 t 0.01 
26.73 t 1.88 
80.85 t 1.59 
12.32 (9.12 to 33.92) 
55.25 (37.47 to 104.87) 
9.16 (4.10 to 26.78) 
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Total PAI-1 Ag and active PAI-1 Ag were significantly elevated in the obese group at 
all time points throughout the trial compared to the non obese group, but there were 
no significant differences in t-PA Ag between groups at any time point. 
5.3.2 T-PA 
T-PA Ag (table 5.2) did not significantly change in the obese group during the trial, 
although there was a trend towards decreased t-PA Ag 30 minutes post exercise 
(P=0.093). In the non obese group, there was a significant increase in t-PA Ag as a 
result of the exercise bout (from 11.26 (8.03 to 29.69) ng/ml to 16.27 (8.86 to 33.83 
ng/ml P= 0.03) and a trend towards baseline levels 30 minutes post exercise 
(P=0.09) 
Table 5.2: The effect of an acute exercise bout at 70% V02 max on plasma t-PA in obeseVs non obese 
sedentary male volunteers. VO = venous occlusion, END = immediately post exercise & POST = 30 
minutes post exercise. Data is shown as median (range). All data is corrected for changes in plasma 
volume compared to baseline values. *= significantly different from previous time point P :s0.05. 






Venous Occlusion 14.38 11.36 to 27.72 12.32 9.12 to 33.92 
Rest (Baseline) 15.26 10.27 to 33.69 11.26 8.03 to 29.69 
End of Exercise 20.41 10.81 to 31.76 16.27* 8.86 to 33.83 
Post Exercise 18.45 11.44 to 25.18 15.95 7.61 to 30.01 
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5.3.3 Total PAI-1 
Total PAI-1 Ag (table 5.3) was significantly elevated in both groups as a result of 
venous occlusion and cannulation compared to resting values (obese group VO 
=125.75 (88.41 to 148.59 ng/ml) Vs REST =112.96 (85.58 to 131.79 ng/ml), P=0.05, 
non obese group, VO=55.25 (37.47 to 106.87 ng/ml) Vs REST = 35.43 (25.65 to 
75.84 ng/ml), P=0.01). There were no significant changes however in either group 
as a result of the exercise bout (REST to END). In addition, there were no significant 
differences in total PAI-1 Ag concentration between END and POST in the non 
obese group, but there was a significant increase in total PAI-1 Ag concentration in 
the obese group (from 110.81 (69.84 to 149.04 ng/mI) to 143.94 (93.16 to 168.51 
ng/mI) P=0.04) 
Table 5.3: The effect of a 30 minute bout of exercise on total PAI-1 Ag concentration in obese Vs non 
obese sedentary male volunteers. VO = venous occlusion & cannulation, END = immediately post 
exercise & POST = 30 minutes post exercise. Data is shown as median (range). All data is corrected 
for changes in plasma volume. * significantly different from previous time point PS 0.05, ** 
=significantly different from the previous time point PS 0.01. += significantly elevated compared to 
the non obese group P< 0.05, = significantly elevated compared with the non obese group PS 0.01 
Time Point Obese Group N=8 Non Obese Groua N=8 
Median Range Median Range 
[PAI-1] ng/mI [PAI-1] ng/mI 
Venous Occlusion 125.72+ 88.41 to 148.59 55.25 37.47 to 106.87 
Rest (Baseline) 112.96+* 85.58 to 131.79 35.43** 25.65 to 75.84 
End of Exercise 110.81+ 69.84 to 149.04 37.06 31.95 to 61.34 
Post Exercise 143.94++* 93.16 to 168.51 32.05 17.83 to 78.08 
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5.3.4 Active PAI-1 
Finally, active PAI-1 Ag (table 5.4) decreased from venous occlusion to rest in both 
the obese group (from 33.98 (7.60 to 98.35 U/ml) VO, to 31.94 (6.05 to 75.66 U/ml) 
REST P= 0.03) and the non obese group (from 9.16 (5.10 to 26.78 U/ml) VO, to 5.28 
(2.14 to 16.81 U/ml) REST P=0.04). In both groups, active PAI-1 further decreased 
as a result of the exercise bout (Obese group 31.94 (6.05 to 75.66 U/ml) REST, to 
23.20 (4.03 to 60.65 U/mi) END P=0.01, Non Obese group 5.28 (2.14 to 16.81 U/ml) 
REST, 4.26 (0.57 to 13.29 U/ml) END P=0.01). There was no significant change in 
active PAI-1 Ag in either group following the 30 minute recovery period. 
Table 5: 4: The effect of a 30 minute bout of exercise on plasma active PAI-1 Ag concentration in 
obese Vs non obese sedentary male volunteers. VO = venous occlusion & cannulation, END = 
immediately post exercise &. POST = 30 minutes post exercise. Data is shown as median (range). All 
data is corrected for changes in plasma volume.. * significantly different form previous time point PS 
0.05, ** =significantly different from the previous time point PS 0.01. += significantly elevated 
compared with the non obese group P< 0.05, ++ = significantly elevated compared with the non obese 
group PS 0.01 
Time Point Obese Group N=8 Non Obese Group N=8 
Median Range Median Range 
[PAI-1] ng/mI [PAI-1 ] ng/mi 
Venous Occlusion 33.98+ 7.60 to 98.35 9.16 4.10 to 26.78 
Rest (Baseline) 31.94**+ 6.05 to 75.66 5.28* 2.14 to 16.81 
End of Exercise 23.20**+ 4.03 to 60.65 4.26** 0.57 to 13.29 
Post Exercise 19.22+ 5.55 to 61.05 4.75 2.84 to 10.95 
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5.4 Discussion 
5.4.1 Summary of the Protocol 
8 obese and 8 non obese sedentary male volunteers undertook an acute walking 
exercise bout at 70% V02 max for 30 minutes. Blood samples were taken 100 
minutes pre exercise (VO) after 3 minutes of venous occlusion and a standard 
cannulation, 15 minutes pre exercise (REST) after a standard 190 kcal breakfast, at 
the end of the exercise bout (END) and thirty minutes post exercise (POST). 
Samples were analysed for t-PA concentrations, total PAI-1 Ag and active PAI-1 Ag. 
5.4.2 Resting Data 
At rest, the obese group were hypofibrinolytic compared to the non obese group at 
rest; shown by both elevated total PAI-1 Ag (112.96 (85.58 to 131.79 ng/ml) obese 
group Vs 35.43 (25.65 to 75.84 ng/ml) non obese group) and active PAI-1Ag (31.94 
(6.05 to 75.66) obese group Vs 5.28 (2.14 to 16.81 U/ml) non obese group) 
concentrations, with no significant differences in t-PA concentration. The total PAI-1 
Ag reported in this study are significantly higher than those reported in the literature. 
This is because the assay used for determination of total PAI-1 included 
measurement of complexed, latent and active PAI-1 whereas the assays used in 
most of the literature only measure latent and active PAI-1 (Vague et a11989, Alessi 
et a11988). Kruithof (1988) defined a total PAI-1 Ag concentration greater than 100 
ng/ml (including complexed PAI-1) as indicative of a hypofibrinolytic state. 
Furthermore, an active PAI-1 Ag concentration greater than 20 t-PA inhibiting units 
/ml is also indicative of a reduced fibrinolytic capacity. The results of this study 
confirm previous reports of a hypofibrinolytic state observed at rest in obese patients 
(Vague et al 1989, Alessi eta! 1998). 
I 
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5.4.3 Exercise Data 
The main finding of this study is that the hypofibrinolytic state observed at rest in the 
obese group persisted following the acute bout of exercise at 70% predicted V02 
max. Total PAI-1 remained unchanged in both groups whilst t-PA significantly 
increased in the non obese by 31 % (P= 0.03), but not the obese group with exercise 
(median increase 25% P=0.107). Active PAI-1 significantly decreased in both the 
obese and non obese subject groups. The reduction in active PAI-1 Ag together with 
unchanged total PAI-1 Ag suggests an increase in the proportion of t-PA bound to 
PAI-1 at the end of the exercise bout. In the non obese group, t-PA concentrations 
significantly rose therefore increasing the proportion of free t-PA available. In the 
obese group however, there were no significant changes in t-PA concentration 
suggesting that in obese populations 30 minutes exercise at 70% V02 max does not 
have a hyperfibrinolytic effect. A measure of t-PA activity would confirm whether this 
is the case. The persistence of significantly elevated total and active PAI-1 Ag 
immediately post exercise with no significant differences in t-PA concentrations 
compared to non obese individuals, suggests that sedentary obese individuals 
remain hypofibrinolytic compared to sedentary non obese populations following an 
acute moderate intensity exercise bout. 
The lack of significant change in plasma t-PA concentration with exercise in the 
obese group however, maybe a result of the large variations in t-PA concentration in 
this group. As this was the first study to examine the effect of an acute exercise 
bout on fibrinolysis in an obese population, the power calculations were based on 
variations in fibrinolytic variables at rest in the obese and the fibrinolytic reactions to 
exercise in the non obese. Retrospective power calculations have indicated that a 
population of 22 (11 experimental subjects and 11 controls) would be required to 
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elucidate with 95% confidence if there were any significant changes in t-PA 
concentration with acute exercise in a sedentary, obese subject group. 
Thirty minutes post exercise, a further reduction in fibrinolytic capacity was observed 
in the obese group as t-PA Ag showed a trend towards declining concentrations 
(P=0.093) but total PAI-1 Ag (table 5.4) significantly increased compared to both 
concentrations recorded at rest and at the end of the exercise bout. (END, 110.81 
(69.84 to 149.04 ng/ml) Vs POST 143.94 (93.16 to 168.51 ng/ml). Active PAI-1 Ag 
remained unchanged from those recorded at the end of the exercise bout but were 
not significantly different from resting values. This suggests, as with the end of the 
exercise bout, an increased proportion of t-PA bound to the inhibitor PAI-1. These 
results suggest that sedentary obese populations are hypofibrinolytic immediately, 
and up to 30 minutes after an acute exercise bout at 70% V02 max. These results 
provide further evidence that hypofibrinolysis may be a potential mechanism in the 
increased incidence of MI onset in obese and sedentary populations during and up 
to one hour following an unaccustomed exercise bout (Mittleman & Siscovick 1996). 
Although the precise mechanism by which exercise may induce MI onset is 
unknown, cadaver data suggests that disruption of atherosclerotic plaques and the 
resultant local activation of prothrombogenic and antifibrinolytic processes may be 
responsible (Mittleman and Siscovick 1996). These processes include platelet 
hyperactivity in sedentary subjects (Kestin et at 1993), increased resting fibrinogen 
concentrations and a hypofibrinolytic state (Vague 1993) contributed to by increased 
local PAI-1 concentrations as result of elevated PAI-1 gene expression in the 
sclerotic artery wall (Mittleman & Siscivick 1996). This local increase in PAI-1 may 
promote the formation and stabilisation of a potentially MI inducing thrombus. 
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The rise in total PAI-1 Ag accompanied by little or no change in active PAI-1 Ag and 
decreasing t-PA, suggests increased PAI-1 release from platelets in response to 
endothelial injury. PAI-1 is stored in the alpha granules of platelets and released in 
response to a variety of chemical as well as mechanical stimuli (Sprengers et al 
1986) but only 15-20% of this PAI-1 is in the active form (Loskutoff & Samad 1998) 
and this rapidly and spontaneously converts to the latent form or binds to t-PA 
resulting in a t-PA/PAI-1 complex. This may account for the elevation in total PAI-1 
without a concomitant increase in active PAI-1: This would need to be confirmed by 
analysis of a marker of platelet a granule secretion such as platelet factor 4 or ß 
thromboglobulin as well as a marker of endothelial damage such as von Willebrand 
factor (vWF) and t-PA activity. 
In contrast to the obese group, the non obese group demonstrated increased 
fibrinolytic capacity at the end of the exercise bout from rest as shown by a lack of 
significant difference in total PAI-1 Ag concentration but significantly decreased 
active PAI-1 Ag concentration and significantly increased concentrations of t-PA Ag 
compared to resting levels. Thirty minutes post exercise, active PAI-1 remained 
unchanged from the end of exercise levels and t-PA declined towards resting levels. 
The non obese group therefore was hypofibrinolytic thirty minutes post exercise 
compared to end of exercise levels, but was still hyperfibrinolytic compared to resting 
values. Similar results have been observed in studies employing a variety of 
exercise protocols and subject groups (Streiff & Bell 1994), 
Our results in the non obese group are also similar to those previously observed in 
sedentary non obese males performing acute exercise of similar intensity. Desouza 
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and co workers (1997) reported a 45% rise in t-PA Ag which returned to baseline 
0 
levels 30 minutes post exercise and a 22% decrease in PAI-1 activity which 
remained unchanged thirty minutes post exercise following 30 minutes exercise at 
65% V02 max. The fibrinolytic response to an acute bout of exercise however has 
not been studied in an obese sedentary population. Work in populations who exhibit 
other markers of the IRS such as NIDDM (Schneider et al 1988) has shown impaired 
fibrinolytic responses compared with non obese sedentary populations immediately 
following moderate (65-75 % V02 max) intensity exercise. This study also indicates 
a decrease in the fibrinolytic capacity of obese subjects immediately following an 
acute exercise bout. The lack of large changes in fibrinolytic capacity with exercise 
may be in part due to the large intra-group variation of fibrinolytic variables in the 
obese group. Furthermore, the use of a sub maximal V02 predictive exercise test 
rather than a maximal oxygen uptake test may have resulted in the volunteers 
exercising at less than 70% V02 max, which is considered a threshold for large 
changes in fibrinolytic variables (Streiff & Bell 1994). 
Overall, we have demonstrated the sedentary obese populations are hypofibrinolytic 
with respect to sedentary non obese population at rest and both immediately and 
thirty minutes following a moderate intensity (70% predicted V02 max) exercise bout. 
Furthermore, obese populations are hypofibrinolytic compared to rest both 
immediately following exercise and 30 minutes post exercise and this may explain 
the increased incidence of MI onset immediately following and up to 1 hour post 
exercise. 
Despite the apparent undesirable effects of acute moderate intensity exercise in 
sedentary obese male subjects on fibrinolytic processes, it is worth reiterating the 
1 
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benefits of chronic exercise training. With or without weight loss, regular aerobic 
exercise training has been shown to reduce resting plasma PAI-1 concentration 
(Streiff & Bell 1994), decrease platelet reactivity (Kestin et al 1993), improve the lipid 
profile, and increase insulin sensitivity (Despres et al 1990) therefore reducing the 
risk of heart disease and MI. 
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Chapter 6: The relationship between total and active PAI-1 concentrations and 
other markers of the insulin resistance syndrome at rest, during exercise and post 
exercise in 16 male volunteers. 
6.1 Introduction 
Numerous research studies (Alessi et al 1988, Jannad-Delanne etal 1998) including 
our own (chapter 4), have demonstrated the close metabolic relationships between 
plasma PAI-1 concentrations and other markers of the insulin resistance syndrome at 
rest in obese individuals. The variations in total and active PAI-1 concentrations are a 
result of variations in secretion of PAI-1, formation of t-PA/PAI-1 complexes, availability 
of vitronectin and hepatic clearance of both free and complexed formations of PAI-1. 
Little is known about the factors involved in the short term regulation of plasma PAI-1 
concentrations. Insulin (Kooistra et a11989, Potter van Loon eta! 1990), triglyceride 
(Tremoli etal 1993, Stiko-Rahm eta11990), HDL cholesterol (Vague 1993, Ren & Shen 
2000) and von Willebrand factor (Gibbons eta! 1990) have all been implicated by both in 
vivo and in vitro studies as potential mechanisms in the short term regulation of PAI-1. 
The aim of this study therefore is to determine if any of these factors has a potential role 
in the short term regulation of PAI-1 in vivo. 
6.2 Subjects and Methods 
8 obese sedentary males were matched for age (+/- 1 year) and ethnic origin with 8 
sedentary non obese males. Obesity was defined as BMI >30 kg/m2 and waist 
circumference >102 cm. Non Obese was defined as BMI < 27 kg/m2 and a waist 
circumference < 95 cm. "Sedentary" was defined as <20 min recreational exercise per 
week and having a non manual profession. 
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6.2.2 Experimental Design 
All subjects underwent physical examinations as well as biochemical and haematological 
screening prior to entry into the study. Maximal oxygen uptake was predicted by means 
of a submaximal fitness test to 80% predicted maximal heart rate, on a motorised 
treadmill, employing a modified Bruce protocol. Expired air was collected (using the 
Douglas bag method) for the last minute of each stage and analysed for FE02, FEC02, 
and volume to allow calculation of V02 (all volumes were corrected to STPD). A workload 
corresponding to 70% V02 max was then determined during a 30 minute treadmill 
walking trial in which subjects were familiarised with the protocol. Measures of height, 
weight, percent body fat (using air displacement plethysmography (BODPODTM)), waist 
circumference and hip circumference were also recorded during this visit. 
On the trial day, all subjects arrived at the laboratory at 09.00h to standardise for the 
effects of diurnal variation having abstained from smoking for 8 hours, alcohol for 24 
hours and strenuous exercise for 48 hours. No subject was taking prescription or "over 
the counter' medication for 6 weeks prior to the commencement of the study. A 21 G 
cannula was inserted into a suitable forearm vein (during 3 minutes of venous occlusion 
at 100 mmHg) and a fasting blood sample (VO) was taken before subjects consumed a 
standardised 281 kcal carbohydrate breakfast. Subjects then rested in a seated position 
for 75 minutes before a resting blood sample (REST) was taken. Subject then performed 
an acute bout of walking exercise on a motorised treadmill for thirty minutes at 70% 
predicted VO2 max before a further blood sample (END) was taken, followed by a5 
minute cool down (2.7 km/h"', 0% gradient). A final blood sample was taken 30 minutes 
after the completion of the exercise bout (Post). 
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6.2.3 Laboratory Methods. 
Blood samples were distributed between evacuated sealed test tubes containing no 
additives, sodium citrate or EDTA. The EDTA samples were analysed immediately for 
concentrations of haemoglobin (azidemethaemaglobin method, Hemocue, Sweden) and 
haematocrit (microcentrifugation, Hawksley, UK). The no additives and sodium citrate 
samples were centrifuged immediately at 3000 rpm for 15 minutes and the resultant 
serum/plasma stored at -70°C until analysis. Samples were analysed by ELISA for total 
PAI-1 Ag concentration (Kit 12075 Technoclone, Austria), active PAI-1 Ag (Kit 16075 
Technoclone, Austria), t-PA Ag (Kit 12005 Technoclone, Austria) and von Willebrand 
Factor (In house ELISA) as well as insulin (DELFIA method), leptin (DELFIA method) 
total cholesterol (Procedure 467825 Beckman systems), triglyceride (Procedure 445850 
Beckman systems) and HDL cholesterol (EZ method, Sigma Diagnostics). LDL 
cholesterol was calculated using the Freidewald equation. 
6.2.4 Calculations and Statistical Analysis 
Plasma volume changes were calculated according to the method of Dill and Costill 
(1974). Mean arterial pressure was calculated by the following equation: 
(Pulse Pressure / 3) + Diastolic Pressure 
All data shown are corrected for plasma volume changes. Data was assessed for 
normality of distribution by multiple Shapiro-Wilks tests. Univariate correlations between 
plasma PAI-1 Ag and other markers of the IRS were assessed by Spearman's rho 
correlation tests. Two tailed significance levels are reported. To assess the effect of 
variables on total and active PAI-1 Ag independently of other significant correlating 
variables data was 'normalised' by log transformations before partial correlations were 
carried out. Finally, a stepwise multiple regression analysis was performed to test the 
joint effect of different variables on both total and active PAI-1 Ag. Differences were 
considered significant when PS 0.05. 
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6.3 Results 
6.3.1 Resting correlations 
The resting correlations between total PAI-1 Ag, active PAI-1 Ag and other measured 
markers of the insulin resistance syndrome are shown in table 6.1. 
Table 6.1: Correlations between total PAI-1 Ag, Active PAI-1 Ag and other markers of the Insulin 
Resistance Syndrome at rest. Significant correlations are shown in red* P=<0.05, ** P=<0.01 N=16 
wwWý av-a w ..... 4........ --.... ----- ------------- .............. Total PAI-1 (ng/ml) Total .. 
M...... w.... - -------- Mwýw .w 
Active PAI-1 lU/ml 
N=16 N=16 
R Value P Value R Value P Value 
Weight (kg) 0.652 0.006** 0.600 0.014** 
BMI (kg/m2) 0.724 0.002** 0.613 0.012** 
Body Fat % 0.702 0.002** 0.482 0.054* 
Body Fat (kg) 0.767 0.001 ** 0.559 0.024* 
Waist to Hip Ratio 0.790 0.000** 0.643 0.007** 
Waist Circumference 0.836 0.000** 0.635 0.008** 
(cm) 
V02 max (ml/kg/min) -0.145 0.592 -0.270 0.312 
Mean arterial Pressure 0.934 0.000** 0.716 0.002** 
(mmHg) 
t-PA (ng/ml) -0.069 0.590 0.019 0.882 
vWF IU/ml 0.376 0.002** 0.169 0.182 
Triglyceride (mmol/I) 0.599 0.000** 0.573 0.000** 
Total Cholesterol 0.304 0.014** 0.392 0.001 ** 
(mmoVl) 
HDL- Cholesterol -0.589 0.000** -0.295 0.018* 
(mmoVl) 
LDL-Cholesterol 0.330 0.008** 0.126 0.332 
(mmoVl) 
Insulin (pmol) 0.335 0.007** 0.263 0.036* 
Leptin (pg/ml) 0.397 0.001** 0.180 0.155 
Total PAI-1 (ng/ml) N/A N/A 0.565 0.000** 
Active PAI-1 (IU/mI) 0.565 0.000** N/A N/A 
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Both total PAI-1 Ag and active PAI-1 Ag were significantly correlated to weight, BMI, 
kilograms of body fat, waist to hip ratio, waist circumference, mean arterial pressure, 
triglycerides, total cholesterol, HDL cholesterol and insulin. Interestingly only total PAI-1 
Ag concentration was correlated with body fat percentage, LDL cholesterol and leptin. 
Using a multiple stepwise regression model only MAP entered the model as predictive of 
both total (R2 adjusted = 0.863, P=0.008) and active (R2 adjusted = 0.512, P=0.000) 
160- 
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Figure 6.1: Positive correlations between active PAI-1, total PAI-1 and mean arterial pressure at rest in the 16 
men. MAP = mean arterial pressure. 
To assess whether the correlating factors were directly responsible for changes in total 
and active PAI-1 Ag or had an indirect influence via other measured factors, multiple 
partial correlations were performed controlling for each correlating factor in turn (Table 
6.2 and 6.3 respectively). Only MAP remained correlated to total PAI-1 Ag irrespective of 
the other measured factors. Furthermore, controlling for MAP removed all positive 
correlations between total PAI-1 Ag and the other measured markers of the IRS at rest. 
No factor positively correlated with active PAI-1 Ag regardless of controlling factors 
ill 
although, with the exception of waist to hip ratio and waist circumference MAP showed a 
significant positive correlation or a trend towards a positive correlation at all times. Only 
waist circumference, waist to hip ratio and MAP removed all significant correlations with 
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6.3.2 Correlations across the Trial 
The correlations between total PAI-1 and active PAI-1 and other markers of the IRS 
throughout the trial are shown in table 5.2. Both total and active PAI-1 correlated with 
triglyceride concentration (total R=0.700 P=0.000, active R=0.685 P=0.000), total 
cholesterol (total R=0.332 P=0.007, active (R = 0.375 P=0.002) HDL cholesterol (R = 
-0.589 P=0.000, active R= -0.377 P=0.002) and insulin (R = 0.373 P=0.002, active R 
= 0.367 P=0.003). Only total PAI-1 correlated with vWF (R = 0.381 P=0.002), LDL 
cholesterol (R = 0.267 P=0.033) and leptin (R = 0.225 P=0.043) and only active PAI-1 
correlated with t-PA (R = 0.225 P=0.042). 
Table 6.4: Correlations between measured markers of the IRS and total and active PAI-1. N=64 
Total PAI-1 (ng/ml) Active PAI-1 U/ml 
N=64 N=64 
R Value P Value R value P Value 
T-PA (ng/ml) 0.108 ............ __........... .......... 0.396 .................. ... _...... ........... 0.225 0.042* 
vWF (IU/mI) 0.381 0.002** 0.188 0.138 
Triglyceride (mmol/I) 0.700 0.000** 0.685 0.000** 
Total Cholesterol 0.332 0.007** 0.375 0.002** 
(mmol/I) 
HDL Cholesterol (mmoVl) -0.589 0.000** -0.377 0.002** 
LDL Cholesterol (mmoVl) 0.267 0.033* 0.150 0.237 
Insulin (pmol) 0.373 0.002** 0.367 0.003** 
Leptin (ng/ml 0.225 0.043* 0.200 0.126 
Again, to determine whether the correlating factors have direct role in the short term 
regulation of total or active PAI-1, or had an indirect influence via other measured factors, 
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multiple partial correlations were performed controlling for each correlating factor in turn 
(Table 5.5 and 5.6 respectively). Both total and active PAI-1 remained independently 
correlated with triglyceride. Total PAI-1 also remained independently associated with 
HDL cholesterol and vWF. Finally, there was a significant positive correlation or a trend 
towards a correlation (P <0.10) between insulin and total PAI-1 Ag regardless of 
controlling factor. The significant correlation between leptin and total PAI-1 was removed 
when controlling for HDL cholesterol (partial R=0.188 P=0.141) and the significant 
correlations between LDL cholesterol and total PAI-1 Ag were removed when controlling 
for total cholesterol (partial R=0.205 P=0.107), HDL cholesterol (partial R=0.160 P= 
0.211) and insulin (partial R=0.197 P=0.122). Finally, the significant correlation 
between total cholesterol and total PAI-1 Ag was removed when controlling for 
triglyceride concentration (partial R=0.151 P=0.237) and LDL cholesterol (partial R= 
0.157 P=0.219) and was reduced to a trend when controlling for vWF (partial R=0.227 
P=0.073). 
Table 6.5: Partial correlations between total PAI-1 concentration and other significant correlating markers of the 
IRS for the 16 men across the trial. Trig = triglyceride, C= cholesterol. Significant correlations P <_0.05N are 
shown in red. N= 64 
CONTROLLING FACTORS 
NONE Trigs Total-C HDL-C LDL-C Insulin Leptin vWF 
Trigs R =. 700 R =. 556 R =. 423 R =. 598 R= . 588 R =. 548 R =. 619 
P=. 000 P=. 000 P=. 001 P=. 000 P=. 000 P=. 000 P=. 000 
Total-C R =. 332 R= . 151 R= . 480 R =. 157 R= . 269 R =. 302 R =. 227 
P=. 007 P=. 237 P=. 000 P=. 219 P=. 033 P=. 016 P=. 073 
HDL-C R =-. 589 R =-. 403 R =-. 668 R =. 534 R =-. 551 R =-. 502 R =-. 601 
P =. 000 P =. 001 P =. 000 P =. 000 P =. 000 P =. 000 P =. 000 
LDL-C R =. 267 R =. 328 R =. 205 R =. 160 R =. 197 R =. 289 R =. 254 
P= . 033 P =. 009 P =. 107 P =. 211 P =. 122 P =. 022 P =. 045 
Insulin R =. 373 R =. 307 R =. 304 R= . 230 R =. 295 R =. 229 R =. 259 
P=. 002 P=. 014 P=. 015 P=. 069 P=. 019 P=. 071 P=. 040 
Leptin R =. 225 R =. 284 R =. 395 R =. 188 R =. 339 R =. 317 R =. 303 
P=. 043 P=. 024 P=. 001 P=. 141 P=. 007 P=. 011 P=. 016 
vWF R=. 381 R=. 417 R=. 321 R=. 401 R=. 273 R=. 314 R=. 273 
P =. 002 P =. 001 P= . 010 P =. 001 P =. 031 P =. 012 P =. 030 
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Interestingly, the partial correlation between triglyceride and total PAI-1 Ag was 
strengthened when controlling for vWF (partial R=0.619 P=0.000 Vs R=0.599 P= 
0.000). The same was seen with HDL-C controlling for both total cholesterol (partial R=- 
. 668 P=0.000 
Vs R= -0.589 P=0.000) and vWF (partial R =-0.601 P=0.000 Vs R=- 
0.589 P=0.000) as well as for vWF controlling for triglyceride (partial R=0.417 P= 
0.001 Vs R=0.376 P =0.002) and HDL cholesterol (partial R=0.401 P=0.001 Vs R= 
0.376 P=0.002). 
Active PAI-1 Ag remained independently correlated with total cholesterol as well as 
triglyceride regardless of controlling factor. HDL cholesterol was significantly correlated 
with active PAI-1 Ag at all times with the exception of controlling for triglycerides that 
completely abolished the correlation (partial R=0.007 P=0.960). The correlation with 
insulin observed before controlling factors were applied (R = 0.263 P=0.036) was 
reduced to a trend after controlling for triglyceride (partial R=0.216 P=0.088) and total 
cholesterol (partial R=0.220 P=0.083) and was non-significant when controlling for 
HDL cholesterol (partial R=0.201 P=0.114). 
Table 6.6: Partial correlations between active PAI-1 concentration and other significant correlating markers of 
the IRS for the 16 men across the trial. Trig = triglyceride, C= cholesterol. Significant correlations P <0.05N 
are shown in red. N= 64 
1 CONTROLLING FACTOR 
NONE Trig Total-C HDL-C 
I 
Insulin 
Trigs R=. 685 R=. 515 R=. 515 R=. 559 
P=. 000 P=. 000 P=. 000 P=. 000 
Total-C R =. 375 R =. 271 R =. 457 R =. 368 
P=. 002 P=. 032 P=. 000 P=. 003 
HDL-C 8.. 377 R=. 007 R=. 383 R=. 243 
P=. 002 P= . 960 P=. 002 P=. 054 
Insulin R =. 367 R= . 216 R =. 220 R= . 201 
P=. 003 P=. 088 P=. 083 P=. 114 
As with total PAI-1 correlations, the correlations between active PAI-1 and total 
cholesterol were strengthened when controlling for HDL cholesterol (partial R=0.457 P 
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= 0.000 Vs R=0.392 P=0.001) and for HDL cholesterol when controlling for total 
cholesterol (partial R= -0.383 P=0.002 Vs R= -0.295 P=0.018). 
When all the significant correlations with total PAI-1 were entered into a stepwise multiple 
regression model, triglyceride was the first factor to enter the model (coeff icient = 11.861, 
P=0.013) followed by vWF (coeff icient = 0.346 P=0.004), HDL cholesterol (coefficient 
_ -93.913 P=0.000) and total cholesterol (coefficient = 11.157, P=0.043). This model 
predicts 59.2% of total PAM Ag (R2 = 0.592 P=0.009 constant = 84.316 P=0.009). 
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Figure 6.2: Correlation between actual total PAM concentration and PAM concentration predicted by the 
stepwise multiple regression model. Data is included for all 16 men at all 4 time points 
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When all the significant correlations with active PAI-1 Ag were entered into a stepwise 
multiple regression model only triglyceride concentration (coefficient = 9.704 P= 0.000) 
and total cholesterol concentration (coefficient = 5.909 P=0.032) remained independently 
associated with active PAI-1 (constant = -26.776). This model however (Figure 6.3) only 
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Figure 6.3: Correlation between measured active PAI-1 concentration and active PAI-1 concentration 
predicted by the stepwise multiple regression model. Data is included for all 16 men at all 4 time points. 
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6.4 Discussion 
6.4.15urnmary of the Protocol 
8 obese and 8 non obese sedentary male volunteers undertook an acute walking 
exercise bout at 70% VO2 max for 30 minutes. Blood samples were taken 100 minutes 
pre exercise (VO) after 3 minutes of venous occlusion and a standard cannulation, 15 
minutes pre exercise (REST) after a standard 190 kcal breakfast, at the end of the 
exercise bout (END) and thirty minutes post exercise (POST). Samples were analysed 
for t-PA, total PAI-1, active PAI-1, insulin, leptin, total cholesterol, LDL cholesterol, HDL 
cholesterol and triglyceride. 
6.4.2 Resting Correlations 
Both total and active PAI-1 Ag were positively correlated with total body mass (R=0.652 
P=0.006, R=0.600 P=0.014 respectively), BMI (R = 0.724, P=0.002, R=0.613 P=0.012), 
body fat percentage (R=0.702, P=0.002, R=0.482, P=0.054), kilograms of body fat 
(R=0.767 P=0.001, R=0.559, P=0.024), waist to hip ratio (R=0.790, P=0.000, R=0.643, 
P=0.007) and waist circumference (R=0.836, P=0.000, R=0.635, P=0.008). Adipose 
tissue, specifically visceral depots have recently been postulated as a major source of 
elevated PAI-1 Ag in obesity (Janand-Delenne eta/1998). Resting PAI-1 Ag and activity 
have been shown on numerous occasions to positively correlated with BMI, waist to hip 
ratio, waist circumference and visceral fat mass (Janand-Delenne et a11998, Vague et al 
1989). Moreover, clinical studies have demonstrated that weight loss due to surgical 
treatment and diet significantly reduces PAI-1 Ag in obese volunteers (Loskutoff & 
Samad 1997). Yudkin et al (1999) however attempted to quantify the contribution of 
adipose to total PAI-1 secretion by measuring the arterio-venous difference in PAI-1 Ag 
across the subcutaneous fat depot in lean subjects. This group determined that the 
relative contribution of subcutaneous adipose tissue to total PAI-1 Ag is only 1.6% and 
3.1 % to PAI-1 activity. 
120 
Although the contribution of visceral fat to PAI-1 Ag is greater than that of subcutaneous 
fat and the obese have greater amounts of both types of fat, the contribution of adipose 
tissue to the expression and secretion of PAI-1 is often over exaggerated as a result of 
correlations between other markers of the IRS, such as triglyceride, and anthropometric 
measures. Further evidence for this is provided in the present study as when controlling 
for markers such as triglyceride and mean arterial pressure (table 6.2) the correlations 
between PAI-1 Ag and anthropometric measures are weakened or abolished. These 
resting results however are in conflict with those obtained in males in chapter 4, 
highlighting the complex nature of the insulin resistance syndrome. The discrepancy 
may be due to the small number of subjects in this study, the inclusion of non obese 
subjects and the upper BMI limit of 45 kg/m2. 
Total and active PAI-1 Ag was also significantly correlated to triglyceride (R=0.599, 
P=0.000, R=0.573, P=0.000 respectively), total cholesterol (R=0.304, P= 0.014, 
R=0.392, P=0.001), HDL cholesterol (R=-0.589 P=0.000, R=-0.295, P=0.018) and insulin 
(R=0.335, P=0.007, R=0.263, P=0.036). Again, these are correlations observed by 
numerous studies both in vitro (Kooistra et al 1989, Tremoli et al 1993) and in vivo 
(Potter van Loon et a11993, Cimminello et a11997) and each has been proposed as a 
mechanism for elevated PAI-1 Ag. 
The relationship between mean arterial pressure and total PAI-1 was the closest by far 
(R = 0.936 P=0.000) and this relationship was independent of body mass, BMI, fat 
percentage, fat mass, WHR, WC, insulin, total cholesterol, triglycerides, HDL cholesterol, 
LDL cholesterol, vWF and leptin. Mean arterial pressure therefore was the only factor to 
enter the multiple regression model. The relationship between total PAI-1 Ag and vWF 
suggests that increasing mean arterial pressure may result in elevated PAI-1 
concentrations via endothelial damage. Endothelial damage results in activation of 
platelets and release of PAI-1 from the alpha granules as well as release of PAH from 
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the endothelium and therefore may account for the elevated total PAI-1 Ag. As vWF is 
also released from the alpha granules of platelets (Best & Taylor, 1993), the correlation 
between the two suggests the presence of platelet hyperactivity that has previously been 
described in sedentary populations (Kestin et al 1993). An additional marker of platelet 
alpha granule release, such as platelet factor 4 or ß thromboglobulin would need to be 
measured to confirm this. 
Another possible mechanism for the relationship between MAP and PAI-1 is the 
involvement of the renin angiotensin aldosterone system (RAAS). Obesity is associated 
with elevated plasma angiotensin, plasma renin activity, tissue specific angiotensin 
converting enzyme (ACE) and plasma aldosterone levels (Egan of al 2001). In vitro 
evidence implicates angiotensin II, angiotensin IV and aldosterone in increased secretion 
of PAI-1 as well as hypertension through sodium retention and vasoconstriction (Huber et 
al 2001 a). Increased ACE activity further contributes to a hypofibrinolytic state by 
reducing the half-life of bradykinin that is known to stimulate t-PA release from 
endothelial stores as well as promote vasodilatation via the actions of nitric oxide. 
Active PAI-1 Ag were significantly correlated with body mass (R = 0.600 P=0.014), BMI 
(R= 0.613 P= 0.012), body fat percentage (R=0.482 P=0.054), fat mass (R=0.559 
P=0.024), WHR (R= 0.643,0.007), WC (R=0.635 P=0.008), MAP (R=0.716 P=0.002), 
triglyceride (R=0.573 P=0.000), total cholesterol (R=0.392 P=0.001), HDL cholesterol 
(R=-0.295 P=0.018) and insulin (R=0.263 P=0.036). No factor remained independently 
correlated with active PAI-1 at rest but as MAP had the strongest statistical relationship 
with active PAI-1 and as this relationship eliminated all other significant relationships 
between markers of the IRS and active PAI-1 Ag, only MAP entered the multiple 
regression model. The significant correlation between MAP and "active PAI-1 Ag 
however was removed when controlling for anthropometric variables and triglyceride 
concentration unlike total PAI-1 Ag which remained independently associated with MAP 
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regardless of controlling factor. This highlights the complex nature of both the insulin 
resistance syndrome as a whole and the mechanisms responsible for the regulations of 
PAI-1 secretion. 
The active PAI-l concentration at a given time point is dependent not only on secretion 
from the endothelium, platelets and other sources but also on free t-PA concentrations 
and hepatic clearance rates. The significant correlation between total and active PAI-1 
(R=0.565 P=0.000) suggests that only 31.9% of the variability of active PAI-1 Ag is 
explained by total PAI-1 Ag. Additional variables may include variation in latent PAI-1 
secretion, availability of vitronectin to stabilise the active PAI-1 conformation and free t- 
PA concentrations. As these factors were not measured in this study, it is impossible to 
say whether they influenced active PAI-1 Ag at rest. 
6.4.3 Correlations Across the Trial 
Variations in PAI-1 release with exercise and recovery are thought to be a result of 
endothelial damage and subsequent platelet activation and alpha granule secretion 
(Streiff & Bell 1994). Multiple correlations were performed on both total and active 
concentrations across the trial to determine the potential role of other measured markers 
of the IRS in the short term regulation of PAI-1 secretion. 
Across the trial total PAI-1 Ag were significantly correlated with vWF (R= 0.381 P= 
0.002), triglyceride (R=0.700 P=0.000), total cholesterol (R=0.332 P=0.007), HDL 
cholesterol (R=-0.589 P=0.000), LDL cholesterol (R=0.267 P=0.033), insulin (R=0.373 
P=0.002) and leptin (R=0.225 P=0.043). Only triglyceride concentration, HDL 
concentration and vWF concentration remained independently associated with total PAI- 
1 Ag throughout the trial after multiple partial correlations were performed. 
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The role of triglyceride in the short term regulation of PAI-1 Ag has been extensively 
studied in vitro. Application of triglyceride rich VLDL to cultured endothelial cells and 
hepatocytes has been shown to increase PAI-1 secretion (Tremoli et al 1993). Moreover, 
the larger VLDL particles, commonly seen in hypertriglycerideamic patients, result in a 
greater PAI-1 response than the smaller VLDL particles seen in normotriglyceridaemic 
patients (Stiko-Rahm etal1990). PAI-1 secretion from hepatic and endothelial cells as a 
result of triglyceride application can be further potentiated by insulin (Sironi et al 1996) 
explaining the persisting relationship between PAI-1 and insulin despite controlling for 
triglyceride concentration. 
The relationship between HDL cholesterol and total PAI-1 Ag has generally been 
attributed to the close metabolic relationship between HDL cholesterol and triglyceride 
concentration (Vague 1993, Vague et al 1995). This study shows however that although 
the relationship weakens as a result of controlling for triglyceride, there is a significant 
independent relationship between the two factors. Research in this area is limited but 
Ren& Shen (2000) described an increased PAI-1 secretion from endothelial cells in 
response to glycated HDL cholesterol from patients with type II diabetes mellitus. 
Furthermore, the level of HDL glycation is proportional to insulin resistance and may 
therefore explain the lack of a significant relationship between insulin and total PAI-1 Ag 
after controlling for HDL cholesterol. 
The relationship between total PAI-1 Ag and vWF over the trial can be attributed to the 
co-release of the two factors from the alpha granules of activated platelets and the 
endothelium in response to damage and exposure of the sub-endothelium (Gibbons etal 
1990). The damage to the endothelium occurs as a result of increased shear stress on 
the blood vessel wall. The increased shear stress occurs due to elevated blood pressure 
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especially during exercise, and may in extreme cases cause the rupture of vulnerable 
atherosclerotic plaques which may in turn lead to MI onset (Mittleman & Siscovik 1996). 
The multiple regression model included triglyceride, vWF, HDL cholesterol and total 
cholesterol and accounted for 59% of the variation in total PAI-1 Ag. This confirms that 
the regulation of PAI-1 secretion is a complex process involving a number of different 
factors including triglyceride, vWF, insulin, HDL cholesterol and other unknown factors. 
Another consideration is the expression of the 2 PAI-1 transcripts. The larger of the 2 
transcripts (3.2 kb Vs 2.2 kb) is less stable and therefore has a shorter biological half life 
(Tremoli et al 1993). The ratio of the 2 transcripts will affect the overall half-life of PAI-1 
thus aff ecting the PAI-1 Ag. Stiko-Rahm etal (1990) observed that VLDL molecules from 
hypertriglyceridaemic patients stimulates the preferential expression and release of the 
more stable PAI-1 transcript and this may contribute to the increased PAI-1 Ag observed 
in those with other symptoms of the IRS. 
Across the trial active PAI-1 Ag (table 6.6) was significantly correlated with triglyceride 
concentration (R=0.573 P=0.000), total cholesterol (R=0.392 P=0.000), HDL cholesterol 
(R=-0.295 P=0.018) and insulin (R=0.263 P=0.036). Following multiple partial 
correlations, controlling for each significantly correlated factor in turn, only triglyceride 
concentration and total cholesterol concentration were independently correlated to active 
PAI-1 levels. 
Triglyceride accounted for a similar amount of the variation in active PAI-1 Ag as it 
accounted for in total PAI-1 Ag (active PAI-1=36%, total PAI-1 = 36%). This provides 
additional evidence for the role of triglyceride In the short term regulation of PAI-1 
secretion. When controlling for triglyceride concentration the relationship between PAI-1 
and insulin was reduced to a trend. This still suggests that as with total PAI-1, insulin 
potentiates the effect of triglyceride on PAI-1 secretion. Unlike the relationship seen with 
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total PAI-1 Ag, controlling for triglyceride abolished the correlation between HDL 
cholesterol and active PAI-1 Ag (R=0.007, P=0.960). This implies that the association 
between active PAI-1 Ag and HDL cholesterol is purely a result of the close metabolic 
relationship between HDL and triglyceride thus confirming the results of Cimminello et al 
(1997) who demonstrated that only patients with both elevated triglycerides and low HDL 
had elevated PAI-1 compared to those with low HDL cholesterol only. 
The independent correlation between active PAI-1 Ag and total cholesterol was not 
observed with total PAI-1. This association is independent of HDL cholesterol as 
controlling for this factor strengthens the relationship (R=0.392 without controls, R=0.457 
with controls). Controlling for triglyceride concentration weakens the association but 
does not abolish it suggesting that a single lipoprotein sub-fraction is not the contributing 
factor. We can postulate therefore that a combination of LDL and VLDL cholesterol is 
contributing to this association but a direct measure of the all lipoprotein sub-fractions 
would be needed to confirm this. 
The multiple regression model containing both triglyceride and total cholesterol, only 
accounted for 36% of the variability in active PAI-1 Ag. This suggests that factors that 
have not been measured in this study are primarily responsible for the short term 
regulation of PAI-1. 
Free t-PA concentration would be a better measure as the t-PA/PAI-1 complex is rapidly 
formed thus decreasing plasma active PAI-1 Ag. This rapid complex formation may mask 
the effect of other factors in the short term regulation of active PAI-1 Ag. Another 
consideration when accounting for the variability of active PAI-1 Ag over time is the 
availability of vitronectin, which stabilises the active conformation and thus increases its 
biological half life (Van Meijer & Pannekoek 1995). 
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Overall this study cannot provide any firm conclusions about the factors involved in the 
short term regulation of PAI-1 secretion. The large number of variables including PAI-1 
secretion rate from different tissues, hepatic clearance rate and availability of such 
factors as vitronectin and t-PA all contribute to the large variability observed with a study 
such as this. Another limitation is the assumption that the metabolic markers of the IRS 
stimulate PAI-1 secretion almost immediately. This research therefore does not account 
for delayed reactions including larger non measured metabolic pathways or stimulation of 
PAI-1 expression. 
Triglyceride concentration however was the only measured factor to remain significantly 
correlated to both active and total PAI-1 Ag at rest, during exercise and in the post 
exercise period despite controlling for a number of markers of the IRS. This suggests a 
role for triglyceride in the regulation of PAI-1 secretion and expression and confirms both 
the in vivo (Cimminello eta11997, Vague eta11995) and in vitro (Stiko-Rahm eta11990, 
Sironi et a11996) data. Many more studies are needed to assess the effect of different 




The effect of a maximal oxygen 
uptake test on fibrinolytic 
capacity in sedentary, 
overweight & obese, healthy, 
premenopausal, female 
volunteers 
Chapter 7: The effect of a maximal oxygen uptake test on fibrinolytic capacity 
in sedentary, overweight & obese, healthy, premenopausal, female volunteers. 
7.1 Introduction 
The results of the study assessing the effect of an acute bout of moderate intensity 
exercise on obese males volunteers (chapter 5) did not show any significant change 
in total PAI-1 concentrations suggesting that the decrease in active PAI-1 was merely 
a result of increased t-PA. Numerous groups have reported a significant decrease in 
total PAI-1 concentrations in non obese populations following acute bouts of 
strenuous exercise (El Sayed 1996, Szymanski & Pate 1994). 
The hypothesis for this study therefore is that strenuous exercise, in the form of a 
maximal oxygen uptake test to exhaustion will result in decreased total PAI-1 
concentrations. 
The results from the previous study also showed that the obese group remained 
hypofibrinolytic and therefore at increased risk of MI onset compared to the non 
obese group both during and post exercise. These results suggest that subjecting 
obese male volunteers to a strenuous maximal oxygen uptake test may further 
increase the risk of MI onset. In order to avoid this which would present ethical 
problems for a research project, obese and overweight premenopausal females were 
used in this study. 
Premenopausal females produce lower amounts of PAI-1 than both men and 
postmenopausal women (Gebara et al 1995). Premenopausal women commonly 
display gynoid obesity (accumulation of fat around the hips and buttocks). This fat is 
relatively benign in terms of cardiovascular risk and the IRS and as such, 
premenopausal women display less symptoms of the IRS (Despres & Lamarche 
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1993). Comparison of these results with those obtained in obese males (chapter 6) 
may provide a further insight into the mechanisms responsible for elevated PAI-1 
concentrations and possible allow prediction of PAI-1 changes with exercise from 
resting data. 
The primary aim of this research study therefore is to determine the effect of a single 
multi-stage maximal oxygen uptake test on plasma fibrinolytic capacity In overweight 
and obese premenopausal women. The secondary aim is to determine if the change 
in fibrinolytic capacity can be predicted from resting anthropometric and blood 
markers. 
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7.2 Subjects & Methods 
19 (powered to 95% confidence and 20% type II error) overweight and obese 
premenopausal female volunteers were recruited for participation in the study. 
Inclusion criteria for the study were BMI >27 kg/m2 and a waist circumference 
>88cm. "Sedentary' was defined as <20 minutes recreational exercise per week and 
having a non manual profession. All subjects were free of any ongoing disease or 
impairment of gait or balance. 
7.2.2 Experimental Design 
All subjects underwent a physical examination prior to entry into the study. 
Volunteers arrived at the laboratory at 09.00h to reduce the effects of diurnal 
variation having fasted overnight, abstained from smoking for 8 hours, alcohol for 24 
hours and strenuous exercise for 48 hours. No subject was taking prescription or 
"over the counter" medication for 6 weeks prior to the commencement of the study 
and the test was performed in the early follicular phase (days 7-11) of each 
volunteer's menstrual cycle. 
On the trial day subjects underwent measures of height, weight, percent body fat (by 
bioelectrical impedance (Body Stat 1500T"") waist circumference, hip circumference 
and blood pressure. Blood pressure was determined by the average of three values 
recorded 10 minutes apart (Omron 711). A 21 G cannula was then inserted into a 
suitable forearm vein (after 3 minutes of venous occlusion at 100 mmHg). Subjects 
then rested in the seated position for 15 minutes before a 25ml blood sample (PRE) 
was taken. Maximal oxygen uptake was determined by means of a maximal fitness 
test on a motorised treadmill employing a modified Bruce protocol. Expired air was 
analysed on a breath by breath basis using the MetaMax 3B online telemetry system, 
for FEO2, FECO2, volume and temperature to allow calculation of V02 (all volumes 
were corrected to STPD) and RER. Heart rate was recorded by the Metamax via a 
131 
PolarTM heart rate monitor and, perceived exertion was recorded in the last 30 
seconds of each stage using 3 of the following 4 criteria to ascertain that subjects 
had reached maximal oxygen uptake. 
1. A heart rate > 220 - subjects age 
2. V02 that remained unchanged over 2 consecutive stages 
3. A rating of perceived exertion > 18 over 2 consecutive stages 
4. RER>1.1 
Subjects then performed a3 minute cool down period (2.7 km h'', 0% gradient) 
before a second 25 ml blood sample (POST) was taken. 
7.2.3 Laboratory Methods 
Blood samples were distributed between sealed evacuated test tubes containing no 
additives, sodium citrate or EDTA. The EDTA samples were analysed immediately 
for haemoglobin concentration (GDS systems) and haematocrit (micro centrifugation 
Hawksley International). Sodium citrate samples were centrifuged at 3000rpm (IEC 
Centra-2) for 15 minutes and the resultant plasma was pipetted into eppendorf tubes 
and immediately frozen at -80°C. The plasma samples were analysed by ELISA for 
t-PA Ag (Biopool International procedure 101005), Total PAI-1 (Biopool International 
procedure 101005), active PAI-1 Ag (Technoclone procedure 16075) and vWF 
(Immunozym procedure 5450200). No additives samples were allowed to clot for 30 
minutes before centrifugation at 3000rpm (IEC Centra-2) for 15 minutes and the 
resultant serum was pipetted into eppendorf tubes and stored at -20°C. The serum 
samples were analysed for insulin by MEIA (Imx Systems), leptin by ELISA (R&D 
systems procedure DLPOO), total cholesterol (Beckman Synchron CX systems 
procedure 467825), triglyceride (Beckman Synchron CX systems 445850) and HDL 
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cholesterol (Sigma diagnostics procedure 345L). LDL concentration was determined 
using the Friedewald equation. 
7.2.4 Calculations and Statistical Analysis 
Plasma volume changes were calculated according to the method of Dill & Costhill 
(1974). All data shown is corrected for plasma volume changes. Normality of 
distribution determined using a Shapiro-Wilks test. Comparisons between PRE and 
POST samples were determined using paired T tests for normally distributed data 
and Mann Whitney test for skewed data. The relationships between measures were 
determined using Spearman's rho correlation coefficients and multiple stepwise 
regression models. Two tailed significance levels are reported and differences were 
considered significant when P<0.05. 
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7.3 Results 
7.3.1 Demographic Data 
The physical characteristics of the subjects are shown in table 7.1.5 subjects were 
overweight (BMI 27-30 kg/m) and 14 were obese (BMI > 30 kg/m2). 17 subjects 
were Caucasian and 2 were Afro Caribbean in origin. All subjects had a waist 
circumference > 88cm which is indicative of elevated cardiac risk. 
Table 7.1: The h ical characteristics and fibrinol is variables of the 19 subjects. 
Variable Mean ± SEM Median (Range) 
Body Mass (kg) 87.34 (72.70 to 110.00) 
BMI (kg/m) 
Body Fat (%) 
Body Fat (kg) 
Waist Circumference (cm) 
Waist to Hip Ratio 
V02 max (ml/kg/min) 
Systolic Pressure (mmHg) 
Diastolic Pressure (mmHg) 
t-PA Ag (ng/mI) 
Total PAI-1 Ag (ng/ml) 
7.87+0.72 
11.28 ± 1.27 
32.12 (27.50 to 38.10) 
41.84 (30.00 to 49.70) 
36.90 (22.20 to 51.92) 
94.11 (88.00 to 108.00) 
0.83 (0.74 to 0.94) 
18.94 (10.66 to 25.90) 
132.83 (120.00 to 160.00) 
85.86 (60.00 to 96.00) 
Active PAI-1 Ag (U/ml) 5.99+1.00 
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Concentrations of the other measured blood markers of the insulin resistance 
syndrome are shown in table 7.2. 
Table 7.2: Concentrations of the measured blood markers of the Insulin Resistance syndrome at rest. 
N=19 
Variable Mean ± SEM Median (Range) 
Total Cholesterol (mmolL) 5.17 (3.7 to7.4) 
Triglyceride (mmoVL) 1.30 (0.55 to 2.98) 
HDL Cholesterol (mmoVL) 1.33 (0.78 to2.68) 
LDL Cholesterol (mmol/L) 3.26 (2.0 to4.3) 
Insulin (pmol/L) 6.41 ± 0.69 
Leptin (ng/mI) 28.64± 6.85 
VWF (IU/ml) 0.42+0.05 
k 
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7.3.2 Fibrinolytic Factors with Maximal Exercise 
T-PA Ag (fig 7.1) significantly increased by 62% from (mean (SEM)) 7.87 ± 0.72 
ng/ml to 12.74 ± 1.58 ng/ml (P=0.02) as a result of the maximal exercise test. Total 











Figure 7.1: The effect of a maximal exercise test on t-PA Ag, total PAI-1 Ag and active PAI-1 Ag. 
Data is shown as mean ± SEM. All data is corrected for changes in plasma volume. *= P< 0.05. 
To determine whether 'responders' and 'non-responders' to maximal exercise can be 
identified from resting data, subjects were grouped according to response to 
exercise. Those subjects whose total or active PAI-1 concentration decreased with 
exercise were termed "responders" and those subjects in whom total or active PAI-1 
increased with exercise were termed "non-responders". 
Concerning total PAI-1 Ag, the women studied included 11 'responders' to exercise 
(in whom total PAI-1 Ag decreased with exercise) and 8'non-responders' to exercise 
(in whom total PAI-1 Ag increased with exercise). Group comparisons showed that 
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t-PA Ag (ng/mI) Total PAI-1 Ag (ng/ml) Active PAI-1 Ag (U/mI) 
the 'responders' had a significantly higher VO2max (P = 0.025) than the 'non 
responders', as well as higher resting t-PA concentration and lower resting total PAI- 
1 concentrations. 
Concerning active PAI-1 concentrations, the women studied included 10 
"responders" to exercise (active PAI-1 concentrations decreased) and 9 non- 
"responders" to exercise (active PAI-1 concentrations increased with exercise). 
Comparisons between the two groups revealed that the responder group had a 
significantly higher V02 max (P=0.043) and non significant trends towards lower 
resting total cholesterol concentrations (P = 0.066) and lower resting triglyceride 
concentrations (P = 0.079). 
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7.3.3 Total PAI-1 Ag 
To assess the possible contribution of other markers of the insulin resistance 
syndrome in the short-term regulation of fibrinolytic variables over the trial, multiple 
correlations were performed (tables 7.3 & 7.4). Total PAI-1 Ag was significantly 
positively correlated with total body mass, BMI, body fat percentage, fat mass and 
waist circumference. 
Table 7.3: Correlations between total PAl-1 Ag concentrations and other anthropometric and blood 
measures of the Insulin Resistance Syndrome at rest and at the end of the exercise bout. N=19. * = 
P=<0.05, T= p<0.10 
Marker R Value P Value 
Body Mass (kg) 0.517 0.023* 
BI VII 0.465 0.045* 
Fat Percentage (%) 0.455 0.050* 
Fat Mass (kg) 0.554 0.014* 
Waist Circumference (cm) 0.447 0.050* 
Waist to Hip Ratio -0.135 0.583 
V02 max (ml/kg/min) -0.470 0.043* 
Systolic Pressure 0.034 0.890 
Diastolic Pressure 0.209 0.390 
Rest Insulin (pmoVL) 0.147 0.380 
Rest Total-C (mmol/I) -0.036 0.830 
Rest Triglyceride (mmol/L) 0.121 0.469 
Rest HDL-C (mmol/L) -0.218 0.188 
Rest LDL-C (mmol/L) 0.015 0.927 
Rest Leptin (pg/ml) 0.096 0.565 
Rest vWF (IU/ml) 0.038 0.819 
Rest t-PA (ng/ml) 0.131 0.434 
Total PAI-1 (ng/ml) - - 
Active PAI-1 (ng/ml) 0.188 0.259 
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Unlike the previous study in a male population (chapter 6) however, no blood 
markers were significantly correlated to total plasma PAI-1 concentrations. Also, 
unlike the previous study total PAI-1 was negatively correlated with V02 max. 
7.3.4 Active PAI-1 Ag 
Finally, unlike the previous trial active plasma PAI-1 Ag was not significantly 
correlated to any of the measured factors. 
Table 7.4: Correlations between active PAI-1 Ag concentrations and other anthropometric and blood measures of 
the Insulin Resistance Syndrome at rest and at the end of the exercise bout. N=19 
Marker R Value P Value 
Body Mass (kg) 0.128 0.601 
BM I 0.131 0.593 
Fat Percentage (%) 0.186 0.445 
Fat Mass (kg) 0.171 0.485 
Waist Circumference (cm) -0.032 0.896 
Waist to Hip Ratio -0.144 0.556 
V02 max (mVkg/min) 0.072 0.770 
Systolic Pressure 0.356 0.134 
Diastolic Pressure 0.281 0.245 
Rest Insulin (pmoVL) 0.091 0.586 
Rest Total-C (mmol/I) -0.108 0.519 
Rest Triglyceride (mmol/L) -0.062 0.711 
Rest HDL-C (mmol/L) -0.157 0.347 
Rest LDL-C (mmol/L) -0.035 0.835 
Rest Leptin (pg/ml) 0.058 0.730 
Rest vWF (IU/ml) 0.001 0.997 
Rest t-PA (ng/ml) 0.213 0.199 
Total PAI-1 (ng/ml) 0.188 0.259 
Active PAI-1 (ng/ml) - - 
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To test whether any of the resting variables were predictive of the actual changes or 
percentage changes in total and active PAI-1 a stepwise multiple regression analysis 
was performed. 
When the dependent variable in the model was percentage change in total plasma 
PAI-1 Ag, WHR was the first variable to enter (t = 7.502, P=0.000). Systolic blood 
pressure (t = 7.425, P=0.000), resting total PAI-1 Ag concentration (t = -2.194 P= 
0.012) and waist circumference (t = -2.890, P=0.000) were the only other variables 
that remained independently associated with percentage change in total PAI-1 
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Figure7.2: Correlation between observed percentage change in [Total PAI-1 Ag] and change in [Total 
PAI-1 Ag] as predicted by the multiple regression equation. N=19 
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When the dependent variable in the model was actual change in PAI-1 concentration 
(ng/ml) systolic blood pressure was the first resting variable to enter the model (t = 
10.021, P=0.000) followed by resting total PAI-1 Ag concentration (t = -6.163 P= 
0.000), WHR (t = 6.830 P=0.000), fat mass (t = -4.159 P=0.001) and resting 
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Figure 7.3: Correlation between observed change in [Total PAI-1 Ag] and change predicted by the 
multiple regression equation. N=19. 
No factors were significantly correlated with either percentage change or actual 




The primary aim of this research study was to determine the effect of a single multi- 
stage maximal oxygen uptake test on plasma fibrinolytic capacity in overweight and 
obese pre menopausal women. The secondary aim was to determine if the change 
in fibrinolytic capacity could be predicted from resting anthropometric and blood 
markers. 
7.4.2 Summary of the Protocol 
19 overweight and obese premenopausal females undertook a graded maximal 
oxygen uptake test on a motorised treadmill. Blood samples were taken at rest and 
immediately following the exercise bout. Samples were analysed for t-PA, total and 
active PAI-1, insulin, leptin, total cholesterol, triglyceride, HDL cholesterol, LDL 
cholesterol and vWF. Measurements of height, weight, body fat and waist and hip 
circumference were recorded before the exercise bout. 
7.4.3 Resting Results 
At rest, the 19 women studied exhibited t-PA Ag concentrations within the normal 
range (Mean ± SEM, 7.87 ± 0.72 ng/mI, normal range = 3-10 ng/ml) as well as 
normal range total PAI-1 Ag (11.28 ± 1.27 ng/ml, normal range 4-43 ng/ml) and 
active PAI-1 Ag concentrations (5.99 ± 1.00 U/ml, normal range 1-7 U/ml). This 
group of patients did not show a reduced fibrinolytic capacity (Total PAI- 
concentration >50 ng/ml & Active PAl-1 concentration >20 IU/ml) despite a waist 
circumference of >88 cm which is indicative of the metabolic disturbances associated 
with an increased risk of coronary heart disease (Han et at 1995) and a mean waist 
to hip ratio > 0.80 which is also indicative of an increased susceptibility to 
atherosclerosis (Despres et al 1995). 
The absence of an impaired fibrinolytic capacity was also evident in all subjects 
despite total cholesterol concentrations of up to 7.4 mmol/L, triglyceride 
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concentrations of up to 2.98 mmoVL, and LDL cholesterol concentrations of up to 4.3 
mmol/L. HDL cholesterol, insulin concentration and leptin concentrations remained 
within the normal healthy range for all subjects. This suggests that the 
hypofibrinolytic state associated with an increased waist circumference occurs after 
the development of a dyslipidaemic profile in the population. The lack of a 
hypofibrinolytic profile in this group of subjects despite a waist circumference >88cm, 
adds evidence to the postulated role for oestrogen in the regulation of PAI-1 
secretion and expression (Huber 2001 a, Teede et al 2000). 
7.4.4 t-PA with Exercise 
Consequent to the exercise test, t-PA Ag rose by 62% (from 7.87 ± 0.72 ng/ml to 
12.74 ± 1.58 ng/ml). T-PA Ag has been reported to rise by 10-3000% with exercise 
of various intensities and durations. The reported exercise intensity threshold for 
increases in t-PA secretion and expression is approximately 50% V02 Max with the 
largest increases occurring at intensities > 70% V02 max (Streiff & Bell 1994). The 
increase in plasma t-PA concentrations observed in this study are modest in 
comparison to a number of other studies at intensities >_ 65% V02 max. These 
studies, in hypertensives and sedentary populations, observed increases of 180% 
(Womack et al 2001) and 225% (Gleerup et al 1995) respectively. Szymanski & Pate 
(1994) demonstrated that exercise at 80% V02 max elicited a 50% greater response 
in t-PA concentration when compared to exercise at an intensity of 50% V02 max. 
The results of our investigation suggest that insufficient ti me was spent exercising at 
an intensity > 70% V02 max to elicit the maximal t-PA response or, as with obese 
males, local changes in fibrinolytic factors are not reflected at the cannulation site 
until the post exercise recovery period. 
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7.4.5 PAI-1 with Exercise 
As with the previous study in a male population, there were no significant changes in 
either total PAI-1 or active PAH concentrations after a maximal exercise bout. The 
majority of studies have reported reductions in total PAI-1 concentration and PAI-1 
activity from 30% of resting values (Rocker et al 1990) to undetectable levels 
(Speiser et al 1988), following an acute bout of exercise at an intensity greater than 
70% V02 max (Strieff & Bell 1994) unlike t-PA, which has been reported to 
significantly increase with exercise at an intensity > 50% V02 max (Streiff & Bell 
1994). In this study, due to that nature of a modified Bruce protocol maximal oxygen 
uptake test, it may be that insufficient time was spent exercising at an intensity of > 
70% V02 max. Also, as the blood sample was taken immediately following the 
cessation of exercise, local changes in PAI-1 concentration resulting from the short 
period of exercise at > 70% V02 max, may not yet have been reflected at the 
cannulation site. An additional blood sample post exercise would have indicated if 
this subject group reacted to exercise the same way as the male population by 
demonstrating significant changes in both total PAH concentration and active PAI-1 
concentration post exercise. Finally, the lack of a statistically significant change in 
total or active PAH concentrations with a maximal exercise test may be due to the 
equal distribution of "responders" and non-'responders" to exercise within the group 
('responders' show a decreased PAH concentration following exercise whereas the 
'non-responders' show an increased PAH concentration following an exercise bout). 
To determine whether 'responders' ý and 'non-responders' to exercise can be 
identified before undertaking an exercise bout, subjects were grouped according to 
PAI-1 response and an analysis of variance performed on all anthropometric and 
resting blood marker data to determine the differences between groups. Subjects in 
the responder group for both total and active PAI-1 had a significantly greater V02 
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max than the subjects in the non-responder group. There were no other differences 
between the two groups suggesting that physical fitness is an important contributor to 
the PAI-1 response to exercise. 
Numerous longitudinal (Koenig & Ernst 2000, Streiff & Bell 1994) and cross sectional 
studies (Kvernmo & Osterud 1997, Earl et al 1987) have recorded significantly lower 
concentrations of both active and total plasma PAI-1 in volunteers undertaking 
regular exercise. Furthermore, Muller et al (1996) recorded a lower incidence of MI 
onset following heavy physical activity in those patients that undertook regular 
physical exercise. Active plasma PAI-1 'responders' (in which a decrease in PAI-1 
was observed) to a maximal oxygen uptake test also had a significantly increased 
resting t-PA concentration compared to the non-responder group. This further 
highlights the importance of regular physical exertion in increasing both resting 
fibrinolytic capacity and the fibrinolytic response to exercise. 
Overall the results suggest that there was an improvement in fibrinolytic capacity as 
shown by a significantly increased t-PA concentration with no significant change in 
either total PAI-1 or active PAI-1 concentrations. This suggests that an 
unaccustomed exercise bout may decrease the risk of MI onset and SCD in the 
premenopausal overweight and obese population studied. This response Is contrary 
to response seen in an obese male population (chapter 5). Pre menopausal females 
display less of the metabolic disturbances associated with obesity as a result of the 
deposition of fat around the buttocks and thighs. The fat in this area is relatively 
benign whereas central fat accumulation, as seen in post menopausal women and 
men is more metabolically active and is strongly associated with the cluster of 
metabolic abnormalities that make up the insulin resistance syndrome and thus 
increase the risk of cardiovascular disease (Despres et al 1994). 
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7.4.6 Relationships between PAI-1 and other markers of the IRS 
As with the previous study in an obese male population (chapter 5), total plasma PAI- 
1 Ag was significantly positively correlated with total body mass, BMI, body fat 
percentage, fat mass and waist circumference. Unlike the previous trial however, 
total PAI-1 Ag was not significantly correlated with systolic, diastolic or mean arterial 
blood pressure nor blood markers of the insulin resistance syndrome but was 
significantly negatively correlated with V02 max. As very few subjects showed any 
biochemical features of the IRS such as increased insulin concentrations and 
hypertension this is not entirely unexpected. Non obese populations do not 
demonstrate the same correlations between markers of the insulin resistance 
syndrome as do obese populations (Landin et al 1990) and as the population in this 
study ranged from overweight to obese, it may be that insufficient obese patients 
were included to allow for significant correlations to be observed. 
Numerous studies have however reported correlations between resting total PAH 
Ag (active & latent PAI-1) and anthropometric measures in premenopausal females. 
De Pergola et al (1997) observed a significant correlation between PAI Ag and waist 
circumference in obese and lean premenopausal females. This finding was 
confirmed by Janand-Delenne et al (1998) who showed that this relationship is due to 
a further significant correlation between PAI-1 Ag and visceral as opposed to 
subcutaneous fat depots. The relationship of PAI-1 Ag to anthropometric measures 
such as waist circumference and body fat percentage irrespective of insulin and 
triglyceride concentrations further supports the in vitro work (Yudkin et al 1999, 
Samad et al 1996) on the role of adipose tissue in the expression and secretion of 
PAI-1. 
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7.4.7 Predicting the PAI-1 response to Maximal Exercise 
Finally, from the analysis of PAI-1 concentrations during this study in premenopausal 
females, we have identified two distinct groups of patients (i. e. 'responders' and 'non- 
responders' to exercise). We have also demonstrated that there are no 
anthropometric or blood markers at rest that directly indicate to a physician which 
category a patient is likely to be in. In view of this, multiple regression analysis was 
performed to determine whether actual changes (e. g. ng/ml) or percentage changes 
in plasma t-PA Ag, active PAI-1 Ag or total PAI-1 Ag could be predicted from 
measures taken at rest in an effort to predict those patients'at risk'. 
As mentioned earlier, V02 max was the only way in which the PAI-1 'non-responders' 
differed from the 'responders'. A stepwise multiple regression equation was 
therefore performed to determine whether percentage or actual change in total PAM 
Ag could be predicted from resting markers of the metabolic syndrome. When 
percentage change in plasma PAI-1 concentration was considered as the dependent 
variable, the stepwise multiple regression equation incorporated waist to hip ratio, 
systolic blood pressure, resting total PAI-1 Ag and waist circumference. The 
predicted values for % change in total PAI-1 Ag concentration with a maximal oxygen 
uptake test were significantly correlated with the values recorded at the end of the 
exercise bout (R2 = 0.898, P=0.000). This suggests that percentage change in total 
PAI-1 Ag with maximal exercise can be predicted with an accuracy of 90%. Only 1 of 
the 19 patients tested was classified as a responder when in fact, the measured PAI- 
1 showed that they were as a non-responder and 1 patient was classified as a non- 
responder when the data showed them to be a responder. In both cases the% 
response to exercise was small (. 20%). 
Similarly, actual change in total PAI-1 (ng/ml) following a maximal oxygen uptake 
test can be predicted with an accuracy of 95% (R2 = 0.947, P=0.000), using the 
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equation provided by the multiple stepwise regression model which incorporates 
systolic blood pressure, resting total PAI-1, WHR, fat mass and resting triglyceride 
concentration. Using this model 3 of the 19 patients were wrongly categorised but 
again the change in total PAI-1 concentration with exercise was very small (<3 
ng/ml). 
If this model could be validated against a large population of lean and overweight 
subjects it may prove to be invaluable in the prediction of a hypofibrinolytic state 
following strenuous exercise and the risk of MI onset following an unaccustomed 
exercise bout in these groups. 
Overall from the data we can conclude that overweight and obese premenopausal 
females exhibit an increase fibrinolytic capacity following a multistage maximal 
oxygen uptake test, as shown by significantly increase t-PA Ag concentrations with 
no significant changes in PAI-1 concentration. This population however can be 
subdivided into two groups of those who show a decreased concentration of PAI-1, 
and therefore an increased fibrinolytic potential, following exercise and those in 
whom an increased PAI-1 concentration is observed. These groups can only be 
directly defined by a V02 max assessment but a multiple regression equation can 
predict both % changes and actual changes in PAI-1 concentration from resting 
anthropometric and blood markers with an accuracy of > 90%. This formula, if 
validated in a larger population, may help to identify those at greatest risk from MI 
onset with unaccustomed exercise and may therefore encourage those patients 
affected to undertake regular submaximal physical activity that is known to increase 
fibrinolytic capacity both at rest and following exercise. 
148 
Chapter 8 
The effect of exercise intensity on 
fibrinolytic capacity in sedentary 
overweight and obese healthy 
premenopausal women. 
Chapter 8: The effect of exercise intensity on fibrinolytic capacity in sedentary 
overweight and obese pre menopausal women. 
8.1 Introduction 
The model proposed by Streiff & Bell (1994) for changes in fibrinolytic factors in lean 
active volunteers with exercise states that as exercise intensity reaches approximately 
50% VO2 max small increases in t-PA concentrations can be recorded. When exercise 
reaches 70% V02 max the largest increases in t-PA are recorded and active PAI-1 
concentrations decrease. The primary aim of this study therefore is to determine if this 
model also applies in overweight and obese healthy premenopausal females performing 
moderate (70% V02 max) and low intensity (50% V02 max) exercise for duration 
equivalent to the expenditure of 300 Kcals.. 
Furthermore, the study in obese male volunteers (chapter 5) showed an elevation in total 
PAI-1 concentrations thirty minutes post exercise. This study aims to establish whether 
this result is reproducible in premenopausal females. If so, the extension to the post 
exercise period may allow an estimation of the time to recovery of PAI-1 to baseline 
levels. 
Finally, following on from the results of the maximal exercise test (chapter 7) in 
premenopausal females the secondary aim of this study is to determine whether the 
changes in total and active PAI-1 with exercise at either 50% or 70% V02 max can be 
predicted from anthropometric and other blood markers of the insulin resistance 
syndrome taken at rest. 
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8.2 Subjects and Methods 
14 overweight and obese pre menopausal females agreed to participate and 6 
completed the study. Inclusion criteria were BMI > 28 kg/m2, waist circumference > 
88cm, participation in less than 20 minutes recreational exercise per week and having a 
non-manual profession. 
8.2.2 Experimental Design 
All subjects underwent physical examinations and biochemical and haematological 
screening prior to entry into the trial. Maximal oxygen uptake was determined by means 
of a maximal oxygen uptake test on a motorised treadmill employing a modified Bruce 
protocol. On a separate day, workloads corresponding to 50% and 70% V02 max were 
determined during thirty minute practice trial in which subjects were familiarised with the 
protocol. Measures of height (standard stadiometer), weight (TanitaTM TBF-310), 
percentage body fat using bioelectrical impedance analysis (BodyStatTM 1500), waist 
circumference and hip circumference were also recorded during this visit. 
On trial days subjects arrived at the laboratory at 09: 00h having fasted for a minimum of 
8 hours. All subjects had abstained from smoking for a minimum of 8 hours, alcohol for 
24 hours and strenuous exercise for 48 hours. No subject was taking prescription or 
'over the counter' medication for 6 weeks prior to the commencement of the study. All 
visits were completed in the early follicular (day 7-11) phase of each volunteer's 
menstrual cycle. 
On arrival at the laboratory a 21 G cannula was inserted into a suitable forearm vein 
(after 3 minutes of venous occlusion at 100 mmHg). Subjects then rested in a seated 
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position for 15 minutes before a blood sample (T-30) was taken. After a further 30 
minutes of rest a second blood sample (TO) was taken before exercise commenced 
which consisted of a three minute warm up stage (2.7 km h", 0% gradient) and then an 
increase in speed and gradient to elicit either 50% or 70% V02 max. This study was of a 
random cross over design. Expired air was analysed on a breath-by-breath basis for 
FEO2 and FECO2 t, volume, temperature and pressure (Metamax 3B TM) to allow 
calculation of V02, RER and caloric expenditure (by indirect calorimetry). Time to 
expend 300 Kcals was predicted by averaging the caloric expenditure over a 10 minute 
period, following 20 minutes of exercise at the given intensity. When the 300 kcal target 
was achieved subjects performed a3 minute cool down period (2.7 km h'', 0% gradient) 
before a further blood sample was taken (END). Finally, subjects rested in a seated 
position for a further 2 hours. During this time, blood samples were taken 30 minutes 
(T+30), 60 minutes (T+60) and 120 minutes (T+120) post exercise. 
8.2.3 Laboratory Methods 
Blood samples were distributed between sealed evacuated test tubes containing no 
additives, sodium citrate or EDTA. The EDTA samples were analysed immediately for 
haemoglobin concentration (GDS systems) and haematocrit (micro centrifugation 
Hawksley International). Sodium citrate samples were centrifuged at 3000rpm (IEC 
Centra-2) for 15 minutes and the resultant plasma was pipetted into eppendorf tubes 
and immediately frozen at -80°C. The plasma samples were analysed by ELISA for t-PA 
Ag (Biopool International procedure 101005), Total PAI-1 Ag (Biopool International 
procedure 101005), active PAI-1 Ag (Technoclone procedure 16075) and vWF 
(Immunozym procedure 5450200). No additives samples were allowed to clot for 30 
minutes before centrifugation at 3000rpm (IEC Centra-2) for 15 minutes and the 
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resultant serum was pipetted into eppendorf tubes and stored at -20°C. The serum 
samples were analysed for insulin by MEIA (Imx systems), leptin by ELISA (R&D 
systems procedure DLPOO), Total cholesterol (Beckman Synchron CX systems 
procedure 467825), triglyceride (Beckman Synchron CX systems 445850) and HDL 
cholesterol (Sigma diagnostics procedure 345L). LDL concentration was determined 
using the Freidewald equation. 
8.2.4 Calculations and Statistical Analysis 
Plasma volume changes were calculated according to the method of Dill & Costhill 
(1974) and all data was corrected for plasma volume changes. Normality of data 
distribution was assessed by means of a Shapiro-Wilks test. Data that displayed a 
normal distribution was assessed by means of a one way analysis of variance (ANOVA) 
followed by Tukey's post hoc analysis. Data for these variables is expressed as Mean ± 
standard deviation. Skewed data is presented as Median (range) and was assessed by 
means of Krushkal-Wallis tests followed by multiple Mann-Whitney paired data tests. To 
assess the relationships between variables and fibrinolytic factors Spearman's rho 
coefficients were performed. Two tailed significance levels are reported and differences 
were considered significant when P<0.05. 
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8.3 Results 
8.3.1 Resting Variables 
The anthropometric measures and resting blood variables of the 6 women are shown in 
table8.1. All 6 women were Caucasian in origin. 5 of the women were classed as obese 
(BMI > 30 kg/m2) and 1 was classed as overweight (BMI 27-29 kg/m2). All 6 women also 
had a waist circumference greater than 88cm that is predictive of the metabolic 
abnormalities associated with the IRS (Despres & Lamarche 1993) 
Table 8.1: The physical characteristics and fibrinolytic variables of the 6 women. Resting concentrations of 
blood variables are averaged over the two trial days. Normally distributed data is shown as mean ± S. D and 
skewed data is shown as median (range). 
Marker Mean ± S. D Median (Range) 
Body Mass (kg) 82.07+8.12 
BMI (kg/rn2) 30.33+1.29 
Body fat (%) 40.10 ± 4.44 
Fat Mass (kg) 32.94+5.95 
Waist to hip Ratio 0.79 (0.74 to 0.96) 
Waist circumference (cm) 88 (88 to 96) 
V02 max (mis/kg/min) 18-89+5.93 
t-PA (ng/mI) 5-40+1.21 
Total PAI-1 (ng/ml) 8.70 (3.40 to 18.50) 
Active PAI-1 (U/ml) 3.50 (0.70 to 11.50) 
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Resting concentrations of other measured blood markers of the insulin resistance 
syndrome are shown in table 8.2. There were no significant differences in any of the 
variables measured at rest between the two trials. 
Table 8.2: Concentrations of the other measured blood markers of the Insulin Resistance syndrome at rest. 
N=6. Normally distributed data is presented as mean ± S. D. and skewed data is presented as median 
(range). Data is taken from resting values of both the 50% and 70% trials 
Marker Mean (S. D) Median (range) 
Total Cholesterol (mmoVL) 
Triglyceride (mmoVL) 0.81+0.30 
HDL Cholesterol (mmol/L) 1.20+0.42 
LDL Cholesterol (mmoVL) 3.01+0.70 
Insulin (pmoVL) 6.28+3.28 
Leptin ng/mI) 
4.29 (4.00 to 5.57) 
58.68 (31.10 to 86.36) 
VWF (IU/ml) 0.69 (0.24 to 1.77) 
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8.3.2 T-PA with Exercise 
T-PA (figure 8.1) increased significantly by 101% following exercise at 70% V02 max 
(P=0.006) returning to baseline levels 30 minutes post exercise (P=0.047). T-PA 
concentrations remained unchanged in the following 90 minutes (T+30 to T+120) 
(P=1.000). No significant alterations in t-PA concentration were observed throughout the 














TO END T+30 T+60 T+120 
Time point (min) 
Figure 8.1: The effect of exercise at 50% and 70% V02 max on plasma t-PA concentrations. Data is shown 
as mean ± S. E. M. *= significant different from previous time point P< 0.05 ** = significantly different 
from previous time point P<0.01. N=6 in each group. 
There were no significant differences in t-PA concentration between the two groups at 
any point during the trial. Also no significant differences between resting t-PA 
concentrations and those observed post exercise were observed in either group. 
-+- 70% 
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8.3.3 Total PAI-1 Ag with Exercise 
Total PAI-1 Ag (table 8.3) did not significantly change with exercise at an intensity of 
either 70% (P = 0.637) or 50% (P=0.307) V02 max. Thirty minutes post exercise (T+30) 
however, total PAI-1 Ag increased significantly by 161% (P=0.03) in the 70% group and 
remained unchanged during the following 90 minutes (T+30 to T+60 P= 0.637, T+60 to 
T+120 P=0.875). 
In the 50% group there was a trend towards increased total PAI-1 concentrations at 30 
minutes post exercise but this did not reach significance (P=0.099). No significant 
variations in total PAI-1 Ag were observed at any of the 5 time points with low intensity 
exercise at 50% V02 max. 
Table 8.3: The effect of 70% and 50% V02 max intensity exercise on total plasma PAI. 1 concentrations. 
Data is shown as median and range. **= Significantly different from previous time point P<0.01. 





[total PAI-1 ] 
n /ml 
Range Median 
[total PAI-1 ] 
n /ml 
Range 
TO 10.40 5.10-14.70 7.05 3.40 -18.50 
END 9.93 2.78 -18.26 7.11 3.23-9.10 
T+30 12.88** 7.48-72.68 9.06 3.07-30.82 
T+60 12.42 3.00-56.10 10.44 2.26-14.14 
T+120 12.87 3.38-76.22 11.19 5.88-37.94 
157 
Despite the significant increases in total PAI-1 concentrations 30 minutes post exercise 
there were no significant differences between the two groups at any time point 
throughout the trials. There was however a non-significant trend towards increased total 
PAI-1 concentrations with higher intensity exercise at the end of exercise (P=0.099) and 
60 minutes post exercise (P=0.099) compared with exercise at 50% V02 max. 
Interestingly, with exercise at 70% V02 max, 3 women were classed as responders (total 
PAI-1 Ag decreased with exercise) and 3 women were classed as non responders (total 
PAI-1 Ag increased with exercise). With exercise at 50% VO2 max 4 women were 
classed as non responders and were classed as responders 
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8.3.4 Predicting change in PAI-1 with Exercise 
Using a stepwise multiple regression model percentage change in total PAI-1 Ag with 
exercise at 70% V02 max could not be predicted from the variables measured at rest. 
With exercise at 50% V02 max however (figure 8.2), only resting active PAI-1 Ag 
entered the model (coefficient = -15.348, constant = 30.071) the model accounts for 84% 
of the variability in total PAI-1 concentration with exercise (R2 = 0.843 P =0.002). Actual 
(ng/ml) changes in PAI-1 Ag (figure 8.2) with exercise at 70% V02 -max could be 
accounted for with 99.8 % accuracy (constant 76.101 R2 = 0.998 P=0.002) from BMI 
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Figure 8.2: The correlation between observed changes in [total PAI-1 Ag] with exercise at 70% V02 Max 
and change in [total PAI-1 Ag] as predicted by the multiple regression equation. 
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With exercise at 50% V02 max, the first factor to enter the model (figure 8.3) to predict 
actual change in total PAI-1 concentration was resting total PAI-1 concentration 
(coefficient = -0.654) followed by resting total cholesterol (coefficient = -1.597). This 
model accounted for 99.6% of the variability in total PAI-1 concentration with an acute 
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Figure 8.3: Correlation between observed changes in [active PAI-1] with exercise at 50% V02 max and the 
changes predicted by the multiple regression model. 
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8.3.5 Active PAI-1 Ag 
Active PAI-1 concentrations significantly fell from (median) 3.55 ng/ml to 2.20 ng/ml as 
result of exercise at 70% V02 max. During the recovery period following the moderate 
intensity exercise bout, active PAI-1 remained significantly decreased with respect to pre 
exercise levels (T+30 Vs PRE P=0.002, T+60 Vs PRE P=0.023, T+120 Vs PRE 
P=0.012). No significant changes in active PAI-1 concentrations were observed with 
exercise at 50% V02 max or in the post exercise period. 
Table 8.4: The effect of 70% and 50% V02 max intensity exercise on active plasma PAI-1 concentrations. 
Data is shown as median and range. +''= Significantly different from rest time point P<0.01. 
Significantly different from rest P<0.05. *= Significantly different from 70% trial P< 0.05. 





[active PAI-1 ] 
U/ml 
Range Median 
[active PAI-1 ] 
U/ml 
Range 
TO 3.55 1.60 to 11.50 3.50 0.70 to 6.6 
END 2.20+ 0.92 to 6.27 2.84' 0.74 to 3.03 
T+30 2.68++ 0.97 to 3.96 2.48 0.58 to 5.66 
T+60 2.65+ 1.09 to 4.61 2.63 2.42 to 3.13 
T+120 2.76++ 0.47 to 3.65 2.92 1.23 to 5.51 
As a result of exercise at 70% VO2 max, active PAI-1 concentrations were significantly 
lower compared to after exercise at 50% V02 max (END 70% VO2 max 2.20 (0.92 to 
6.27), END 50% V02 max 2.84 (0.74 to 3.03) P=0.043). There were no significant 
differences between groups at any other time point in the trial. 
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To attempt to predict percentage and actual (U/ml) changes in active PAI-1 
concentration from resting variables, a stepwise multiple regression model was again 
used. Actual change in PAI-1 concentration with exercise at 70% VO2 max could be 
predicted with an accuracy of 74%. Only resting active PAI-1 concentrations entered the 
model (constant = 0.479, coefficient = -5.34 P=0.027). 
With exercise at 50% V02 max (figure 8.4) resting triglyceride concentration was the first 
factor to enter the model (coefficient= 6.551) followed by V02 max (coefficient = 0.154) 
allowing prediction of active PAI-1 concentration with 96.7% accuracy. 
E 
I- w -4. c 
d 





Measured change in [active PAI-1] (U/ml) 
00 
Figure 8.4: Correlation between observed changes in [active PAI-i] with exercise at 50% V02 max and 
changes in [active PAI-11 predicted by the multiple stepwise regression model. 
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8.4 Discussion 
The primary aim of this research study was to determine the effect of exercise intensity 
on plasma fibrinolytic capacity in overweight and obese pre menopausal females. The 
secondary aim was to determine if the change in PAI-1 concentrations could be 
predicted from anthropometric measures and resting blood markers of the IRS 
8.4.2 Summary of the Protocol 
6 overweight and obese premenopausal women undertook two acute exercise bouts of 
different intensities on separate days. The moderate intensity exercise bout was 
performed at 70% VO2 max and the low intensity exercise bout was performed at 50% 
V02 max. Each exercise bout lasted for a duration equivalent to approximately 300 kcal 
energy expenditure. Blood samples were taken pre exercise (TO), immediately following 
the exercise bout (END), 30 minutes post exercise (T+30), 60 minutes post exercise 
(T+60) and 120 minutes post exercise (T+120). Samples were analysed for 
concentrations of total PAI-1, active PAI-1, t-PA, insulin, leptin, total cholesterol, 
triglyceride, HDL cholesterol, LDL cholesterol and vWF. 
8.4.3 Resting Data 
At rest all t-PA concentrations (Mean ± S. D., 5.40 ± 1.21 ng/ml, normal range = 3-10 
ng/ml) and total PAI-1 concentrations (Median (range) 8.70 (3.40 to 11.50) ng/ml, normal 
range =4 to 43 ng/ml) were within the normal healthy range. A single subject however 
presented with elevated active PAI-1 concentrations at rest that may be indicative of a 
reduced fibrinolytic capacity (11.50 U/ml, normal range = 1-7 U/ml). All others presented 
with active PAI-1 concentrations within the normal healthy range (Median (range) 3.50 
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(0.7-11.50) despite a waist circumference > 88cm which is indicative of the metabolic 
disturbances associated with the IRS in premenopausal women (Han et al 1995). The 
lack of metabolic disturbances in this group despite a waist circumference > 88 cm 
further underlies the cardioprotective role of oestrogen (Huber 2001 a). 
8.4.4 Exercise Data 
Exercise at 70% V02 max significantly increased t-PA concentrations by 101% before 
returning to base line levels 30 minutes post exercise. This is consistent with numerous 
research studies at similar exercise intensities in sedentary and active populations (98 % 
Van den Burg et al 1994,113 % Szymanski & Pate 1994). The rise in t-PA with 
sustained submaximal exercise is postulated to occur as a result of a reduction in blood 
flow to the liver that in turn, may result in reduced hepatic t-PA clearance (Chandler et al 
1995). Post exercise, hepatic blood flow is restored and t-PA rapidly decreases to 
baseline levels (Booth et al 1987). Exercise at 50% V02 max did not significantly affect 
plasma t-PA concentrations and may therefore reflect a less significant alteration in 
hepatic blood flow. Alternatively, as serum catecholamine concentration is the main 
determinant of levels of t-PA levels, affecting both t-PA secretion and clearance 
(Chandler et al 1997). Low intensity exercise (50% V02 max) may not have produced 
sufficiently large alterations in plasma catecholamines to significantly increase plasma t- 
PA concentrations. 
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8.4.5 PAI-1 with Exercise 
a) Exercise at 70% V02 max 
Total PAM concentration did not significantly alter with exercise at either 50% or 70% 
V02 max. This Is consistent with a number of studies (Fernhall et at 2000, Womack et at 
2001, Kawano et at 2000) as well as the studies shown in chapters 5 and 7. There was 
however a significant 38% reduction in active PAI-1 concentrations with exercise in the 
70% V02 max group. These results are similar to Womack et at (2001) who reported a 
40% reduction in active PAI-lconcentrations with no significant change in total PAI-1 
following exercise at 65% V02 max for 30 minutes in patients with peripheral artery 
disease. This group and others (DeSouza et a 1997) suggested that the change in 
active PAI-1 without a significant change in total PAI-1 represented an increase in t- 
PA/PAI-1 complexes. The assay used in this study to measure total PAI-1 however is 
specific for active and latent PAI-1 only. A reduction in active PAI-1 therefore with no 
change in total PAI-1 concentrations represents a concomitant increase in latent PAI-1 
concentrations with higher intensity (70% V02 max) exercise. 
Although PAI-1 is synthesised in the active form, it `spontaneously' converts to the latent 
form. The largest reservoir of latent PAI-t is within the alpha granules of platelets 
(Huber 2001 b). The latent PAI-1 is converted to the active conformation upon platelet 
activation but the exact mechanism by which this occurs is unknown (Huber 2001 a). 
Once secreted from the alpha granule, if available, the active PAI-1 is stabilised by 
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Figure 8.5: A diagrammatic representation of' the conversion of latent PAI- I to active PAI- I quid back to 
latent PAI-1. Vn = vitronectin, PKA = phosphokinase A 
Morgenstern et at (2001) however have reported that phosphokinase A (PKA) is 
translocated onto the fibrin network of the thrombus from the surface of platelets along 
with PAI-1 and vitronectin. Phosphorylation of vitronectin by PKA reduces its grip on 
PAI-1 unleashing it in its free form. The free PAI-1 can then assume its latent (non- 
inhibitory) conformation allowing more t-PA to remain in the free form to trigger the 
formation of active plasmin and initiate fibrinolysis (Morgenstern et al 2001). 
The decrease in active PAI-1 Ag therefore is most likely to be due to increased numbers 
of t-PA/PAI-1 complexes formed as a result of elevated t-PA concentrations whereas the 
increase in latent PAI-1 may be due to increased alpha granule release of PAI-1 from 
activated platelets. A measure of t-PA activity would be useful to clarify this further. 
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Overall therefore fibrinolytic activity at the end of the exercise bout at 70% V02 max is 
increased with respect to baseline levels due to elevated concentrations of t-PA, no 
change in total PAI-1 Ag and decreased concentrations of active PAI-1 Ag. 
Post exercise (T+30) total PAI-1 Ag was significantly increased with respect to levels at 
the end of the exercise bout at 70% VO2 max (Median (range) END = 9.93 (2.78-18.26), 
T+30 = 12.88 (7.48-72.68)). As active PAI-1 was significantly reduced from resting 
levels this again represents an increase in latent PAI-1 possibly via increased platelet 
alpha granule secretion. As t-PA had returned to baseline levels 30 minutes post 
exercise this suggests an increased fibrinolytic capacity with respect to resting levels but 
a reduced fibrinolytic capacity with respect to the end of the exercise bout. As with t-PA, 
total PAI-1 and active PAI-1 concentrations did not significantly alter over the next 90 
minutes this state of increased fibrinolytic capacity therefore was maintained up to two 
hours post exercise. 
b) Exercise at 50% V02 max 
Exercise at 50% V02 max did not elicit any significant changes in t-PA, total PAI-1 or 
active PAI-1 either at the end of the exercise bout or post exercise. This is consistent 
with numerous studies and with the model produced by Streiff & Bell (1994) which states 
that as exercise approaches 50% V02 max the release of t-PA begins although large 
increases are not seen until exercise intensity reaches 70% V02 max. A decrease in 
PAI-1 is not seen until exercise intensity reaches approximately 70% V02 max. 
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8.4.6 Predicting Changes in PAl-1 with Exercise 
The multiple regression models allow prediction of actual change (ng/ml) in total and 
active PAI-1 concentration from resting variables. The models explain 99.8% and 99.6% 
of the variability of actual PAI-1 with exercise in this group at 70% and 50% V02 Max 
respectively. These models although promising must be viewed with caution as there 
are only 6 subjects in each group. If they could be validated in a larger population these 
models will prove useful to clinicians and exercise physiologists in the prescription of 
exercise programmes in overweight and obese subjects. 
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Chapter 9 
The effect of exercise training on 
fibrinolytic variables in 
sedentary, overweight and obese 
premenopausal volunteers 
Chapter 9: The effect of exercise training on fibrinolytic variables in sedentary, 
overweight and obese premenopausal volunteers 
9.1 Introduction 
The previous two studies (chapters 8& 9), demonstrated that acute exercise bouts, 
in overweight and obese premenopausal females, of moderate (70% V02 max) or 
high (graded V02 max test) intensity resulted in significant increases in t-PA 
concentrations and significant reductions in active PAI-1 concentrations. Exercise at 
50% V02 max however did not result in significant changes in either active or total 
PAI-1 concentrations. 
Numerous studies have shown an improvement in fibrinolytic capacity following 
exercise training (Traber 1999, Stratton eta11994, Bowman eta11996). The primary 
aim of this study therefore is to determine whether these results can be reproduced 
in overweight and obese premenopausal women. Furthermore, this study aims to 
determine whether training at 50% or 70% V02 max for a duration equivalent to an 
energy expenditure of 300 Kcals is the most effective in improving fibrinolytic 
capacity both at rest and following a graded maximal oxygen uptake test. 
9.2 Subjects & Methods 
19 overweight and obese, sedentary, premenopausal females were randomly 
assigned to one of three experimental groups, exercise training at 70% V02 max for 
a duration equivalent to the expenditure of 300 Kcals, 3 times per week, for 12 
weeks, exercise training at 50% V02 max for a duration equivalent to the expenditure 
of 300 Kcals, 3 times per week, for 12 weeks or a control, no exercise group. 
Inclusion criteria for the study were BMI >27 kg/m2 and a waist circumference >88cm. 
"Sedentary was defined as <20 minutes recreational exercise per week and having a 
non-manual profession. 
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9.2.2 Experimental Design 
All subjects underwent a physical examination prior to entry into the study. 
Volunteers arrived at the laboratory at 9.00h (to standardise for the effects of diurnal 
variation) having fasted over night, abstained from smoking for 8 hours, alcohol for 
24 hours and strenuous exercise for 48 hours. No subject was taking prescription or 
`over the counter" medication for 6 weeks prior to enrolment into the study. All 
experimental visits were conducted in the early follicular phase (day 7-11) of each 
subject's menstrual cycle. 
On the experimental days, subjects underwent measures of height, weight, percent 
body fat (by Bioelectrical impedance (BodyStat 1500TM)), waist circumference, hip 
circumference and blood pressure. Blood pressure was determined by the mean of 3 
values recorded 10 minutes apart (Omron 711) in the seated position. A 21 G 
cannula was then inserted into a suitable forearm vein (after 3 minutes of venous 
occlusion at 100 mmHg). Subjects then rested in the seated position for 15 minutes 
before a 25 ml blood sample (PRE) was taken. Maximal oxygen uptake was 
determined by means of a maximal fitness test employing a modified Bruce protocol. 
Expired air was analysed on a breath-by-breath basis using the Metamax 3B online 
telemetry system for FE02, FEC02 volume and temperature allowing calculation of 
VO2 (all volumes were corrected to STPD). Heart rate was also recorded by the 
Metamax via a PolarTM heart rate monitor and perceived exertion was recorded in the 
last 30 seconds of each stage using the Borg scale. Maximal oxygen uptake 
considered to have been achieved when subjects fulfilled 3 of the following 4 criteria. 
1. A heart rate > 220-subject's age 
2. V02 that remained unchanged over 2 consecutive stages 




Subjects then performed a3 minute cool down period (2.7 km/h, 0% gradient) before 
a second 25ml blood sample (POST) was taken. 
Following the initial fitness assessment subjects were randomly assigned into 1 of 3 
experimental groups 
1.70% V02 max exercise intensity for a duration equivalent to 300kcal 
2.50% V02 max exercise intensity for a duration equivalent to 300 kcal 
3. control-no exercise. 
Both exercise groups then underwent a further exercise session on a separate day to 
establish the speed and gradient that elicited an intensity of either 50% or 70% V02 
max. During this visit energy expenditure was assessed by indirect calorimetry and 
time taken to expend 300kcal calculated by averaging the caloric expenditure over a 
10-minute period following 20 minutes of exercise at the given intensity. 
9.2.3 Training Period 
The two exercise groups attended a local fitness centre 3 times per week for 12 
weeks. Each session was fully supervised and consisted of a three minute warm up 
period (2.7 km/h, 0% gradient) followed by walking exercise at a speed and gradient 
equivalent to 50% or 70% V02 max for a duration equal to an energy expenditure of 
300kcal. The speed and gradient used to elicit the given intensity were reassessed 
every 14 days. Finally, a 3-minute cool-down period consisting of low intensity 
walking exercise (2.7 km/h, 0% gradient) was performed. Subjects were required to 
achieve a minimum of 90% compliance to remain in the study. All subjects were 
asked not modify any dietary practices and the control group were asked not to make 
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any changes in physical activity levels. This was monitored by means of a 3-day 
food and activity diary at 0 weeks, 6 weeks and 12 weeks. 
Following the 12 weeks training session subjects returned to the laboratory to repeat 
the resting and exercise measures. 
9.2.4 Laboratory Methods 
Blood samples were distributed between sealed evacuated test tubes containing no 
additives, sodium citrate or EDTA. The EDTA samples were analysed immediately 
for haemoglobin concentration (GDS systems) and haematocrit (micro centrifugation 
Hawksley International). Sodium citrate samples were centrifuged at 3000rpm (IEC 
Centra-2) for 15 minutes and the resultant plasma was pipetted into eppendorf tubes 
and immediately frozen at -80°C. The plasma samples were analysed by ELISA for 
t-PA Ag (Biopool International procedure 101005), Total PAI-1 Ag (Biopool 
International procedure 101005), active PAI-1 Ag (Technoclone procedure 16075) 
and vWF (Immunozym procedure 5450200). No additives samples were allowed to 
clot for 30 minutes before centrifugation at 3000rpm (IEC Centra-2) for 15 minutes 
and the resultant serum was pipetted into eppendorf tubes and stored at -20°C. The 
serum samples were analysed for insulin by MEI (Imx systems), leptin by ELISA 
(R&D systems procedure DLPOO), Total cholesterol (Beckman Synchron CX systems 
procedure 467825), triglyceride (Beckman Synchron CX systems 445850) and HDL 
cholesterol (Sigma diagnostics procedure 345L). LDL concentration was determined 
using the Friedman equation. 
9.2.5 Calculations and Statistical Analysis 
Plasma volume changes were calculated according to the method of Dill & Costill 
(1974). All data shown is corrected to the plasma volume of the PRE sample of the 
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initial max test. Data was assessed for normality of distribution using the Shapiro- 
Wilks test. Comparisons between PRE and POST samples were determined using 
paired T tests and comparisons between groups were analysed using one way 
analysis of variance (ANOVA) followed by Tukey's post hoc analysis for normally 
distributed data and Mann Whitney tests for skewed data. The relationships between 
measures were determined using Spearman's rho correlation coefficients and 
multiple stepwise regression models. Two tailed significance levels are reported and 
differences were considered significant when P<0.05. 
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9.3 Results 
9.3.1 Pre Training Data 
The pre training resting anthropometric measures and fibrinolytic variables are shown 
in table 9.1. BMI was significantly lower in the 70% training group compared to the 
50% training group (P=0.005). There were no significant differences in any other 
anthropometric or fibrinolytic variables between groups at rest. 
Table 9.1: Anthropometric, blood pressure, fitness and fibrinolytic variables in the 3 research groups. 
Data is shown as mean ± standard deviation for normally distributed data or median (range). for skewed 
data ** = Significantly lower than 50% training group P <0.01. 
Marker Group 1 Group 2 Group 3 
(70% V02 max) (50% V02 max) (No Exercise) 
N=7 N=7 N=5 
Body Mass (kg) 83.05 (72.70 to 92.00) 86.55 (72.70 to 100.30) 93.65(7400 to 110.00) 
BMI (kg/m2) 29.78 (28.38 to 33.39)** 34.47 (28.07 to 38.10) 32.39 (27.50 to 35.51) 
Body Fat(%) 40.95±2.17 44.53±4.43 40.05±6.18 












33.41 (28.28 to 38.36) 40.03 (26.68 to 49.84) 39.43 (22.20 to 51.92) 
89.5 (88.0 to 97.0) 96.0 (88.0 to 108.0) 93.5 (89.0 to 106.0) 
0.79 (0.74 to 0.95) 0.82 (0.77 to 0.96) 0.86 (0.79 to 0.94) 
20.95 (12.40 to 25.90) 17.26 (10.66 to 24.17) 20.11 (11.58 to 23.51) 
131 (120 to 138) 132 (125 to 140) 135 (120 to 160) 
86 (60 to 96) 
5.7 (4.2 to 8.9) 
91 (78 to 98) 
10.3 (3.2 to 11.2) 
84 (80 to 96) 
9.1 (5.6to 13.9) 
Active PAI-1 3.85 (0.50 to 9.80) 6.05 (2.50 to 14.60) 4.45 (1.51 to 12.50) 
(U/ml) 
Total PAI-1 8.35 (5.10 to 13.00) 10.05 (7.00 to 29.00) 11.75 (8.70 to 17.30) 
(ng/ml) 
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9.3.2 Post Training Resting Data 
a) 70% VO2 max Training Group 
After the three month training period (table 9.2) the group exercising at 70% V02 max 
showed significant reductions in body mass (P=0.026), BMI (P=0.049), body fat 
percentage (P=0.000), fat mass (0.000), waist circumference (P=0.000) and waist to 
hip ratio (P=0.005). 
Table 9.2: Changes in anthropometric, blood pressure, fitness and fibrinolytic variables after 3 month 
exercise training period. Normally distributed data is shown as mean ± SD, Skewed data is shown as 
median (range. ) *= significantly different from baseline P<0.05, **= significantly different from 
baseline P< 0.01. *= Significantly different from 70% group P<0.05, *`= significantly different from 
70% group P<0.01, s= significantly different from 50% group P<0.05, u=significantly different from 
50% group P<0.01. 
Marker Group 1 Group 2 Group 3 
70% V02 max 50% V02 max No Exercise 
N=7 N=7 N=5 
Body Mass (kg) 
BMI (kg/m2) 
Body Fat (%) 
Fat Mass (kg) 
Waist 
Circumference (cm) 








Active PAI-1 (U/ml) 
Total PAI-1 (ng/ml) 
-2.30 (-8.60 - 1.40)*$ 0.35 (-3.80 to 3.00)` 
-0.92 (-3.09 to 0.97)*$ 0.20 (-1.42 to -1.12)` 
-3.60 ± 2.62** -3.15 ± 2.22** 
-4.25 ± 3.08** -2.68 ± 2.91 ** 
-8.5 ± 3.6**$ -4-50± 3.75*** 
-0.03 (0.10 to 0.00)** -0.02 (-0.07 to 0.02)* 
6.67 (2.37 tol 3.39)** 
-8 (-21 to -2)"" 
-5 (-16 to -4)" 
6.20 (6.60 to 9.01) 
-0.55 (-3.90 to 9.70)** 
-5.60 (-10.50 to -3.10)* 
4.54 (1.90 to 9.14)** 
-7 (-9 to -2)" 
-7 (-17 to -3)** 
7.39 (2.51 to 12.18) 
1.15 (8.20 to 16.30) 
-3.25 (-11.70 to 19.00) 
0.25 (0.50 to 2.60)' 
-0.04 (0.29 to 0.80)+ 
0.22+0.92++ss 
0.47±1.43++$ 
2.00 j 3.16" 
0.01 (-0.01 to 0.03)+ 
0.34 (-1.19 to 3.47)+= 
-5 (-13 to 8)` 
-1 (-7 to 8)+ 
3.62 (0.24 to 13.77)' 
4.90 (0.30 to 10.11)' 
-3.15 (-4.90 to 10.80)` 
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This group also showed significantly lowered systolic, blood pressure (P=0.002), 
diastolic blood pressure (P=0.002) resting active PAI-1 concentrations (P=0.002) and 
resting total PAI-1 concentrations (P=0.012) as well as significantly higher V02 max 
(P=0.000) and resting t-PA concentrations (P=0.046) post training. 
b) 50% V02 max Training Group 
The group exercising at 50% V02 max showed significant reductions in body fat 
percentage (P=0.000), fat mass (P=0.000), waist to hip ratio (P=0.036), V02 max 
(P=0.002), systolic pressure (P=0.002) and diastolic pressure (P=0.002). No 
significant changes in the fibrinolytic profile were recorded in this group. 
c) Control Group 
As expected, no significant changes occurred in any of the resting anthropometric or 
fibrinolytic variables in the non-exercising control group. 
All the measured factors were significantly improved in the 70% group when 
compared to controls but in the 50% group only body fat percentage (P=0.012), fat 
mass (P=0.017) waist circumference (P=0.003) and V02 max (P=0.028) were 
significantly improved when compared to the control group. 
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9.3.4 Post Training Fibrinolytic Response to Exercise 
a) t-PA 
As a result of the graded maximal oxygen uptake test, as with the pre training test, 
(table 9.3) t-PA rose significantly in all groups (group 1 P=0.002, group 2 P=0.002, 
group 3, P=0.028). The percentage changes in t-PA with maximal exercise were not 
significantly different however between pre and post training in any of the groups. 
As with the resting value, t-PA was significantly elevated post exercise in group 1 
with respect to the pre training value (P=0.002) but was not significantly altered in 
either group 2 or 3. 
Table 9.3: Changes in t-PA concentration with maximal exercise pre and post training. Data is shown 
as median (range)* = significantly different from resting value P<0.05, ** = significantly different 
from resting value P<0.01. $= Significantly elevated with respect to pre training value P< 0.05, 
ss=significantly elevated with respect to pre training value P<0.01. 
Time Point Group 1 Group 2 Group 3 
70% V02 max 
N=7 
50% V02 max 
N=7 




5.70 (4.20 to 8.90) 
11.65 (7.10 to 13.40)** 
10.25 (3.20 to 11.20) 9.10 (5.60 to 13.90) 
(ng/mI) 
Change in t-PA 






Change in t-PA 
10.85 (5.70 to 30.70)** 
No Exercise 
N=5 
14.75 (2.00 to 22.60)** 
76.63 (42.11 to 141.51) 58.44 (-12.38 to 174.11) 41.58 (64.29 to 198.28) 
6.50 (4.10 to 9.10)* 7.65 (3.10 to 12.80) 7.90 (5.90 to 14.00)' 
11.35 (10.00 to 15.80)** 
110.44 (52.36 to 263.41) 
17.75 (5.60 to 34.20)** 
95.42 (53.13 to 362.16) 
10.55 (3.50 to 18.90)' 
43.77 (-46.97 to 72.86) 
with exercise (%) 
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b) Total PAI-1 
As a result of the post training graded maximal oxygen uptake test, as with the pre 
training test, total PAI-1 concentrations (table 9.4) did not significantly alter from 
resting values in any of the groups. Total PAI-1 was significantly lowered in group 1 
both at rest and following the exercise test (P=0.012 in both cases) when compared 
to pre training values. There were no significant variations in either resting or 
exercise PAI-1 in either of the other two groups. 
Table 9.4: Changes in total PAI-1 concentration with maximal exercise pre and post training. Data is 
shown as median (range)* = significantly different from resting value P<0.05, ** = Significantly 
different from resting value P<0.01. $= Significantly different from pre training value P< 0.05, +` _ 
Significantly different from 70% group P< 0.01. 
Time Point Group 1 Group 2 Group 3 
70% V02 max 50% V02 max No Exercise 
N=7 N=7 N=5 
Pre Training 
Resting total PAI-1 
(ng/ml) 
Exercise total PAI-1 
(ng/ml) 
Change in total PAI-1 
with exercise (%) 
Post Training 
Resting total PAI-1 
(ng/ml) 
Exercise total PAI-1 
(ng/ml) 
Change in total PAI-1 
8.55 (5.10 to 13.00) 
8.95 (4.90 to 11.80) 
10.05 (7.00 to 29.00) 
9.70 (6.50 to 21.70) 
11.75 (8.70 to 15.20) 
9.50 (7.00 to 37.90) 
19.54 (-60.80 to 63.38) -11.19 (60.34 to 210.00) -13.45 (-53.95 to 203.20) 
2.75 (2.00 to 8.20)s 8.15 (3.80 to 26.00) 13.65 (8.80 to 26.00) 
5.10 (2.70 to 7.90)$ 
56.39 (-43.84 to 169.23) 
12.85 (3.40 to 37.90)+' 13.75 (6.70 to 37.90)" 
59.29 (-40.38 to 119.08) -26.91 (-35.42 to 201.10) 
with exercise (%) 
Post training exercise total PAI-1 was significantly lower in group 1 with respect to 
both group 2 (P=0.002) and group 3 (P=0.046). There were no significant 
differences between groups at any other time point. Finally, There was no significant 
0 
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difference in percentage change in total PAI-1 with maximal exercise in any of the 
groups. 
c) Active PAI-1 
Finally, active PAI-1 (table 9.5) was significantly decreased as a result of the post 
training maximal oxygen uptake test in groupl (P=0.02), unlike the pre training test in 
all groups and the post training test in groups 2 and 3. Active PAI-1 concentrations 
were also significantly lower both at rest (P=0.002) and after exercise (P=0.002) 
compared to pre training levels in group 1. There were no significant changes in 
resting or exercise active PAI-1 concentrations in group 2 and at rest in group 3. 
Following the exercise bout active PAI-1 was significantly elevated in group 3 
compared to pre training levels. 
Table 9.5: Changes in active PAI-1 concentration with maximal exercise pre and post training. Data is 
shown as median (range)* = Significantly different from resting value P<0.05, **= significantly 
different from resting value P <0.01. $= Significantly different from pre training value P< 0.05 
Significantly different from group1 P< 0.05. 
Time Point Group 1 Group 2 Control 
70% V02 max 50% V02 max No exercise 
N=7 N=7 N=5 
Pre Tr_ 
Rest active PAI-1 (U/ml) 
Exercise active PAI-1 
3.85 (0.50 to 9.80) 
4.15 (0.50 to 15.40) 
6.05 (2.50 to 14.60) 4.45 (1.51 to 12.50) 
(U/ml) 
Change in active PAI-1 
with exercise (%) 
Post Traininq 
Resting active PAI-1 
(U/ml) 
Exercise active PAI-1 
(U/ml) 
Change in active PAI-1 
5.45 (2.13 to 7.70) 5.85 (0.92 to 17.00) 
20.88 (68.00 to 192.00) 28.10 (-58.24 to 10.00) 13.88 (-39.25 to 100.00) 
2.60 (1.10 to 17.50)s 7.95 (1 . 00 to 21.40) 11.20 (3.80 to 17.30)' 
1.00 (0.50 to 13.80)"$ 5.25 (0.50 to 13.50) 10.10 (1.30 to 14.80)*+ 
-70.46 (86.36 to 0.00) -31.48 (-73.68 to 150.00) -26.23 (-27.27 to 197.37) 
with exercise (%) 
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Active PAI-1 concentrations were significantly lower at rest in group 1 when 
compared to group 3 (P=0.028) and exercise active PAI-1 concentrations were 
significantly lower in group 1 when compared to groups 2 (P=0.026) and 3 (P=0.028). 
As with t-PA and total PAI-1, there was no significant difference in the percentage 
change in active PAI-1 concentrations with maximal exercise before and after the 
training period. 
To determine the possible effect of other markers of the Insulin Resistance syndrome 
on the fibrinolytic variables multiple Spearman's rho correlations were performed. 
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9.3.5 Correlations with Resting Total PAI-1 
Total PAI-1 concentrations (table 9.6) were significantly correlated with resting 
systolic blood pressure pre and post training both at rest (pre training R=0.481, 
P=0.001, post training R=0.428, P=0.018) and after the graded maximal oxygen 
uptake test (pre training R=0.398 P=0.029, post training R=0.428 P=0.018). 
Similarly, HDL cholesterol was significantly negatively correlated at all measured time 
points (pre training rest, R= -0.375 P=0.051, exercise (R=-0.402 P=0.028, post 
training R=-0.374 P=0.042 exercise R=-0.471 P=0.009). 
Table 9.6: Correlations between total PAI-l concentrations at rest and post exercise, pre and post training. Significant 
correlations are shown in red. *= Significant correlation P<0.05, ** = significant correlation P<0.01 . 
......,., ý,.,.... w,.. m., ý, ý,..., M.....,. V,....,.. ý...... Marker .., m, M..,., M. M.. M,... M......, k,. w.. _..,... _, M. Pre Training ... ý..,.,. w... M, M. ý... w.. w., ý.,.....,.,.,....... M Post Training . M..,,...,..., ý.. ý..,.... n_,. _,.,..., _....., Pre Training w,., ý ,. w, _...,. _,... _,.....,..........,.,... Post Training 
Resting total PAI-1 Resting total PAI- Exercis e total Exercise total 
(nq/ml) n! l) 1 PAI-1 ( n /ml) PAI-1 (n /ml) 
__........ R ................... .. P ...... _. _. _..... _... R .. _.... _ ...... .... P ....... _. .. R ...... _..... P __.. R ......... P 
BMI (kg/m) 0.249 0.185 ___... __... _. 0.465'" . _.. _........... _....... _ 0.0.0 .......... _.. _............ _.. _ 0.162 .. _.. _...... _........... _.. _ 0.392 _.. _...... _..... _.. _. _.. _. _ 0.465"' __..... _.. _.. __.... O. OtO 
Body Fat (%) 0.123 0.516 0.232 0.217 0.395* 0.031 0.232 0.217 
Fat Mass (Kg) 0.168 0.374 0.414* 0.023 0.325 0.079 0.414* 0.023 
Waist Circumference 0.115 0.546 0.375` 0.041 0.204 0.280 0.375' 0.041 
(cm) 
Waist to Hip Ratio -0.346 0.061 0.219 0.244 0.457` 0.011 0.219 0.244 
V02 max (mis/kg/min) -0.661 0.000 -0.247 0.188 0.090 0.636 -0.247 0.188 
Systolic Pressure 0.481 0.001 0.428" 0.018 0.398" 0.029 0.428* 0.018 
(mmHg) 
Diastolic Pressure 0.101 0.594 0.219 0.245 0.437` 0.016 0.219 0.245 
(mmHg) 
Body Mass (kg) 0.152 0.424 0.376* 0.041 0.361 " 0.050 0.376* 0.041 
Insulin (pmol/L) -0.118 0.585 0.682** 0.000 0.168 0.376 0.645** 0.000 
Total Cholesterol 0.197 0.297 0.303 0.103 0.155 0.413 0.177 0.350 
(mmol/L) 
Triglycerides 0.163 0.390 0.296 0.112 0.078 0.683 0.432* 0.017 
(mmol/L) 
HDL Cholesterol -0.372= 0.051 -0.374* 0.042 -0.402` 0.028 -0.471" 0.009 
(mmol/L) 
LDL Cholesterol 0.192 0.310 0.405` 0.026 0.301 0.105 0.149 0.430 
(mmol/L) 
Leptin (pmoVL) 0.132 0.488 -0.007 0.970 -0.138 0.466 -0063 0.741 
vWF (U/ml) -0.125 0.512 -0.128 0.499 0.614" 0.000 -0.099 0.604 
t-PA (ng/ml) 0.596" 0.001 0.466" 0.009 -0.097 0.609 0.167 0.377 
Active PAl-1 (U/mi) -0.212 0.261 0.584"* 0.001 0.207 0.273 0.491- 0.006 
Resting total PAI-1 concentrations were significantly correlated to resting t-PA 
concentrations (pre training R=0.596 P=0.001, post training R=0.466 P=0.009) and 
exercising total PAI-1 concentrations were significantly correlated to body mass (pre 




9.3.6 Correlations with Active PAI-1 
Finally, as with total PAI-1, active PAI-1 concentrations (table 9.7) were significantly 
correlated with resting systolic blood pressure both pre and post training at rest and 
after the acute bout of maximal exercise (pre training rest R=0.467 P=0.009, exercise 
R=0.511 P=0.044, post training rest R=0.512, P=0.004, exercise R=0.481 P =0.007). 
Table 9.7: Correlations between active PAI-1 concentrations at rest and post exercise, pre and post training. Significant 
correlations are shown in red *= Sign ificant correlation P<0.05, ** = sig nificant correlation P<0.01. 
Marker Pre Training Post Training Pre Training Post Training 
Resting a ctive Resting active Exercise active Exercise active 
PAI-1 PAI-1 PAI-1 PAI-1 
_.. 
(U/ml ).. 
_.. ...... _.. __.. 
(U/ml)... 
_ .. _...... _........ __...... .. 
ýU/m 
...... .. _....... _........ _. 
(U/ml).. 
_. -......... .......... R P P R R P R P 
. _.. _.. _. _.. _.. _.. _.. _.... _ BMI (kg/m) . _.. _.... _. _.. w.............. 0.018 _.... _. _...... -.. _.. _ 0.924 .. _.. _.. _.. ...... -. 1-1-1.1.1.1 -0.026 0.891 -1-- ..................... _. -0.027 0.885 -0.030 0.873 
Body Fat (%) 0.087 0.649 0.031 0.869 -0.035 0.854 0.101 0.596 
Fat Mass (Kg) 0.019 0.921 0.083 0.663 -0.090 0.636 0.063 0.743 
Waist -0.208 0.270 0.186 0.324 -0.174 0.358 0.180 0.341 
Circumference (cm) 
Waist to Hip Ratio -0.066 0.270 0.542" 0.002 -0.209 0.267 0421 ` 0.021 
V02 max 0.076 0.729 -0.108 0.571 0.324 0.080 -0.190 0.315 
(mis/kg/min) 
Systolic Pressure 0.467`" 0.009 0.512"" 0.004 0.511' 0.044 0.481 0.007 
(mmHg) 
Diastolic Pressure 0.189 0.690 -0.242 0.197 0.327 0.078 -0.118 0.535 
(mmHg) 
Body Mass (kg) -0.032 0.317 0.070 0.714 -0.194 0.303 -0.048 0.800 
Insulin (pmol/L) 0.045 0.812 0.437' 0.016 0.161 0.397 0.302 0.105 
Total Cholesterol 0.034 0.860 -0.147 0.439 -0.121 0.525 -0.080 0.674 
(mmol/L) 
Triglycerides -0.123 0.517 -0.059 0.756 -0.153 0.419 0.037 0.846 
(mmol/L) 
HDL Cholesterol -0.176 0.351 -0.364* 0.048 0.166 0.381 -0.312 0.094 
(mmol/L) 
LDL Cholesterol 0.125 0.511 -0.060 0.754 -0.094 0.621 -0.088 0.645 
(mmol/L) 
Leptin (pmoVL) 0.361" 0.050 0.093 0.627 0.018 0.925 -0.087 0.647 
vWF (U/ml) 0.008 0.967 -0.252 0.178 -0.190 0.314 0.191 0.311 
t-PA (ng/ml) 0.302 0.104 0.514" 0.004 0.189 0.316 0.175 0.355 
Active PAI-1 (U/ml) -0.212 0.261 0.584" 0.001 -0.170 0.369 0.491" 0.006 
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No other factors were significantly correlated with either resting or post exercise 
active PAI-1 concentrations both pre and post training. 
9.4 Discussion 
9.4.1 Summary of the study 
19 sedentary, overweight and obese premenopausal women underwent a maximal 
oxygen uptake test before being randomly assigned to one of three groups. Group 1 
exercised at 70% V02 max for a duration equivalent to 300 kcal energy expenditure 
three times per week for 12 weeks, group 2 
, 
exercised at an intensity of 50% V02 
max for a duration equivalent to 300kcals energy expenditure three times per week 
for 12 weeks and group 3 had no exercise intervention for 12 weeks. Measurements 
were recorded at rest and after a graded treadmill maximal exercise test before and 
after the exercise intervention. 
9.4.2 Pre Training Data 
Pre training, there were no significant differences in anthropometric measures, 
fitness levels, fibrinolytic variables or other markers of the Insulin Resistance 
syndrome between the three training groups with the exception of BMI which was 
significantly lower in group 1 compared to group 2. This difference was not 
considered meaningful as BMI is a crude predictor of the metabolic abnormalities 
associated with the IRS and there were no significant differences in body fat 
percentage, fat mass, waist circumference or waist to hip ratio which are factors that 
can influence fibrinolytic variables either directly or via other markers of the IRS. 
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9.4.3 The Effect of Exercise Training on Fibrinolysis 
a) Resting t-PA 
Following the three month exercise training programme, significant increases in 
resting t-PA were observed in the group trained at 70% V02 max compared to both 
pre training levels and control group values. There were no significant increases in t- 
PA in the group trained at 50% V02 max compared to either pre training levels or 
controls. Fibrinolytic activity in the blood is regulated by the release of t-PA from the 
endothelial cells, the rapid inhibition of t-PA by PAI-1 and the rate of clearance of t- 
PA by the liver (Stratton et al 1991). In most individuals approximately 90% of 
circulating t-PA is in complex with PAI-1 (Chandler eta! 1997). Following endurance 
exercise training however, Stratton et al (1991) demonstrated that the fraction of t-PA 
circulating in the free form is increased. 
The increase in t-PA concentration recorded in this study following 70% V02 max 
exercise training did not occur with a concomitant significant increase in vWF. The 
lack of a significant change in vWF, (which is concurrently secreted with t-PA by the 
endothelial cells) suggests that the elevated t-PA concentrations post training are not 
due to an increase in secretion. An alteration in the metabolism of t-PA with exercise 
training therefore, via a reduced hepatic clearance of free t-PA or t-PA/PAI-1 
complexes may be the source of the elevated t-PA concentrations. More work, 
including the measurement of t-PA activity needs to be conducted on the kinetics of t- 
PA clearance to elucidate the mechanism responsible for elevated t-PA at rest 
following exercise training. 
The majority of studies, both longitudinal (DePaz et al 1992) and cross sectional 
(Szymanski & Pate 1994, Kvernmo & Osterund 1997) have shown either unchanged 
(DePaz et al 1992)or significantly reduced t-PA Ag at rest (Szymanski & Pate 1994, 
Stratton et al 1994) in regularly physically active subjects. These studies have 
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however, reported significant increases in t-PA activity and therefore a greater 
proportion of t-PA in the active form (Stratton et a/ 1991). A measure of t-PA activity 
in this study would confirm whether this is the case in overweight and obese 
premenopausal women. The studies that have reported a reduced plasma t-PA Ag 
with exercise training have employed protocols that included either high intensity 
exercise (80-85% V02 max, Stratton et a11991) or long training periods (athletes Vs 
controls, Szymanski & Pate 1994, >6 months Stratton et al 1991). It may be that 
exercise training results in an initial increase in t-PA Ag followed by a long term 
reduction when active PAI-1 decreases. Another possibility for this rise in t-PA Ag is 
the effect of the process' of venous occlusion and cannulation. There may be a 
greater t-PA response to venous occlusion and cannulation post training and 
although there was 15 minutes between cannulation and withdrawal of the first 
sample both pre and post training t-PA Ag may still have been elevated. 
b) T-PA Following a Maximal Exercise Test 
As with the pre training results, t-PA Ag increased significantly with the graded 
maximal oxygen uptake test in all three groups but only the group training at 70% 
V02 max displayed increased t-PA concentrations post exercise compared to pre 
training values. There have been several reports of elevated t-PA Ag and activity 
post exercise following exercise training > 70% V02 max (Szymanski & Pate 1994, 
Speiser eta! 1988). As with the resting values this rise in t-PA was not accompanied 
by a similar rise in vWF indicating that rise in t-PA is not solely due to elevated 
endothelial store release. This again suggests that a modification in t-PA clearance 
occurs, improving the fibrinolytic profile both at rest and during maximal exercise. 
Another possibility is that increased physical fitness allows subjects to increase the 
time spent at intensities greater than 50% V02 max during the graded oxygen uptake 
test and therefore increase the release of t-PA. 
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The lack of change in resting and post exercise t-PA concentrations in the group 
trained at 50% VO2 max compared to controls and pre training values suggests that 
there is a training intensity threshold for these alterations to occur. Although the 
intensity threshold for t-PA release is 50% V02 max, the greatest increases in t-PA 
concentration occur with exercise intensities greater than 70% V02 max (Streiff & 
Bell 1994) suggesting that regular sustained large increases in t-PA concentration as 
a result of increased intensity exercise training may be required for training 
adaptations to occur. More work needs to be conducted on the effect of exercise 
training intensity on fibrinolytic variables, in an attempt to elucidate the mechanism by 
which elevations in t-PA occur. 
c) Resting PAI-1 
Both total PAI-1 and active PAI-1 were significantly reduced at rest in the 70% group 
(group 1) compared to controls and pre training levels. As with t-PA, neither total nor 
active PAI-1 was significantly changed in the 50% group (group 2) or controls 
compared to pre training values. This finding is consistent with many other 
longitudinal (Stratton et al 1991) and cross sectional studies (Speiser et al 1988). 
Stratton et al (1991) reported a 58% decrease in PAI-1 activity in older male 
volunteers following a6 month training programme at 80-85% V02 max and Speiser 
et al (1988) reported significantly lower PAI-1 Ag and activity levels in young athletes 
compared to sedentary age-matched controls. Kvernmo & Osterund (1997) reported 
no difference in PAI-1 Ag or activity between athletes and controls. In this study 
however, the control group were physically fit individuals (mean V02 max = 52 
mis/kg/min) suggesting that there is a maximal training effect. 
These findings suggest that exercise training at an intensity equal or greater than 
70% V02 max decreases the stimulus for PAI-1 synthesis and secretion. As PAI-1 is 
released from multiple sites, it is impossible from the measures used in this study to 
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determine if this reduction is purely due to decreased PAI-1 secretion or is 
compounded by increased PAI-1 clearance from the circulation. The decrease in 
active PAI-1 may be a consequence of increasing t-PA concentrations. The 
magnitude of the rise in t-PA compared to the decrease in PAI-1 further suggests that 
the rise in t-PA observed in this group is also accompanied by an increase in the free 
active fraction of t-PA suggesting that, if measured, an increase in t-PA activity 
similar to that described in non-obese populations (Stratton et al 1991, DePaz et al 
1997) would be observed. 
d) PAI-1 Following a Maximal Exercise Test 
As with t-PA, the lack of change in both resting and exercise concentrations of total 
and active PAI-1 50% V02 max training group compared to controls and pre training 
values suggests that there is a training intensity threshold for these modifications to 
occur. The threshold for decreases in PAI-1 concentration with acute exercise is 
70% V02 max (Streiff & Bell 1994). As group 2 trained at an intensity below this 
threshold, significant alterations in either total or active PAI-1 did not occur. 
There was a significant decrease in active PAI-1 concentrations as a result of the 
post training maximal exercise bout in group 1 (median (range) 2.60 (1.10 to 17.50) 
REST Vs 1.00 (0.50 to 13.80) END P=0.001). Furthermore, both total and active PAI- 
1 concentrations were significantly decreased with respect to pre training values in 
this group. There were no significant differences in either total or active PAI-1 with 
acute exercise or exercise training in either the group trained at 50% V02 max or 
controls. 
As with t-PA the decreases in active PAI-1 concentrations observed in the 70% 
group with maximal exercise may purely be due to an increased duration of exercise 
at an intensity greater than 70% V02 max during the post training oxygen uptake test. 
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The significant lowering of both total and active PAI-1 factors at rest however, 
indicates that this may not be the only reason. Exercise training at an intensity > 70% 
V02 max is known to reduce platelet activity and aggregation (Rauramaa & Vaisanen 
1999) both at rest and during exercise. Decreased secretion of PAI-1 from the alpha 
granules of activated platelets may account for the reductions in active and total PAI- 
1compared to pre training values observed in the 70% group. More work is needed 
to determine the effect of exercise training on fibrinolytic factors in obese populations 
both at rest and during exercise. 
Overall we can conclude that exercise training at 70% V02 max three times per week 
for 12 weeks results in favourable changes in the fibrinolytic capacity of overweight 
and obese premenopausal women, as shown by elevated t-PA and reduced total and 
active PAI-1. Exercise training at 50% V02 max neither improves nor reduces 
fibrinolytic capacity. 
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9.4.4 Correlations with PAI-1 
When evaluating the correlations between total and active PAI-1 and other markers 
of the IRS it is important to remember the fluctuating nature of PAI-1 (Fig 9.1). Active 
PAI-1 `spontaneously' converts to the latent conformation due to a lack of cystiene 
residues (Huber 2001 a). This latent conformation can be reactivated as a result of 
platelet activation as well as denaturing agents such as SDS, guanidium chloride and 
urea (Debrock & Declerk 1997). The third conformational change results in the 
formation of complexed PAI-1 via the pseudosubstrate actions of active PAI-1 on t- 
PA (van Meijer & Pannekoek 1995). These reactions occur rapidly and may 
therefore mask any potential effects of other markers of the IRS. 
Latent PAI-1 Active PAI-1 =: 
> Complexed PAI-1 
Figure 9.1: Schematic representation of the major conformations of PAI-1 
Another consideration is that the main actions of PAI-1 occur locally and may not 
therefore be reflected at the cannulation site. These factors must be remembered 
when interpreting the statistical relationships between PAI-1 and other markers of the 
IRS. 
9.4.5 Correlations with Total PAI-1 
Total PAI-1 concentrations were significantly correlated with resting systolic blood 
pressure pre and post training both at rest (pre training R=0.481, P=0.001, post 
training R=0.428, P=0.018) and after the graded maximal oxygen uptake test (pre 
training R=0.398 P=0.029, post training R=0.428 P=0.018). This relationship 
suggests a role for the RAAS in the regulation of PAI-1 as at rest and after the post 
training exercise bout PAI-1 did not correlate with vWF indicting that this relationship 
may not solely be a result of shear stress induced endothelial damage and 
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subsequent platelet and endothelial store PAI-1 release. There was a correlation 
after the pre training maximal exercise test between total PAI-1 and vWF suggesting 
that increased endothelial damage as a result of the increased shear stresses of 
exercise may result in elevations in PAI-1. With exercise training however, this 
association disappeared suggesting that exercise training alters the PAI-1 response 
to endothelial damage. Exercise training at both 50% and 70% V02 max resulted in 
significant reductions in systolic and diastolic blood pressures thus reducing the 
theoretical shear stress on the endothelial wall. The reductions in blood pressure 
(<10 mmHg) however were not clinically significant and could be accounted for by 
the variability in both systolic and diastolic blood pressure at rest. Also PAI-1 Ag was 
significantly reduced post training in the 70% group both at rest and after maximal 
exercise whereas vWF did not significantly alter at either time point with training. 
Similarly, HDL cholesterol was significantly negatively correlated with total PAI-1 at 
all measured time points (pre training rest, R=-0.375 P=0.051, exercise (R=-0.402 
P=0.028, post training R=-0.374 P=0.042 exercise R=-0.471 P=0.009). Negative 
correlations between HDL and PAI-1 have been observed in numerous 
epidemiological studies (Vague 1993, Vague eta! 1995) and this has been attributed 
to the close metabolic relationship between HDL cholesterol and triglyceride as HDL 
concentrations are dependent on triglyceride uptake into adipose tissue (Frayn 1995) 
and there is a large body of evidence (Tremoli et at 1993, Nilsson et at 1999) to 
suggest that triglyceride stimulates PAI-1 expression and secretion from a number of 
different cell types. There was no significant correlation between triglyceride and 
total PAI-1 in this study however suggesting that this may not always be the case. 
There is limited research that suggests that glycated HDL cholesterol that occurs with 
insulin resistance and type II diabetes increases PAI-1 secretion from vascular 
endothelial cells independently of triglyceride (Ren & Shen 2000). The women in this 
study did not show the elevated concentrations of insulin associated with resistance 
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(median (range) insulin pmoVL 6.41 (2.70 to 11.70)) and this group were 
premenopausal and overweight to mildly obese suggesting that they were unlikely to 
be experiencing pancreatic beta cell failure. This suggests that an alternative 
mechanism may be responsible for the relationship between PAI-1 and HDL 
cholesterol, possibly hepatic blood flow and therefore hepatic uptake of the two 
molecules. 
The assay used for the quantification of total PAI-1 concentrations recognises only 
non-complexed PAI-1 (latent and active conformations). This allows large variation 
between total PAl-1 concentration including the complexed form and total PAI-1 as 
measured by the assay. The variation in the percentage of total PAI-1 in the 
complexed form may account for the lack of correlations previously described 
between total PAI-1 and the other markers of the insulin resistance syndrome 
measured. 
9.4.6 Correlations with Active PAI-1 
Active PAI-1 concentrations were significantly correlated with resting systolic blood 
pressure both pre and post training at rest and after the acute bout of maximal 
exercise (pre training rest R=0.467 P=0.009, exercise R=0.511 P=0.044, post 
training rest R=0.512, P=0.004, exercise R=0.481 P=0.007). No other factors were 
significantly correlated with either resting or post exercise active PAI-1 
concentrations both pre and post training. 
9.4.7 Overall Conclusions 
Overall, we have shown that exercise training at an intensity of 70% V02 Max for a 
duration equivalent to an energy expenditure of 300 kcal three times per week results 
in significant improvements in the resting fibrinolytic profile of overweight and obese 
previously sedentary women as shown by elevated t-PA concentrations and reduced 
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total and active PAI-1 concentrations. Exercise training at 70% V02 max also results 
in a significant improvement in the fibrinolytic response to maximal exercise, with 
further increases in t-PA and reductions in active PAI-1 elicited. This is in contrast to 
the group training at 50% V02 max for the same period also for a duration equivalent 
to 300 kcal energy expenditure in whom no significant fibrinolytic changes were 
observed. We can therefore deduce that there may an exercise training intensity 
threshold for fibrinolytic changes to occur. 
It has also been shown that the favourable changes in the fibrinolytic profile observed 
in the 70% V02 max group occurred independently of weight loss, loss of body fat, 
reductions in waist circumference and lowering of the waist hip ratio. Systolic blood 
pressure was determined to be the main contributing factor to both total and active 
PAI-1 concentrations possible acting through the RAAS as well as endothelial 
damage related mechanisms. 
The mechanisms and kinetics of PAI-1 production and hepatic clearance are poorly 
understood. More work is needed to determine the precise effects of exercise 




10.1 Aims of the Research 
The aims of this series of studies were firstly, to determine the effect of acute 
exercise bouts and exercise training on fibrinolytic capacity in overweight and obese 
volunteers and secondly, to examine the relationships between PAH concentrations 
and other markers of the IRS to highlight the potential for a role for these factors in 
the short term regulation of PAI-1. 
10.2 Fibrinolytic Response to Acute Exercise in Overweight & Obese Subjects 
10.2.1 Tissue Plasminogen Activator (t-PA) 
A summary of the results is shown in table 10.1. T-PA increased with acute exercise 
in all cases, with the exception of 30 minutes at 70% V02 max in obese males and 
50% V02 max for duration equivalent to 300 kcal in overweight and obese 
premenopausal females. This is consistent with the model of Streiff & Bell (1994) for 
non obese populations. They suggested that although increases in t-PA are seen 
with exercise at intensities greater than 50% V02 max, large changes are not seen 
until exercise reaches an 70% V02 max. The lack of significant t-PA change in the 
obese males may be due to the fact that the exercise intensity for this group was 
based on predicted rather than actual V02 max and therefore may have been below 
the 70% V02 max threshold. 
T-PA concentrations decreased significantly (70% V02 max in overweight and obese 
premenopausal females) or showed non significant trends towards decreasing (non 
obese males & obese males 30 minutes post exercise. This is again consistent with 
the majority of research studies in non obese populations (Van Den Burg eta! 1994, 
Szymanski & Pate 1994) and the model proposed by Streiff & Bell (1994). 
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therefore a decreased rate of hepatic clearance of t-PA from the circulation (Chandler 
et al 1995). T-PA rises gradually during the exercise period in parallel to the reduced 
hepatic blood flow as well as secretion from endothelial stores. When exercise 
ceases, hepatic blood flow and therefore t-PA concentrations rapidly return to 
baseline levels (Booth et all 987). 
A training response was also shown. Regular exercise training at both low (50% V02 
max) and moderate (70% V02) intensities in obese premenopausal females 
significantly increased the t-PA response to a single graded exercise test to 
exhaustion. This is consistent with the results of De Paz et a11992 (cross sectional 
data) who showed that athletes were hyperfibrinolytic compared to controls due to an 
increased release of t-PA Ag following a maximal exercise test and Ferguson & 
Guest (1994) who observed, that the magnitude of increase in t-PA as a result of 
acute exercise is dependent on both current and former physical fitness. 
10.2.2 Plasminogen Activator Inhibitor type 1 (PAI-1) 
No significant changes in total PAI-1 concentrations (Table 10.1) were detected 
immediately post exercise following the acute exercise bouts. Exercise bouts at 70% 
V02 max for periods equal or greater than 30 minutes in obese males and overweight 
and obese premenopausal females did however lead to significant increases in total 
PAI-1 concentration during the recovery period. These rises were seen within the 
first 30 minutes of the recovery period and remained unchanged for up to 2 hours 
post exercise. 
These results were somewhat surprising, as other groups have observed significant 
reductions in PAI-1 immediately following exercise and during post exercise recovery 
from intensities as low as 50% V02 max. The increase in PAI-1 Ag post exercise may 
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be an effect specific to obese populations. The groups studying non obese 
populations however did not state the time between cannulation and withdrawal of 
baseline samples. As has been demonstrated in the study in obese Vs non obese 
sedentary male volunteers, the process of venous occlusion and cannulation results 
in significant increases in PAI-1 concentrations. It may be that the decrease in PAl-1 
seen with exercise by other groups was merely a return to baseline values following 
the cannulation process. 
The results from this research fit well with the model proposed by Streiff & Bell 
(1994) in that changes in PAI-1 concentration are not seen until exercise intensity 
reaches 70% V02 max although it is not possible to identify a more precise threshold 
as the critical intensity may lie between 50% and 70% V02 max. Based on such 
evidence we would therefore have expected to see a reduction in PAI-1 
concentrations in the overweight and obese premenopausal women following 
exercise at 70% V02 max for a duration equivalent to 300 kcal (mean duration 49.17 
min ± 6.18 min). The number of subjects recruited for this study (i. e. the statistical 
power) however was based on the fibrinolytic response to exercise of non obese 
sedentary subjects as obese populations showed more variability in their response 
the results of the study were subject to type II error. 
The rise in total PAI-1 during the recovery from exercise at 70% V02 max (sedentary 
males & overweight and obese sedentary premenopausal females) has not 
previously been recorded in the literature and may be a phenomenon unique to 
obese sedentary populations. 
Regular exercise training at 50% V02 max did not significantly change total PAI-1 
concentrations at rest or following a maximal exercise bout. Exercise training at 70% 
V02 max however significantly decreased the total PAI-1 concentration at rest and 
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following the V02 max test although there was no significant change in total PAI-1 
concentration from rest to exercise post training. Exercise training at intensities > 
70% V02 max is known to reduce platelet activity and aggregation both at rest and 
during exercise (Rauramaa & Vaisanen 1999), which may account for the reduced 
concentrations of both total and active PAI-1 following exercise training at the higher 
intensity. 
10.2.3 Active Plasminogen Activator Inhibitor type 1 (PAI-1) 
As total PAI-1 remained unchanged immediately following acute exercise, active PAI- 
1 concentrations were measured to gain an insight into overall fibrinolytic capacity. 
Active PAI-1 was significantly decreased following a single exercise bout at 70% V02 
max in both obese and non obese sedentary males. As total PAI-1 Ag remained 
unchanged this may suggest an increase in the number of t-PA/PAI-1 complexes. 
No other sedentary population in these studies displayed significant decreases in 
active PAI-1 immediately following acute exercise. Again, low subject numbers and a 
possible large type II error may be responsible for the lack of significant change. 
With regular exercise training at a moderate intensity (70% V02 max) although not at 
a low intensity (50% V02 max), overweight and obese premenopausal women 
showed significant reductions in active PAI-1 concentrations both at rest and 
following maximal exercise to exhaustion. This may be due to an increased t-PA 
response to the test following training at 70% V02 max increasing the proportion of 
PAI-1 in the complexed formation with t-PA or, this may be a training effect on active 
PAI-1 directly resulting in a decreased PAI-1 secretion. Following the training at 70% 
V02 max however the volunteers were physically fitter (as evidenced by increased 
V02 max) and therefore able to exercise at intensities greater than 70% V02 max for 
a longer period of time that may have provided sufficient exercise duration to trigger 
the PAI-1 response. 
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10.2.4 Overall Fibrinolytic Capacity 
All the individual studies indicated that there was either no change or an 
improvement in fibrinolytic capacity compared to rest, following acute exercise in 
overweight and obese populations and therefore it can be suggested that response 
of obese populations to acute exercise is similar to that of non obese populations. 
The elevations in total PAI-1 post exercise were compounded by decreasing t-PA 
concentrations in the groups exercising at 70% V02 max suggesting that there may 
be a reduced fibrinolytic capacity post exercise. A measure of t-PA activity would be 
needed to confirm or refute this. 
There were no significant changes in any of the fibrinolytic variables following 
exercise at 50% V02 max for duration equivalent to the expenditure of 300 kcal. 
Graded maximal oxygen uptake tests to exhaustion and exercise at 70% V02 max for 
a duration equivalent to 300 kcal energy expenditure (in overweight and obese 
premenopausal women) as well as a 30 minute exercise bout at 70% V02 max (in 
non obese men) were sufficient to improve fibrinolytic potential by significantly 
increasing t-PA concentrations. A 30 minute exercise bout at 70% V02 max in males 
was also sufficient to further improve fibrinolytic potential by significantly reducing 
active PAI-1 concentrations and this was maintained 30 minutes into recovery period. 
Although t-PA concentrations had returned to baseline at this point fibrinolytic 
potential was still increased with respect to baseline levels. 
It is important to note however from the single study comparing obese and non obese 
males, that although the obese subjects exhibited a similar fibrinolytic response to 
acute exercise when compared to the non obese subjects, the obese were still 
hypofibrinolytic with respect to non obese at all times throughout the trial. 
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Furthermore, obese populations are known to exhibit elevated concentrations of 
fibrinogen at rest, possibly due to impaired fibrinolysis suggesting that an increased 
fibrinoytic capacity may therefore be desirable to reduce thrombotic risk (Ferguson et 
al 1987). Exercise training at 70% V02 max (in overweight and obese 
premenopausal women) was shown to increase fibrinolytic potential both at rest and 
after a maximal exercise bout. Further research is required to establish if exercise 
training is sufficient to fully reverse the hypofibrinolytic state observed in obesity. 
10.3 Correlations with PAI-1 
There was little consistency across the studies with respect to the correlations 
between PAll concentrations and other markers of the IRS particularly post 
exercise. This may be due to differences in subject demographics and study 
protocols as well as variability between subjects. 
At rest, anthropometric measures such as body mass, BMI, body fat percentage, 
waist circumference and waist to hip ratio were however consistently the main 
predictors of plasma PAI-1 concentrations. These results support numerous 
research studies reporting that at least one anthropometric variable is the main 
determinant of plasma PAI-1 concentrations (Jannad-Delanne et al 1998, Vague et al 
1989). These results provide further evidence for the postulated role of adipose 
tissue, particularly visceral adipose tissue in the regulation of PAI-1 expression and 
secretion (Samad & Loskutoff 1997). 
Blood pressure also showed significant correlations with both total and active PAI-1 
at rest. Unexpectedly this relationship was not dependent on endothelial damage 
(measured as vWF) but was dependent on anthropometric measures. This 
suggested a possible role for the RAAS, a system that not only influences blood 
pressure via vasoconstriction and blood volume but also stimulates the dose 
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dependent release of PAI-1 via angiotensin IV (Kerins e al 1995). This system is 
known to up regulate in obesity via increased concentrations of tissue specific ACE 
and increased production of plasma angiotensin and plasma renin (Egan et al 2001). 
In vivo studies have shown that infusions of angiotensin II increase PAI-1 Ag 
selectively in both normotensive and hypertensive individuals (Brown et al 1998). 
Blood markers of the IRS showed inconsistent relationships with PAI-1 across the 
trials highlighting the complex nature of the IRS and the possible limitations of the 
statistical analyses. Interestingly, HDL cholesterol maintained a significant 
relationship with PAI-1 concentrations despite controlling for triglyceride. Although 
the explanation of stimulation of PAI-1 by glycated HDL cholesterol is viable (Ren & 
Shen 2000) it may not apply to all the populations studied in particular overweight 
and obese premenopausal females who did not show significant signs of insulin 
resistance. Changes in hepatic blood flow with exercise would alter the hepatic 
uptake and clearance of these two factors from the plasma and this may be a more 
likely explanation for the continuing relationship. 
Finally, the use of stepwise multiple regression models to predict the PAI-1 response 
to exercise from routinely measured markers of the IRS proved a promising 
approach. The prediction equations accounted for approximately 90% of the 
variability in PAI-1 with submaximal exercise and 60% of the variability with maximal 
exercise. The results however should be viewed with caution as the subject numbers 
in each case were exceptionally low. Further studies therefore incorporating a large 
population with varying degrees of obesity and resultant co morbidities are required 
to validate this particular approach. 
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10.4 Limitations 
The major limitation of these studies is the low subject numbers. Although all 
experiments were powered on published data, there are no published studies on the 
effect of acute exercise on fibrinolytic variables in obese populations. Numbers 
therefore were based on non obese populations that may demonstrate less variability 
than the obese. The low subject numbers can also be attributed to low subject 
compliance. On average 29 were contacted and 14 patients were screened for every 
patient that completed the studies. 
Secondly, the lack of measure of t-PA activity only allowed speculation as to the 
change in fibrinolytic capacity with exercise. Measures of t-PA activity as well as 
measures of fibrin, fibrinogen and their breakdown products would allow a more 
accurate picture of fibrinolysis to be obtained. 
The use of the correlation studies to gain a possible insight into the role of markers of 
the IRS in the short term regulation of PAI-1 only accounted for immediate dose 
response reactions of a particular marker on PAI-1 release and, the dual effect of an 
unmeasured variable on PAI-1 and another marker of the IRS. This approach did not 
account for delayed dose response reactions involving up regulation of PAI-1 
expression and synthesis or delayed responses involving long signalling pathways. 
10.5 Further Research 
Further research is required into the effect of exercise in both an acute and chronic 
sense on fibrinolysis in obese populations. Studies employing a number of specific 
exercise intensities and durations are required to gain a more accurate picture on the 
effect of acute exercise on fibrinolysis. Training studies are required to clarify if 
regular exercise training is sufficient to abolish the hypofibrinolytic state observed at 
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rest and post exercise in obesity in males, premenopausal and post menopausal 
females. 
Studies examining the role of platelet activity (through alpha granule released factors 
such as platelet factor 4 and ß thromboglobulin) cytokines (such ad TNFa and IL-6), 
endothelial release of PAI-1 as well as hepatic tissue and adipose tissue expression 
and secretion of PAI-1 are required to fully understand the regulation of PAI-1 
secretion, expression and clearance both at rest and during exercise. Furthermore, 
the role of hepatic blood flow in the secretion and clearance of both t-PA and PAI-1 
requires further investigation to determine the exact mechanism by which fibrinolytic 
capacity changes with exercise. The possible role for RAAS as the link between 
obesity induced hypertension and elevated PAI-1 concentrations looks promising but 
further studies will be required to examine this relationship fully. Finally, research 
needs to be carried out to examine the effect of acute exercise on coagulation 
pathways so that an overall view of haemostatic balance in the obese during exercise 
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